Official Title:  A 26 -week Randomized, Double- blind, Controlled, Parallel- group, 
Multicenter  Study to Evaluate the Efficacy and Safety of Sotagliflozin 
compared to  Empagliflozin, and Placebo in Patients with Type 2 
Diabetes Who Have Inad equate  Glycemic Control on Dipeptidyl 
Peptidase 4 Inhibitor (DPP4(i)) With or Without  Metformin  
NCT Number:  NCT0335147 8 
Document Date: Protocol Version 2:  12-A pril -2 018 
Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipient for the agreed purpose an d must not be 
disclosed, published or otherwise communicated to any unautho rized persons, for any reason, in any form whatsoever without the prior written 
consent of Sanofi (or the concerned affiliated company); â€˜affiliated companyâ€™ means any corporation, partnership or other entity which at the date 
of communication or afterward s (i) controls directly or indirectly Sanofi, (ii) is directly or indirectly controlled by Sanofi, with â€˜controlâ€™ meaning 
direct or indirect ownership of more than 50% of the capital stock or the voting rights in such corporation, partnership or o ther enti ty
Page 1AMENDED CLINICAL TRI AL PROTOCOL NO. 02
COMPOUND: sotagliflozin/SA R439954
A 26-week Randomized, Double -blind, Controlled, Parallel- group, Multicenter 
Study to Evaluate the Efficacy  and Safety of Sotagliflo zin compared to 
Empagliflozin, and Placebo in Patients with Type 2 Diabetes Who Have Inadequate 
Glycemic Control on Dipeptidy l Peptidase 4 Inhibitor (DPP4(i)) With or Without 
Metformin
STUDY NUMBER: EFC14867
STUDY NA ME: SOTA -EMPA
VERSION DA TE / STA TUS: Approval date ( 11-Apr-2018 ) / Approv ed
Protocol Amendment 0 2 Version number: 1 (electronic 1.0 ) Date : 11-Apr-2018
Amended Clinical Trial P rotocol 01 Version number: 1 (electronic 1.0) Date : 29 -Sep-2017
Protocol Amendment 01 Version number: 1 (electronic 1.0 ) Date : 29-Sep-2017
Clinical Trial Protocol Version number: 1 (electronic 1.0) Date : 27 -Jun-2017
Version Number: 1 EudraCT: 2016- 001803 -22
IND Number(s):
WHO universal trial: U1111 -1190 -7607
Date: 11-Apr-2018 Total number of pages: 122
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 2 of 298

$PHQGHG&OLQLFDO7ULDO3URWRFRO1R $SU
()&  VRWDJOLIOR]LQ 9HUVLRQQXPEHU
3URSHUW\RIWKH6DQRIL*URXS VWULFWO\FRQILGHQWLDO 3DJHNAMES AND ADDRESSES OF
COORDINATING 
INVESTIGATOR1DPH
$GGUHVV
7HO
)D[
(PDLO
MONITORING TEAMâ€™S 
REPRESENTATIVE1DPH
$GGUHVV
7HO
)D[(PDLO
SPONSOR &RPSDQ\$GGUHVV
OTHER EMERGENCY 
TELEPHONE NUMBERS
HOHFWURQLF 


HOHFWURQLF 

Page 3 of 298Type here
Type here
Type here
Type here
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 3CLINICA L TRIAL SUMM ARY
COM POUND: sotagliflozin/SA R439954STUDY No .: EFC14867
STUDY NA ME: SOT A-EMPA
TITLE A 26-week Randomized, Double -blind, Controlled, Parallel- group, 
Multicenter Study to Evaluate the Efficacy and Safety of Sotagli flozin 
compared to Empagliflozin, and Placebo in Patients with Type 2 Diabetes 
Who Have Inadequate Glycemic Co ntrol on Dipeptidyl Peptidase 
4Inhibitor (DPP4(i)) With or Without Metformin
INVESTIGA TOR/TRIA L LOCA TION Multinational
PHASE OF DEVELOPMENT 3
STUDY OBJECTIVE(S) Primary objective:
The primary objective of this study is to demonstrate the superiority of 
sotagliflozin 400 mgversus placebo on h emoglobin A1c (HbA1c) reduction 
at Week 26 in patients with T ype 2 diabetes (T2D) who have inadequate 
glycemic control on a DPP4 (i)with or without metformin .
Secondary objective :
The secondary objectives of this study are to demonstrate:
ï‚· Noninferiority of sotagliflozin 400 mgversus empagliflozin on 
HbA1c reduction from Baseline at Week 26
ï‚· Superiority of sot agliflozin 400 mg versus placebo with respect 
to:
- Change from Baseline in 2-hour postprandial glucose 
(PPG) reduction following a mixed meal tolerance test 
(MMTT) at Week 26
- Change from Baseline in Fasting plasma glucose (FPG) 
reduction at Week 26
- Change from Baseline in Body weight reduction at Week 26
- Proportion of patients with HbA1c <6.5% and <7.0% at 
Week 26
- Change from baseline in sitting systolic blood pressure 
(SBP)reduction at Week 12 in Patients with SBP
â‰¥130 mmHg at Baseline
- Change from baseline in sitting SBP reduction at Week 12 
in allpatients
ï‚· Superiority of sotagliflozin 400 mgversus empagliflozin with 
respect to change from baseline in 
- HbA1c reduction at Week 26
- Sitting SBP reduction at Week 12 in patients with SBP
â‰¥130 mmHg at Baseline
- Sitting SBP reduction at Week 12 in all patients
ï‚· To evaluate the safety of sotagliflozin 400 mgversus 
empagliflozin 25 mg, and placebo, throughout the 26 -week trial .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 4 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 4Other objectives :
Other objectives of this stu dy are:
ï‚· To compare sotagliflozin versus empagliflozin and placebo with 
respect to change from Baseline in:
- Estimated glomerular filtration rate (eGFR)
- Serum creatinine
- Urinaryglucose excretion (UGE) and urine glucose to 
creatinine ratio (UGCR)
- Urine album in to creatinine (UACR) for all patients and
patients with UACR >30mg/g at Baseline
- Sitting SBP for patients with Baseline SB P <130mmHg at 
Weeks 12 and 26
- Sitting SBP for patients with Baseline SBP â‰¥130 mmHg at 
Week 26
- Sitting SBP for all patients at Week 26
- Sitting diastolic blood pressure (DBP) for patients with 
Baseline SBP â‰¥130 mmHg at Weeks 12 and 26
- Reduction in body weight by â‰¥2%, â‰¥5%, and â‰¥10% .
ï‚· To compare sotagliflozin vers us empagliflozin with respect to 
change from B aseline in:
- 2-hour PPG reduction following a nMMTT at Week 26
- FPG reduction at Week 26
- Body weight reduction at Week 26 .
ï‚· To compare the use of rescue medications for hyperglycemia in 
the sotagliflozin and empag liflozin treatment groups
ï‚· To assess plasma levels of sotagliflozin and sotagliflozin -3-O-
glucuronide in the sotagliflozin treatment arm
ï‚· To compare hemodynamic markers (including plasma renin 
activity [ PRA], aldosterone, angiotensinogen 1, angiotensinogen 
2and glucagon) in the sotagliflozin and empagliflozin treatment 
groups.
Ambulatory Blood Pressure Monitoring substudy
A substudy will be undertaken to monitor ambulatory blood pressure (BP) over 24 hours (in addition to all other study assessments) in a su bset of 
the study population (approximately 180 patients).
The objective of the ambulatory blood pressure monitoring ( ABPM )
substudy is to compare the effect of sotagliflozin ,empagliflozin ,and
placebo in a subset of patients based on:
ï‚· 24-hour average SBP and DBP
ï‚· Average adjusted awake time BP as measured by SBP and DBP 
with adjustment based on actigraphy
ï‚· Average adjusted sleeping time BP as measured by SBP and 
DBP with adjustment based on actigraphy .
STUDY DESIGN This study is a Phase 3, multicenter and multinational, 2:2:1 randomized, 
double -blind (single -blind Run -in Phase) , placebo -and active -controlled, 
double -dummy, parallel -group study that is anticipated to enroll 
approximately 700subjects. Patients with T2D who have inadequate 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 5 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 5glycemic control on DPP4(i) with or without metformin for at least 
12weeks prior to Screening will be eligible for enrollment in this study . To 
ensure an approximately equal number of patients have Screening SBP 
<130 mmHg or SBP â‰¥130 mmHg , the number of patients enrolled in each 
category will be limited to 60% of all patients ( â‰¤420 patients).
Allpatients will have an up to 4-week S creening Period (consisting of a 
Screening Phase up to 2 -week s and a 2 -week, single -blind Run -in phase 
prior to randomization, followed by a 26 -week Double -blind Treatment 
Phase and a 4 -week post -treatment Follow -up visit. To qualify for 
randomization, patients must demonstrate compliance based upon tablet 
and capsule count ( â‰¥80%) during the Run -in Phase .
Randomization will be stratified by:
ï‚· HbA1c at Screening ( â‰¤8.5%, >8.5%)
ï‚· SBP at Screening (<130 mmHg, â‰¥130 mmHg)
ï‚· Metformin useat Screen ing (Yes, No)
Patients will be randomly assigned 2:2:1 to the following 3 treatment 
groups on top of DPP4(i) with or without metformin:
ï‚· Sotagliflozin 400 mg
ï‚· Empagliflozin 25 mg
ï‚· Placebo
The patientâ€™s HbA1c, FPG, PPG, UGE , and UGCR will be masked to study 
centers and patient safter randomization and until the end of the study . 
Additionally, urinalysis by dipstick will not include the measurement of 
urine glucose. Urine glucose, albumin, calcium ,and creatinine will be 
measured separately at Visits 3, 6, and 8 by the central laboratory.
To further evaluate the diurnal effect of sotagliflozin on SBP compared 
with the comparator arms (placebo and empagliflozin) and to avoi d the 
white- coat effect, SBP will be evaluated by 24-hourABPM in a subset of 
180 patients .
Early termination
If a patient discontinues treatment with investigational medicinal product 
(IMP) early during the double -blind Treatment Period, the patient will have 
a Premature End ofTreatment (EOT) Visit, and Follow -up Visit 4weeks
after the last dose of IMP. In addition, every effort will be made to have the 
patients return to the site at the time corresponding to their scheduled 
visits, particularly the Week 26 Visit. If the patient does not agree to site 
visits, they will be contacted by telephone to inquire about safety status 
and collect adverse event ( AE)data.
STUDY POPUL ATION
Main selection criteriaInclusion criteria:
ï‚· Patients with Type 2 Diabetes on DPP4(i) with or without 
metformin at a stable dose for at least 12 weeks prior to 
Screening Visit will be included . Metformin dose will be 
â‰¥1500 mgper day (or maximum tolerated dose [documented]). 
DPP4(i) dose must be the appropriate dose as per local label .
ï‚· Signed written informed consent .
Exclusion criteria:
ï‚· At the time of Screening age <18 years or less than legal a ge of 
majority, whichever is greater
ï‚· Type 1 diabetes mellitus
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 6 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 6ï‚· Body mass index (BMI) â‰¤20kg/mÂ² or >45 kg/mÂ² at Screening
ï‚· Use of any antidiabetic drug other than DPP4(i) and metformin 
within 12 weeks preceding the Screening Visit
ï‚· Use of systemic glucocortico ids (excluding topical or ophthalmic 
application, nasal spray or inhaled forms) for more than 
10consecutive days within 90 days prior to the Screening Visit
ï‚· Use of weight loss medications or weight change of 5 kgor more 
during the 12 weeks before Screeni ng
ï‚· Likelihood of requiring treatment during the study period with 
drugs not permitted by the study protocol (eg, long -term 
systemic glucocorticoids) and refusing to or unable to take 
alternative treatment
ï‚· Patients who have previously participated in any cl inical trial of 
sotagliflozin/LX4211
ï‚· Use of a selective sodium -glucose cotransport type 2 ( SGLT2 ) 
inhibitor (eg, canagliflozin, dapagliflozin, or empagliflozin) within 
3months prior to Screening Visit.
ï‚· Patients with severe anemia, severe CV (including con gestive 
heart failure New York Heart Association IV), respiratory, 
hepatic, neurological, psychiatric, or active malignant tumor or 
other major systemic disease or patients with short life 
expectancy that, according to Investigator , will preclude their 
safe participation in this study, or will make implementation of 
the protocol or interpretation of the study results difficult
ï‚· Current diag nosis of chronic hepatitis, and/or other clinically 
active liver disease requiring treatment
ï‚· Known presence of factors t hat interfere with the central 
laboratory HbA1c measurement (eg ,genetic Hb variants) 
compromising the reliability of HbA1c assessment or medical 
conditions that affect interpretation of HbA1c results (eg, blood 
transfusion or severe blood loss in the last 3 months prior to 
Randomization Visit, any condition that shortens erythrocyte 
survival)
ï‚· Patient who has taken other investigational drugs or prohibited therapy for this study within 12 weeks or 5half-lives from prior to 
Screening, whichever is longer
ï‚· Patients with contraindication to empagliflozin as per local 
labeling
ï‚· Patients with contraindication to metformin as per local labeling
ï‚· Hemoglobin A1c <7 .0% or > 11.0% at Screening (central 
laboratory)
ï‚· FPG >270 mg/dL ( >15.0 mmol/L ) measured by the central 
laboratory at Screening ( Visit 1), and confirmed by a repeat test 
(>270 mg/dL [>15.0 mmol/L ]) before Randomization
ï‚· Previous use of any types of insulin for >1 month (except for 
treatment of gestational diabetes )
ï‚· Pregnant (confirmed by serum pregnancy test at Screening) or breast- feeding women
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 7 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 7ï‚· Women of childbearing potential not willing to use highly 
effective method(s) of birth control during the study treatment 
period and the follow- up period, or who are unwilling or unable to 
be tested for pregnancy (see Appendix A ), during the study
ï‚· Mean of 3 separate BP measurements >180 mmHg (SBP) or 
>100 mmHg (DBP)
ï‚· History of hypertensive crisis resulting in emergency medical 
care within 12 weeks prior to Screen ing
ï‚· Known alle rgies, hypersensitivity, or intolerance to SGLT2 
inhibitor or any inactive component or placebo 
(ie,microcrystalline cellulose, croscarmellose sodium 
[disintegrant], talc, silicone dioxide, and magnesium stearate [nonbovine]), orintolerance of empagliflo zin unless the reaction 
is deemed irrelevant to the study by the Investigator
ï‚· Laboratory findings with the central laboratory tests at Visit 1:
- Alanine aminotransferase or aspartate aminotransferase >3 times the upper limit of the normal laboratory range ( x ULN)
- Total bilirubin >1.5 times the ULN (except in case of Gilbertâ€™s syndrome)
- Neutrophils <1 500/mm
3(or according to ethnic group) 
and/or platelets <100 000/mm3
- Amylase and/or lipase >3 times the ULN
- Patients with renal impairment as defined by the eGF R 
criterion that precludes initiation of empagliflozin as per the 
approved local label (eg, <45mL/min/1.73 m2inthe United 
States; < 60mL/min/1.73 m2in EU)
ï‚· At the sites with participating ABPM patient s, patient works a 
night (third) shift (defined as 11:00 PM [2300] to 7 :00AM [0700])
ï‚· Patient has an upper arm circumference <24 cm or >42 cm
ï‚· Secondary hypertension of any etiology (eg, renovascular 
disease, pheochromocytoma, Cushing's syndrome )
ï‚· If the patient is on hypertensive medications, the 
antihyperten sive has been changed in the 8 weeks prior to 
Screening (new drug or new dose)
Total expected number of patients Approximately 700patients
STUDY TREA TMENTS Single -blind placebo Run -in Phase :Allpatients will receive two (2) 
placebo tablets (identical t o sotagliflozin in appearance) and one placebo 
capsule (identical to empagliflozin capsule in appearance).
26-week Randomized Double- blind Treatment P eriod :Patients will 
receive sotagliflozin, empagliflozin ,orplacebo treatment.
Investigational medicina l product s Sotagliflozin arm : sotagliflozin 400 mg, given as two (2) 200 mgtablets 
and one (1) placebo capsule (identical to empagliflozin capsule), once 
daily before the first meal of the day .
Empagliflozin arm: placebo, given as two (2) placebo tablets (identical to 
sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once 
daily before the first meal of the day.
Placebo :given as two (2) placebo tablets (identical to sotagliflozin) and 
one placebo capsule ( identical to empagliflozin) once daily before the first 
meal of the day.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 8 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 8Formulation: Tablet or capsule
Route(s) of administration: Oral
Dose regimen: Once daily before the first meal of the day
Noninvestigational medicinal products Patients will continue on their existing DPP4(i) with or without metformin, if 
applicable . The doses should remain unchanged during the study period 
unless as needed for safety reason.
Rescue therapy (Glycemic Parameters)
The threshold values for rescue are defined as follows, depending on the 
study period :
ï‚· From Baseline Visit (V3, Day 1) to Visit 5 (Week 8) (including 
value at Visit 5): FPG >270 mg/dL (>15 .0mmol/L )
ï‚· From Visit 5 (Week 8) to Visit 6 (Week 12) (including value at 
Visit 6): FPG >240 mg/dL (>13.3 mmol/L)
ï‚· From Visit 6 (Week 12) up to the end of the treatment period 
Visit 8 (Week 26): FPG >200 mg/dL (> 11.1 mmol/L) or HbA1c 
â‰¥8.5% (the 8.5% criteria does not apply if the HbA1c decrease 
from Baseline was â‰¥1.0% )
Routine fasting self -monitored blood glucose (SMBG) and central 
laboratory alerts on FPG (and HbA1c after Week 12 and onwards) are set 
up to ensure that glycemic parameter results remain within predefined 
thresholds.
If a central laboratory FPG and/or HbA1c is above the threshold, the 
Investigator will receive an alert from the central laboratory. Upon receipt 
of a central laboratory rescue alert, a centr al laboratory re testmust be 
completed and confirmed.
Likewise, patients are instructed to contact the sites for a confirmatory 
FPG test via central lab oratory in case of high fasting SMBG readings for 
3consecutive days. Hyperglycemia must be confirmed as exceeding the 
criterion for rescue before rescue the rapy is initiated. The central 
laboratory FPG confirmation should be performed as soon as possible 
preferably within 7 days by unscheduled visit.
If rescue thresholds are reached, it is recommended to us e sulfonylurea 
(glimepiride, if available) first (unless there is a contraindication to 
sulfonylurea treatment per label). In case of contraindication to 
sulfonylurea, another antidiabetic medication ,eg, insulin or oral 
antidiabetic drugs (except SGLT2 in hibitors) will be added according to the 
Investigatorâ€™s clinical judgment a nd in accordance with the treatment 
guidelines.
If a patient requires rescue, the IMP received at Randomization should 
continue and must remain blinded until the end of the study .
ENDPOINT(S) Primary efficacy endpoint:
ï‚· Change from Baseline to Week 26 in HbA1c .
Secondary efficacy endpoint s:
ï‚· Change from Baseline to Week 26 in 2- hour PPG following a n
MMTT
ï‚· Change from Baseline to Week 26 in FPG
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 9 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 9ï‚· Change from Baseline to Week 26 in body weight
ï‚· Proportion of patients with HbA1c <6.5%, <7.0% at Week 26
(HbA1c responders)
ï‚· Change from Baseline to Week 12 in sitting SBP in patients with 
SBP â‰¥130 mmHg at B aseline
ï‚· Change from Baseline to Week 12 in sitting SBP in all patients.
Other efficacy end points :
ï‚· Change from Baseline in :
- eGFR
- Serum creatinine
- UGE and U GCR
- UACR for all patients and patients with UACR >30mg/g
- Sitting SBP for patients with Baseline SB P <130mmHg at 
Weeks 12 and 26
- Sitting SBP for patients with Baseline SBP â‰¥130 mmHg at
Week 2 6
- Sitting SBP for all patients at Week 26
- Sitting DBP for patients with Baseline SBP â‰¥130 mmHg at 
Weeks 12 and 26
- Reduction in body weight byâ‰¥2%, â‰¥5%, and â‰¥10%
ï‚· Use of rescu e medications for hyperglycemia in the sotagliflozin 
and empagliflozin treatment gr oups .
ï‚· Plasma concentration of sotagliflozin and 
sotagliflozin -3-O- glucuronide for patients receiving sotagliflozin
ï‚· Hemodynamic markers (including plasma renin activity [PRA], 
aldosterone, angiotensinogen 1, angiotensinogen 2 and 
glucagon) .
Safety endpoints :
To be collected throughout trial:
ï‚· Adverse events (AEs), hypoglycemia ( all, severe, and /or
documented symptomatic hypoglycemia ), events of special 
interest (EOSI), adverse events of special interest (AESI), AEs 
leading to discontinuation from the IMP, serious adverse events 
(SAEs) , and deaths
ï‚· Acute renal failure
ï‚· Clinical laboratory and vital signs results .
Other endpoints:
ï‚· Plasma levels of sotagliflozin and sotagliflozin -3-O- glucuronide 
in the sotagliflozin treatment arm
ï‚· Hemodynamic markers (including PRA, aldosterone, 
angiotensinogen 1, angiotensinogen 2 and glucagon)
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 10 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 10ABPM substudy endpoints:
The ABPM endpoints are changes from Baseline to Week 12 and 
Week 26 for all patients participating in the substudy, patients with 
baseline 24 -hour average SBP â‰¥130 mmHg and patients with baseline 
24-hour average SBP <130 mmHg in:
ï‚· 24-hour average SBP and DBP
ï‚· Average adjusted awake time BP as measured by SBP and DBP 
with adjustment based on actigraphy
ï‚· Average adjusted sleeping time BP as measured by SBP and DBP wi th adjustment based on actigraphy .
ASSESSMENT SCHEDULE See Study Flow Chart(Section 1.2)
STATISTICA L CONSIDERA TIONS Sample size determination:
A sample size of 280 patients in the sotagliflozin group and 140 patients in 
the placebo group will provide more than 90% power to detect a difference 
of 0.6% for change from Baseline to Week 26 in HbA1c between 
sotagliflozin and placebo ( standard deviation [SD] =1.1% ; 5% significance 
level 2 -sided) .
A sample size of 280 patients in the sotagliflozin group and 280 patients in 
the empagliflozin group will ensure that the upper bound of the 2 -sided 
95% confidence interval ( CI)of the adjusted mean difference would not 
exceed 0.3% with more than 80% power to show noninferiority for 
intent -to-treat (ITT) analysis and for com pleter analysis considering 
15% dropout . This calculation assumes a common SD of 1.1 %, and the 
true difference between sotagliflozin and empagliflozin is zero for change from Baseline to Week 26inHbA1c .
Thetotal sample size will be 700 patients to be randomized (sotagliflozin 
group: 280; empagliflozin group: 280; placebo group: 140).
Analysis population:
Efficacy analyses will be based on the ITT population, defined as all 
randomized patients, irrespective of compliance with the study protocol 
and procedures.
Analysis of the primary efficacy endpoint :
Analysis of the primary efficacy endpoints will be performed using the ITT 
population, using measurements obtained during the study, including 
those obtained after IMP discontinuation or introduction of rescue therapy.
The statistical test will be two -sided tests at a nominal 5% significance 
level.The primary efficacy endpoint of change from Baseline to Week 26 in 
HbA1c will be analyzed with missing post- baseline values imputed by 
placebo control -based copy reference multiple imputation method under 
the missing not at random framework.
ï‚· For placebo patients, missing data will be imputed based on the 
placebo group data
ï‚· For pat ients in the active arms (sotagliflozin and empagliflozin) ,
missing data will be imputed as if the patient swere on placebo 
group throughout the study, where all patientsâ€™ measurements 
including the on -treatment measurements will be considered as 
if the me asurements were from the placebo group in the 
imputation model .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 11 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 11Each of the complete datasets will be analyzed by the analysis of 
covariance ( ANCOVA )model with treatment groups (sotagliflozin, 
empagliflozin, placebo), randomization strata of Screen ing HbA 1c (â‰¤8.5%, 
>8.5% ), randomization strata of Screening SBP (<130 mmHg, 
â‰¥130 mmHg) and metformin useat Screen ing (Yes, No) ,and country as 
fixed effects, and Baseline HbA1c value as a covariate. Results from each 
complete dataset will be combined to provide the adjusted mean change 
from Baseline to Week 26 in HbA1c for each treatment group, as well as 
the between -group difference (comparing sotagliflozin 400mgversu s 
placebo) and the 95% CI for the between -group difference .
Summary statistics (for Screening value, Baseline value, observed values, 
and observed changes from Baseline) at scheduled visits will be provided 
for each treatment group. The summary will include the number of 
observations, mean, SD, standard error (SE), minimum, median, and 
maximum. Gra phical presentations will also be used to examine trends 
over time using mean values (Â±SE) and mean changes from Baseline
(Â±SE) at each of the scheduled visits (using observed cases [OC] ).
Analysis of secondary efficacy endpoints:
For each of the continuou s secondary endpoint s, a similar approach to the 
primary efficacy endpoint will be used, with missing values imputed by placebo control -based copy reference multiple imputation method under 
the missing not at random framework:
ï‚· For placebo patients, missing data will be imputed based on the 
placebo group data
ï‚· For patients in the active arms (sotagliflozin and empagliflozin) 
missing data will be imputed as if the patient swere on placebo 
group throughout the study, where all patientsâ€™ measurements 
including t he on- treatment measurements will be considered as 
if the measurements were from the placebo group in the imputation model .
Each of the complete datasets will be analyzed by the ANCOVA model with treatment groups (sotagliflozin, empagliflozin, placebo), ra ndomization 
strata of Screen ing HbA1c ( â‰¤8.5%, >8.5%), randomization strata of 
Screen ing SBP (<130 mmHg, â‰¥130 mmHg) and metformin useat 
Screen ing (Yes, No) and country as fixed effects, and Baseline value as a 
covariate. Results from each complete dataset will be combined to provide 
the adjusted mean change from Baseline to Week 12/Week 26 for each 
treatment group, as well as the between -group difference s and the 95% 
CIs for the differences .
Categorical secondary endpoint ssuch as HbA1c responders (<6.5 %, 
<7.0%) at Week 26 will be analyzed using a Cochran -Mantel -Haenszel 
method stratified by randomization strata of Screen ing HbA1c ( â‰¤8.5%, 
>8.5% ), Screen ing SBP (<130 mmHg, â‰¥ 130mmHg), and metformin useat 
Screen ing (Yes, No). The proportion in each treatment group will be 
provided, as well as the difference of proportions between sotagliflozin and 
placebo with associated 2 -sided 95% CI. For HbA1c responders at 
Week 26, all values at Week 26 will be used to determine whether a 
patient is a responder or not, even if they are measured after IMP 
discontinuation or rescue medication use. Patients who have no HbA1c 
measurement at Week 26 will be treated as nonresponders.
A sensitivity analysis to noninferiority tes t will be conducted with the 
26-week treatment completers (ie, a ll patients who complete the 26 -week 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 12 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 12Treatment Period and do not start rescue therapy) using the Week 26 
values and the same ANCOVA model described above.
Multiplicity considerations:
To control for the family -wise T ype I error, a fixed -sequence testing 
procedure will be applied.Once the primary hypothesis (superiority of the change from Baseline to 
Week 26 in HbA1c comparing sotagliflozin 400 mg versus placebo) is 
established statistically significant for the primary efficacy endpoint, the following secondary hypotheses will be tested in the following prioritized 
order:
1. The noninferiority of sotagliflozin ver sus empagliflozin on HbA1c 
reduction at Week 26
2. The superiority of sotagliflozin versus placebo on 2 -hour PPG 
reduction at Week 26
3. The superiority of sotagliflozin versus placebo on FPG reduction at Week 26
4. The superiority of sotagliflozin versus placebo o n body weight 
reduction at Week 26
5. The superiority of sotagliflozin versus placebo on HbA1c 
responder analysis (HbA1c<7.0 % at Week 26)
6. The superiority of sotagliflozin ver sus placebo on sitting SBP 
reduction at Week 12 in patients with Baseline SBP â‰¥130 mmHg
7. The superiority of sotagliflozin versus placebo on sitting SBP reduction at Week 12
8. The superiority of sotagliflozin versus empagliflozin on HbA1c 
reduction at Week 26
9. The superiority of sotagliflozin versus empagliflozin on sitting SBP reduction at Week 12 in patients with Baseline SBP 
â‰¥130 mmHg
10. The superiority of sotagliflozin versus empagliflozin on sitting SBP reduction at Week 12.
If any hypothesis is found to be no t statistically significant, the testing 
procedure will be stopped and the following hypotheses will not be tested. 
The noninferiority hypothesis will be declared statistically significant if the 
upper bound of the 2 -sided 95% CI for the adjusted mean diff erence is 
<0.3. The superiority hypothesis will be declared statistically significant at Î± = 0.05 (2- sided).
Analysis of other efficacy endpoints:
The analysis of other endpoints will be descriptive with no formal testing. Summary statistics at scheduled visits using OC will be provided by each treatment group. Graphical presentations will also be used to illustrate 
trends over time.
Analysis of safety data:
All safety summaries will be descriptive; no statistical significance tests will 
be performed on safety data. These analyses will be based on the Safety 
Population, which is defined as all randomized patients who receive at 
least 1 dose of double -blind treatment, regardless of the amount of 
treatment administered. Patients will be analyzed for safety ana lyses 
according to the treatment actually received.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 13 of 298
Amended Clinical Trial Protocol No. 02 11-Ap r-2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 13Analysis of A BPM endpoints:
The analysis of ABPM endpoints will be descriptive with no formal testing. 
Summary statistics at scheduled visits using OC of sufficient quality will be 
provided by each treatm ent group.
DURA TION OF STUDY PERIOD (per 
patient) Up to 34 weeks, including a Screening Phase of up to 2 weeks , a 2-week 
Run-In Phase, a 26 -week double -blind Treatment Period and a 4 -week 
post- treatment Follow -up Period to collect safety information . 
STUDY COMMITTEES Steering Committee: Yes No
Data monitoring committee: Yes No
Clinical Endpoint Committees: Yes No
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 14 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 141 FLOW CHA RTS
1.1 GRA PHICA L STUDY DESIGN
Abbreviations: ABPM = ambulatory blood pressure monitoring; BP = blood pressure; DPP4(i) = d ipeptidyl peptidase 4 inhibitor; HbA1c = hemoglobin A1c; R = randomization; T2D = Type 2 Diabetes ; V = visit; 
W =week .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 15 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 151.2 STUDY FLOW CHA RT
Screening Period Double -blind Treatment Perioda Follow -
upbScreening Run-in
Visit 1 2 3A
ABPM3 
Rando -
mization4 5 6A
ABPM6 7 8A
ABPM8 9
Week Up to -4 -2 -1 0 
Baseline4 8 12 12 18 26 26 30
Day (window [days]) -14 
(Â±3)-7 1 28 
(Â±3)56 
(Â±3)83 
(Â±3) 84 
(Â±3)126 
(Â±5)181 
(Â±5)182 
(Â±5)210 
(Â±5)
Informed consent X
Interactive Response 
Technology (IRT) contactX X X X X X X X X
Inclusion criteria X
Exclusion criteria X X
Demographics X
Medical and surgical history X
Medication history X
Concomitant medication X X X X X X X X X
Body weight, heightc X X X X X X X X X
Vital signsd X X X X X X X X X
Physical examination:
Complete X X
Abbreviatede X X X X X X X
Diet and exercise instruction X X X
Instruction on basic 
genitourinary (GU) hygiene and 
hydrationX X X X X X X
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 16 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 16Screening Period Double -blind Treatment Perioda Follow -
upbScreening Run-in
Visit 1 2 3A
ABPM3 
Rando -
mization4 5 6A
ABPM6 7 8A
ABPM8 9
Week Up to -4 -2 -1 0 
Baseline4 8 12 12 18 26 26 30
Day (window [days]) -14 
(Â±3)-7 1 28 
(Â±3)56 
(Â±3)83 
(Â±3) 84 
(Â±3)126 
(Â±5)181 
(Â±5)182 
(Â±5)210 
(Â±5)
Randomization X
Dispense glucose meter X
Collect glucose meter X
Dispense diary X X X X X X X
Collect/revie w diary X X X X X X X
Instruction on diabetic 
ketoacidosis symptoms and 
glucose testingX X X X X X X
Dispense investigational 
medicinal product (IMP)X X X X X X
IMP accounting and compliance X X X X X X
SMBGf X X X X X X X
12-lead electrocardiogramg X X
MMTT/ Postprandial glucoseh X X
Ambulatory blood pressure 
monitoring (ABPM)iX X X
Central Laboratory testingj
Fasting plasma glucose (FPG)
kX X X X X X X
HbA1c X X X X X
Chemistry X X X X X X
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 17 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 17Screening Period Double -blind Treatment Perioda Follow -
upbScreening Run-in
Visit 1 2 3A
ABPM3 
Rando -
mization4 5 6A
ABPM6 7 8A
ABPM8 9
Week Up to -4 -2 -1 0 
Baseline4 8 12 12 18 26 26 30
Day (window [days]) -14 
(Â±3)-7 1 28 
(Â±3)56 
(Â±3)83 
(Â±3) 84 
(Â±3)126 
(Â±5)181 
(Â±5)182 
(Â±5)210 
(Â±5)
Hematology X X X X X
Fasting lipids X X
Pregnancy test (WOCBP)l X X X X X X X
FSH and/or estradiol as 
neededlX
Sotagliflozin plasma 
concentrationmX X X
Hemodynamic markersn X X X
Urinalysis with microscopyo X X X
Collection of home overnight 
urine fo r albumin, total protein, 
creatinine, calcium, phosphorus, 
magnesium, and glucose ppX X X
Evaluate for glycemic rescue To be assessed and reported throughout the treatment period
Hypoglycemia To be assessed and reported throughout the studys
AEs/SAEs/AESI/EOSIsTo be assessed and rep orted throughout the studys
aIf a patient discontinues treatment with IMP early during the Double -blind Treatment Period, the patient will have a Premature EOT Visit (similar to Visit 8) and a Follow -up Visit 4weeks Â± 5 days after the last dose 
of IMP. In addition, every effort will be made to have the patient return to the site at the time corresponding to their scheduled visits, particularly the Week 26 Visit. If the patient does not agree to a site visit, they 
will be contac ted by telephone to inquire about safety status.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 18 of 298

Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly confidential Page 18bThe Follow -up Visit will take place 4 weeks Â± 5 days after the last dose of IMP. All attempts will be made to contact the patient to inquire about safety status .
cHeight will be measured only at Screening Visit.
dVital sign measurements (sitting blood pressure [BP ]and heart rate ): At theScreening Visit, BP will be measured on both arms to identify and select the appropriate arm for future measurements. Three separate 
seated BP and heart rate measurements shou ld be taken with at least 1 minute between readings, following a 5 -minute rest period and prior to phlebotomy. Assess ment for volume contraction and correct volume 
status ,if indicated ,will be done before randomization.
eThe abbreviated physical exam inatio n should focus on cardiac and respiratory systems, as well as any areas important for assessment of adverse events if necessary.
fThe SMBG is to be performed fasting (before first meal of the day) for at least 3 days in the week prior to each study visit. The SMBG should be performed in case of hypoglycemia symptoms ; any SMBG values 
â‰¤70mg/dL (â‰¤ 3.9mmol/L) should be documented in the diary and collected in the hypoglycemia event case report form ( CRF). The SMBG will be presented as equivalent SMPG .
gThe 12 -lead ECG should be performed after the patient has spent at least 10 minutes in supine position and prior to IMP administration . The ECG results will be evaluated as â€œnormalâ€ or â€œabnormalâ€.
hPlasma p ostprandial glucose will be assessed at Baseline Week 0 and Week 26, 2 hours after consuming a standard mixed liquid breakfast meal via an MMTT .
iVisit for ABPM for asubset of patients (180 patients ) will occur 1 week before the Randomization Visit; patients will return the ABPM device by mail after 24 -hour monito ring is complete. Patients will also have 
additional in-person visits for placement of the ABPM device onthe day before Week 12 and 26 visits. At least 70% recording of the expected BP recording is needed in each 24 -hour period. The measurement will 
be done on the nondominant upper arm .Patients who discontinue the IMP before the visit for ABPM will not continue in the ABPM substudy post-IMP discontinuation. Patients who receive rescue therapy but 
remain on IMP will continue on the ABPM substudy as planned .
jWith the exception of PPG, all laboratory assessments will occur prior to IMP administration on the day of the visit . All visit dates will be scheduled based on the date of randomization with a Â±3- dayvisit window 
allowed during the core treatment perio d, except for Visits 7, 8A, 8, and 9, when a Â±5 days visit window will apply .Laboratory tests are outlined in Table 2.
kThe FPG collection will be performed on the morning of visit.
lSerum pregnancy testing will be performed only at Screening and urine pregnancy testing is performed at subsequent visits . Serum pregnancy test results mus t be reviewed prior to beginning the Run -in Phase for 
allwomen of childbearing potential ( WOCBP, Appendix A). Any positive urine test results must be confirmed based on serum pregnancy test. The Investigator may perform additional te sts at their discretion or as 
required by local regulations. For women of nonreproductive potential ( Appendix A ), follicle -stimulating hormone ( FSH)and/or estradiol levels should be tested if the definition of postmenopausal or prem enopausal 
cannot be satisfied, eg , no medical document of hysterectomy or cessation of m enses <12 months without an alternative medical cause .
mPlasma concentration samples (ie, of sotagliflozin and sotagliflozin -3-O-glucuronide) should be drawn with the other laboratory assessments . However, timing should be carefully recorded ;previous dose should be 
captured in the eCRF .Samples will be collected at pre dose and for Week26 an additional sample will be collected 3 hours postdose.
nHemodynamic markers including PRA, aldosterone, angiotensinogen 1, angiotensinogen 2,andglucagon will be checked to provide better characterization of hemodynamic markers in relation to sotagliflozin 
treatment .
oUrinalysis will include urine dipstick and microscopy. Dipstick will include assessment of specific gravity, pH, protein, blood, ketones , bilirubin, urobilinogen, nitri te, and leukocyte esterase. Microscopy will include , 
butnot be limited to, detection of formed cellular elements, casts, bacteria, yeast, parasites, and crystals in centrifuged urine sediment. In the event of abnormal urinalysis findings suspic ious of urinary tract 
infection (UTI) , urine culture should be performed. Positive urine culture determination will be based upon the criteria of the reporting la boratory. Additionally, urine culture should be performed if at any point the 
Investigator sus pects the presence of a UTI.
pPatients will collect overnight urine on Week 0, 12, and 26 (Visits 3, 6 and 8) . In the night prior to the visits, the urine before sleep will be discarded and the urine during sleep and the first morning urine 
(after getting u p) will be collected. The visits should be rescheduled to allow for urine collection in case a patient missed it. Urinary alb umin, total protein, creatinine, calcium (adjusted for creatinine), phosphorus 
(adjusted for serum phosphorus and creatinine), magn esium (adjusted for serum magnesium and urinary creatinine), and glucose will be assessed.
sAll SAEs, AEs, AESI, and EOSI will be collected starting from signing informed consent and cont inue until the end of the study. All AEs that occur during treatment should be followed until study completion (or unt il 
patients leave the study) or until the event has resolved, the condition has stabilized or the patient is lost to fo llow-up.All patients will have a Follow- up visit 4 weeks Â±5 days after the last dose of IMP to collect 
safety information.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 19 of 298

Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 192 TABLE OF CON TENTS
1 FLOW CHA RTS............................................................................................................................. 14
1.1 GRAPHICAL STUDY DESIGN ...................................................................................................... 14
1.2 STUDY FLOW  CHART .................................................................................................................. 15
2 TABLE OF CONTENTS ................................................................................................................ 19
2.1 LIST OF TABLES ........................................................................................................................... 25
2.2 LIST OF FIGURES ......................................................................................................................... 25
3 LIST OF A BBREVIA TIONS .......................................................................................................... 26
4 INTRODUCTION A ND RATIONA LE............................................................................................. 28
4.1 BACKGROUND: SOTAGLIFLOZIN AND DISEASE ..................................................................... 28
4.2 CLINICAL TRIALS OF SOTAGLIFLOZIN IN HUMANS ................................................................ 29
4.3 RATIONALE FOR SELECTION OF DOSE ................................................................................... 30
4.4 RATIONALE FOR STUDY DESIGN AND CONTROL GROUPS .................................................. 31
4.5 BENEFIT/RISK OF SOTAGLIFLOZIN ........................................................................................... 32
5 STUDY OBJECTIVES ................................................................................................................... 33
5.1 PRIMARY ....................................................................................................................................... 33
5.2 SECONDARY ................................................................................................................................ 33
5.3 OTHER ........................................................................................................................................... 33
5.4 AMBULATORY BLOOD PRESSURE MONITORING SUB STUDY .............................................. 34
6 STUDY DESIGN ............................................................................................................................ 35
6.1 DESCRIPTION OF THE STUDY ................................................................................................... 35
6.1.1 Screening Period ............................................................................................................................ 35
6.1.1.1 Screening Phase ............................................................................................................................ 35
6.1.1.2 Single -blind Placebo Run -in Phase ............................................................................................... 35
6.1.2 Double -blind Treatment Period ...................................................................................................... 36
6.1.3 Ambulator y blood pressure monitoring substudy ........................................................................... 36
6.1.4 Follow -up period ............................................................................................................................. 37
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 20 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 206.2 DURATION OF STUDY PARTICIPATION .................................................................................... 37
6.2.1 Duration of study participation for each patient ............................................................................. 37
6.2.2 Determination of end of clinical trial (all patients) .......................................................................... 37
6.3 INTERIM ANALYSIS ...................................................................................................................... 37
6.4 STUDY COMMITTEES .................................................................................................................. 37
6.4.1 Steering Committee ....................................................................................................................... 37
6.4.2 Data Monitori ng Committee ........................................................................................................... 38
6.4.3 Clinical Endpoint Committee .......................................................................................................... 38
6.4.4 Safety adjudication of events requiring ongoing monitoring .......................................................... 38
7 SELECTION OF PA TIENTS .......................................................................................................... 39
7.1 INCLUSION CRITERIA .................................................................................................................. 39
7.2 EXCLUSION CRITERIA ................................................................................................................ 39
7.2.1 Exclusion criteria related to study methodology ............................................................................ 39
7.2.2 Exclusion criteria related to mandatory background therapies ...................................................... 40
7.2.3 Exclusion criteria related to the current knowledge of sotagliflozin and empagliflozin .................. 41
7.2.4 Additional exclusion criteria during or at the end of screening befor e randomization ................... 42
8 STUDY TREA TMENTS ................................................................................................................. 43
8.1 INVESTIGATIONAL MEDICINAL PRODUCT(S) .......................................................................... 43
8.2 NONINVESTIGATIONAL MEDICINAL PRODUCT(S) .................................................................. 43
8.2.1 Background medications ................................................................................................................ 44
8.2.2 Rescue therapy .............................................................................................................................. 44
8.3 BLINDING PROCEDURES ............................................................................................................ 46
8.3.1 Methods of blinding ........................................................................................................................ 46
8.3.2 Randomization code bre aking during the study ............................................................................. 46
8.4 METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP .............................................. 47
8.5 INVESTIGATIONAL MEDICINAL PRODUCT PACKAGING AND LABELING ............................. 47
8.6 STORAGE CONDITION S AND SHELF LIFE ................................................................................ 48
8.7 RESPONSIBILITIES ...................................................................................................................... 48
8.7.1 Treatment accountability and compliance ...................................................................................... 48
8.7.2 Return and/or destruction of treatments ........................................................................................ 49
8.8 CONCOMITANT MEDICATION ..................................................................................................... 49
8.8.1 Prohibited prior and concomitant medications ............................................................................... 49
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 21 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 218.9 POSTSTUDY TREATMENT .......................................................................................................... 50
9 ASSESSMENT OF INVESTIGA TIONA L MEDICINA L PRODUCT .............................................. 51
9.1 EFFICACY ENDPOINT .................................................................................................................. 51
9.1.1 Primary efficacy  endpoint ............................................................................................................... 51
9.1.2 Secondary efficacy  endpoints ........................................................................................................ 51
9.1.3 Other efficacy  endpoints ................................................................................................................ 51
9.1.4 Assessment methods of efficacy endpoints ................................................................................... 52
9.1.4.1 Hemoglobin A1c ............................................................................................................................. 52
9.1.4.2 Blood pressure ............................................................................................................................... 52
9.1.4.3 Postprandial glucose via M MTT..................................................................................................... 52
9.1.4.4 Fasting plasma glucose ................................................................................................................. 53
9.1.4.5 Body weight .................................................................................................................................... 53
9.1.4.6 Kidney function parameters ........................................................................................................... 53
9.1.4.7 Use of rescue medications for hyperglycemia ............................................................................... 54
9.2 SAFETY ENDPOINTS ................................................................................................................... 54
9.2.1 Assessment methods of safety  endpoints ..................................................................................... 55
9.2.1.1 Adverse events .............................................................................................................................. 55
9.2.1.2 Hypogly cemia................................................................................................................................ .55
9.2.1.3 Laboratory safety variables ............................................................................................................ 55
9.2.1.4 Urinalysis ........................................................................................................................................ 56
9.2.1.5 Vital signs and phy sical examination ............................................................................................. 57
9.2.1.6 Electrocardi ogram variables .......................................................................................................... 58
9.2.1.7 Self-monitored blood glucose ........................................................................................................ 58
9.3 OTHER ENDPOINTS ..................................................................................................................... 59
9.3.1 Pharmacokinetics of sotagliflozin ................................................................................................... 59
9.3.1.1 Sampling time ................................................................................................................................ 59
9.3.1.2 Pharmacokinetics handling procedure ........................................................................................... 59
9.3.1.3 Bioanalytical method ...................................................................................................................... 59
60
60
9.3.3 Hemodynamic markers .................................................................................................................. 60
9.3.4 Ambulator y blood pressure monitoring substudy ........................................................................... 61
61
9.5 APPROPRIATENESS OF MEASUREMENTS .............................................................................. 61
10 STUDY PROCEDURES ................................................................................................................ 63
10.1 VISIT SCHEDULE .......................................................................................................................... 63
10.1.1 Screening Period ............................................................................................................................ 63
10.1.1.1 Screeni ng phase ............................................................................................................................ 63
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 22 of 298

Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 2210.1.1.2 Run-in Phase ................................................................................................................................ .65
10.1.2 Double -blind Randomized Treatment Period (Day 1 to Week26)................................................ 66
10.1.2.1 Visit 3, Randomization, Day 1 (Baseline; W eek0)........................................................................ 66
10.1.2.2 Week4 to W eek18 (Visit 4 to Visit 7)............................................................................................ 68
10.1.2.3 Week26 (Visit 8) -End of Treatment ............................................................................................. 69
10.1.3 Post- treatment Follow -up Period ................................................................................................... 70
10.2 DEFINITION OF SOURCE DATA .................................................................................................. 70
10.2.1 Source data to be found in patientâ€™s file ......................................................................................... 70
10.2.2 Source data verification requirements for screen failures ............................................................. 71
10.3 HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT 
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION ....................................... 71
10.3.1 Temporary  treatment discontinuation with investigational medicinal product(s) ........................... 72
10.3.2 Permanent treatment discontinuation with investigational medicinal product(s) ........................... 72
10.3.3 List of criteria for permanent treatment discontinuation ................................................................ .72
10.3.4 Handling of patients after perma nent treatment discontinuation ................................................... 73
10.3.5 Procedure and consequence for patient withdrawal from study .................................................... 74
10.4 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING .......................... 74
10.4.1 Definitions of adverse events ......................................................................................................... 74
10.4.1.1 Adverse event ................................................................................................................................ 74
10.4.1.2 Serious adverse event ................................................................................................................... 75
10.4.1.3 Adverse event of special interest ................................................................................................... 76
10.4.1.4 Events of special Interest ............................................................................................................... 76
10.4.2 General guidelines for reporting adverse events ........................................................................... 77
10.4.3 Instructions for reporting serious adverse events .......................................................................... 78
10.4.4 Guidelines for reporting adverse events of special interest ........................................................... 78
10.4.5 Guidelines for reporting events of special interest ......................................................................... 79
10.4.6 Guidelines for management of specific laborator y abn ormalities .................................................. 79
10.4.7 Guidelines for reporting product complaints (IMP/NIMP) .............................................................. 79
10.5 OBLIGATIONS OF THE SPONSOR ............................................................................................. 79
10.6 SAFETY INSTRUCTIONS ............................................................................................................. 80
10.6.1 Hypogly cemia ................................................................................................................................ .80
10.7 ADVERSE EVENTS MONITORING .............................................................................................. 82
11 STATISTICA L CONSIDERA TIONS .............................................................................................. 83
11.1 DETERMINATION OF SAMPLE SIZE ........................................................................................... 83
11.2 DISPOSITION OF PATIENTS ....................................................................................................... 83
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 23 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 2311.3 ANALYSIS POPULATIONS ........................................................................................................... 84
11.3.1 Efficacy  populations ....................................................................................................................... 84
11.3.2 Intent â€“to-treat population ............................................................................................................... 84
11.3.3 Safety population ........................................................................................................................... 84
11.4 STATISTICAL METHODS ............................................................................................................. 85
11.4.1 Extent of study treatment exposure and compliance ..................................................................... 85
11.4.1.1 Extent of investigational medicinal product exposur e.................................................................... 85
11.4.1.2 Compliance .................................................................................................................................... 86
11.4.2 Analyses of efficacy  endpoints ....................................................................................................... 86
11.4.2.1 Analysis of primary  efficacy endpoint ............................................................................................. 86
11.4.2.2 Analyses of secondary efficacy endpoints ..................................................................................... 88
11.4.2.3 Analysis of other efficacy  endpoints ............................................................................................... 88
11.4.2.4 Multiplicity considerations .............................................................................................................. 89
11.4.3 Analyses of safety  data .................................................................................................................. 89
11.4.3.1 Analysis of adverse events ............................................................................................................ 90
11.4.3.2 Analyses of hypoglycemia ............................................................................................................. 91
11.4.3.3 Analyses of adverse events of special interest .............................................................................. 91
11.4.3.4 Analyses of events of special interest ............................................................................................ 91
11.4.3.5 Analyses of laborator y variables .................................................................................................... 92
11.4.3.6 Analyses of vital sign variables ...................................................................................................... 92
11.4.3.7 Analysis of 12 -lead electrocardiogram status ................................................................................ 92
11.4.4 Analyses of other endpoints ........................................................................................................... 92
11.4.4.1 Pharmacokinetic ............................................................................................................................. 92
11.4.4.2 Hemodynamic markers .................................................................................................................. 93
11.4.4.3 Ambulatory blood pressure monitoring substudy ........................................................................... 93
11.5 INTERIM ANALYSIS ...................................................................................................................... 93
12 ETHICA L AND REGULA TORY CONSIDERA TIONS ................................................................... 94
12.1 ETHICAL AND REGULATORY STANDARDS .............................................................................. 94
12.2 INFORMED CONSENT ................................................................................................................. 94
12.3 HEALTH AUTHORITIES AND INSTITUTIONAL REVIE W BOARD/INDEPENDENT 
ETHICS COMMITTEE (IRB/IEC) ................................................................................................... 94
13 STUDY MONITORING ................................................................................................................... 96
13.1 RESPONSIBILITIES OF THE INVESTIGATOR ............................................................................ 96
13.2 RESPONSIBILITIES OF THE SPONSOR OR SERVICE PROVIDER ......................................... 96
13.3 SOURCE DOCUMENT REQUIREMENTS .................................................................................... 96
13.4 USE AND COMPLETION OF CASE REPORT FORMS (CRFS) AND ADDITIONAL 
REQUEST ...................................................................................................................................... 97
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 24 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 2413.5 USE OF COMPUTERIZED SYSTEMS .......................................................................................... 97
14 ADDITIONA L REQUIREMENTS ................................................................................................... 98
14.1 CURRICULUM VITAE .................................................................................................................... 98
14.2 RECORD RETENTION IN STUDY SITES .................................................................................... 98
14.3 CONFIDENTIALIT Y....................................................................................................................... 98
14.4 PROPERTY RIGHTS ..................................................................................................................... 99
14.5 DATA PROTECTION ..................................................................................................................... 99
14.6 INSURANCE COMPENSATION .................................................................................................. 100
14.7 SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES ............................... 100
14.8 PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE -OUT OF 
A SITE .......................................................................................................................................... 100
14.8.1 By the Sponsor ............................................................................................................................. 100
14.8.2 By the Investigator ....................................................................................................................... 101
14.9 CLINICAL TRIAL RESULTS ........................................................................................................ 101
14.10 PUBLICATIONS AND COMMUNICATIONS ............................................................................... 101
15 CLINICA LTRIA L PROTOCOL A MENDMENTS ........................................................................ 103
16 BIBLIOGRA PHIC REFERENCES ............................................................................................... 104
17 APPENDICES .............................................................................................................................. 106
APPENDIX A CONTRACEPTIVE GUIDAN CE AND COLLECTION OF PREGNANCY 
INFORMATION ................................................................................................................. 107
APPENDIX B AMBULATORY BLOOD PRESSURE MONITORING SUB STUDY .................................. 110
APPENDIX C TWO-HOUR STANDARDIZED MI XED MEAL .................................................................. 112
APPENDIX D RECOMMENDATIONS ON B ASIC GENITOURINARY H YGIENE, MAINT AINING 
HYDRATION AND RECOGN IZING DIABETIC KETOA CIDOSIS .................................... 114
APPENDIX E MEASUREMENT OF BLOOD PRESSURE AND HEART R ATE...................................... 117
APPENDIX F GENERAL GUIDANCE FOR THE FOLLOW -UP OF LABORATORY 
ABNORMALITIES BY SANOFI ......................................................................................... 118
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 25 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 252.1 LIST OF TA BLES
Table 1 -Summary  of investigational medicinal products during Treatment Period ..................................... 43
Table 2 -Blood safety parameters ................................................................................................................ 56
Table 3 -Sotagliflozin samples identification ................................................................................................ 59
Table 4 -Highly  Effective Contraceptive Methods ...................................................................................... 108
2.2 LIST OF FIGURES
Figure 1 -Hypogly cemia classification in Study EF C14867 .......................................................................... 80
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 26 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 263 LIST OF A BBREVIATIONS
ABPM: ambulatory  blood pressure monitoring
AE: adverse event(s)
AESI : adverse event(s) of special interest
ALT: alanine aminotransferase
ANCOVA: analysis of covariance
AST: aspartate aminotransferase
BMI: body  mass index
BP: blood pressure
CEC: Clinical Endpoint Committee
CI: confidence interval
CRO: contract research organization
CSR: clinical study  report
CV: cardiovascular
DBP: diastolic blood pressure
DILI: drug-induced liver injury
DKA: diabetic ketoacidosis
DMC: Data Monitoring Committee
DNA: deox yribonucleic acid
DPP4(i): dipeptidy l peptidase 4 inhibitor
ECG: electrocardiogram
eCRF: electronic case report form
eGFR: estimated glomerular filtration rate
EOSI : event(s) of special interest
EOT: End of Treatment
FDA: Food and Drug Administration
FPG: fasting plasma glucos e
FSH: follicle -stimulating hormone
GCP: Good Clinical Practice
GI: gastrointestinal
GLP-1: glucagon-like peptide-1
GU: genitourinary
HbA1c: hemoglobin A1C
HLGT: high level group term
HLT: high level term
HR: heart rate
HRT: hormone replacement therap y
IB: Investigatorâ€™s Brochure
ICF: informed consent form
ICH: International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
ID: identification
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 27 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 27IEC: Independent Ethics Committee
IMP: investigational medicinal product
IRB: Institutional Review Board
IRT: Interactive Response Technology
ITT: intent -to-treat
MACE: major adverse cardiovascular event(s)
MI: myocardial infarction
NIMP: noninvestigational medicinal product
OC: observed cases
PCSA: potentially  clinicall y significant abnormalit y
P-gp: P-glycoprotein
PK: pharmacokinetic
PPG: postprandial glucose
PRA: plasma renin activity
PT: preferred term
PYY: peptide YY
SAE: serious adverse event(s)
SAP: statistical analy sis plan
SBP: systolic blood pressure
SC: Steering Committee
SD: standard deviation
SE: standard error
SGL T1: sodium -glucose cotransporter t ype 1
SGL T2: sodium -glucose cotransporter t ype 2
SMBG: self-monitoring of blood glucose
SOC: system organ class
T1D: type 1 diabetes
T2D: type 2 diabetes
TEAE: treatment -emergent adverse event(s)
UACR: urine albumin to creatinine ratio
UGCR: urine glucose to creatinine ratio
UGE: urinary  glucose excretion
ULN: upper limit of normal
US: United States
UTI: urinary  tract infection
WOCBP: women of childbearing potent ial
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 28 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 284 INTRODUCTION AND RA TIONA LE
4.1 BACKGROUND: SOTAGLIFLOZIN AND DISEASE
Sotagliflozin is a dual inhibitor of the sodium -glucose cotransporters T ype 1 and 2 (SGLT- 1 and 
2) being developed for use in T ype 2 diabetes (T2D ), a metabolic disorder characterized b y 
hypergl ycemia that results from a combination of increased insulin resist ance and beta -cell 
dysfunction ( 1). The microvascular complications of diabetes are well known and can result in 
impaired renal function, retinopathy ,and neuropathy . Other comorbidities that are frequently  
associated with diabetes are h ypertensi on, obesit y, and cardiovascular (CV ) disease (2). 
TheCenters for Disease Control and Prevention released a report in 2010 stating that if current 
trends continue , 1 in 3 Americans will have diabetes by  the year 2050 (3). According to the most 
recent International Diabetes Federation Diabetes Atlas, the estimates in 2015 were that 1 in 
11adults have diabetes, which me ans 415 million people and is estimated to be 642 million by  
2040 ( 4).
According to the World Health Organization, there are about 60 million people with diabetes in 
the European Region, or about 10.3% of men and 9.6% of women aged 25 y ears and over (5). 
While these numbers include both people with T2D and T ype 1 diabetes (T1D ), over 90% of 
adults with diabetes have T2D. Diabetes is among the leading causes of death by  disease and is a 
leading cause of heart disease, stroke, blindness, kidney  disease, and amputation (4, 5).
The sodium -glucose cotransporter T ype 1 (SGLT1) is expressed predominantly  in the 
gastrointestinal (GI ) tract; SGL T1 is responsible for the majority  of glucose absorption by  the 
small intestine (6). Inhibition of SGL T1 in the GI tract delay sglucose from being absorbed. 
Additionally , there is accumulating evidence that SGL T1 inhibition stimul ates secretion of 
glucagon-like peptide- 1 (GL P-1) and peptide YY (PYY ),gut hormones that are involved in 
pancreatic beta- cell function and appetite c ontrol, respectivel y. Reduced glucose absorption in the 
proximal intestine leads to more glucose being delivered distally , which allows L  cells in both the 
ileum and the colon to sense glucose and its b yproducts, and as a result, they secrete GLP -1 and 
PYY . Although a complete lack of functional SGLT1 may  be associated with sy mptoms of 
glucose and galactose malabsorption ( 7), pharmacologic inhibition of SGLT1 by sotagliflozin has 
not produced these effects in preclinical models or in patients with T2D. Selective inhibitors of 
the SGL T1 transporter are in earl y stages of development.
Extensive clinical studies conducted for selective sodium -glucose cotransporter type 2 (SGLT2 ) 
inhibitors have established this class as effective agents for the treatment of T2D (8, 9, 10, 11, 12, 
13)and have led to approvals by  the United States ( US)Food and Drug Administration (FDA ) 
and the European Medicines Agency . Studies with sotagliflozin, a potent, dual inhibitor of SGL T2 
and SGL T1, have shown that this agent produces significant glucosuria in preclinical animal 
models, healthy  human volunteers, and patients with T2D. Single -and multiple -dose 
administration of sotagliflozin to healthy  human patients has resulted in dose -dependent increases 
in glucosuria. Multiple -dose (28-day) administration in diabetic patients produced improvements 
in several metabolic parameters, including urinary glucose excretion (UGE ), fasting plasma 
glucose (FPG ), hemoglobin A1c (HbA1c ), GLP -1, and PYY (14). These data suggest that 
sotagliflozin should be of therapeutic benefit to patien tswith T2D.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 29 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 29In Stud y LX4211.1 -202- DM, patients with sy stolic blood pressure (SBP ) â‰¥130 mmHg at Baseline
had reduction in SBP after 12 weeks of treatment with sotagliflozin (15). The reduction noted in
patients with Baseline SBP â‰¥130 mmHg (a target based on guidelines for management of blood 
pressure ( BP)in diabetic patients and used b y several SGLT2 inhibitors) was 1, 3, 10, 16, and 
17mmHg , respectivel y,in placebo, 75 mgonce daily , 200 mg once daily, 400 mgonce daily , and 
200mgtwice daily of sotagliflozin. Similar to other parameters, the sotagliflozin 400- mgdaily  
dose has optimal effect on the SBP reduction.
Empagliflozin is shown to reduce BP and HbA1c. Patients (N = 825) with T2D and mean seated 
SBP of 130 to 159mmHg and diastolic blood pressure (DBP ) of 80 to 99mmHg were 
randomized (doub le-blind) to 10 mgor 25 mgempagliflozin or placebo once dail y for 12 weeks . 
At Week 12, adjusted mean difference versus placebo in change from Baseline in mean 24 -hour
SBP (ambulatory  blood pressure monitoring [ABPM ]) was -3.44 mmHg (95% confidence interval 
[CI]: -4.78, - 2.09) with 10 mgempagliflozin and -4.16 mmHg (95% CI : -5.50, -2.83) with 25 mg
empagliflozin (both p < 0.001). At Week 12, adjusted mean difference versus placebo in change 
from Baseline in mean 24 -hour DBP (ABPM) was -1.36 mmHg (95% CI : -2.15, - 0.56) with 
10mgempagliflozin and -1.72 mmHg (95% CI - 2.51, -0.93) with 25 mgempagliflozin 
(both p <0.001). Changes in office BP were consistent with ABPM. Adjusted mean difference 
versus placebo in change from Baseline toWeek 12 in HbA1c was -0.62% (95% CI : -0.72, - 0.52) 
(-6.8 mmol/mol [95% CI: -7.9, - 5.7]) with 10 mgempagliflozin and -0.65% 
(95% CI: -0.75, - 0.55) ( -7.1mmol/mol [95% CI: -8.2, - 6.0]) with 25 mgempagliflozin (both 
p <0.001) ( 13).
Based on the glucose -lowering and BP -lowering effects of sotagliflozin and empagliflozin, the 
purpose of this trial is to evaluate the effects of sotagliflozin (a SGLT1/2 inhibitor) compared with 
empagliflozin (a SGL T2 inhibito r) and placebo. In addition, patients in this study  will be taking 
concomitant dipeptidy l peptidase 4 inhibitor (DPP4[i] ), which will enable the investigation of the 
increase in medium chain fa tty acid and sodium excretion in patients treated with sotagliflozin 
compared with patients treated with empagliflozin.
4.2 CLINICA L TRI ALS OF SOTA GLIFLOZIN IN HUMA NS
Approximately  840 subjects (698 assigned to sotagliflozin and 229 assigned to placebo) have 
participated in completed clinical studies of sotagliflozin. No significant safety  concerns have 
been identified in the sotagliflozin drug program, and s otagliflozin has been well -tolerated in all 
studies to date. Serious adverse events (SAE s) and discontinuations due to adverse events (AEs) 
have been infrequent and have been balanced between treatment and comparator groups. Reports 
of treatment -emergent AEs (TEAEs ) across all sotagliflozin studies for which data are available 
were generally  balanced between treatment and comparator groups. The most frequentl y reported 
TEAEs ( â‰¥2.0%) were headache, nausea, diarrhea, constipation, dizziness, and upper respiratory  
tract infection, all of which were reported at a greater frequency  with sotagliflozin than with 
placebo. However, most were described as mild to moderate, and most resolved spontaneously  
and without discontinuation of the study  drug.
In completed and ongoing clinical trials, no safet y issues in addition to those alread y descri bed in 
the current Investigator â€™sBrochure (IB ) have been observed. In general, no significant imbalances 
of SAE/AEs between sotagliflozin and comparators were observed in completed studies. 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 30 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 30Cumulat ively , across the completed studies 8 SAEs were reported in 6 patients (4 patients with 
T2D and 2 patients with T1D), all of which were assessed as unrelated to study  drug; those 
reported in 4 patients with T2D who received sotagliflozin included pulmonary embolism, deep 
vein thrombosis, bile duct stone, cholangitis and lower limb fracture, while a my ocardial 
infarction (MI ) was experienced by  a patient receiving placebo. Two SAEs of diabetic 
ketoacido sis (DKA ) were reported in 2 patients with T1D receiving 400 mgonce dail y 
sotagliflozin in the Phase 2 T1D study  LX4211.1 -203- TIDM(16); both SAEs were assessed as 
due to failure of insulin delivery  via insulin pump.
Study  LX4211.1-114- NRM, a drug interaction study  with digoxin, a sensitive P -glycoprotein 
(P-gp) substrate, indicated that sotagliflozin ac ts as a weak P -gp inhibitor . Thus , sotagliflozin 
increases sy stemic exposure of digoxin and other substrates of P -gp(17).
The efficacy  of sotagliflozin has been shown in other studies in T2D patients. Study  
LX4211.1 -202-DM, which was also described in Section 4.1, was a Phase 2, multicenter, 
randomized, double -blind, placebo -controlled , parallel- group stud y evaluating the safet y and 
efficacy  of sotagliflozin in combination with metformin in patients with T2D who had inadequate 
glycemic control on metformin monotherap y (N = 299) ( 15). The primary  objective of this 
dose-ranging stud y was to evaluate the change from B aseline to Week 12 in HbA1c of 4 different 
dosing regimens of sotagliflozin (75 mgonce daily , 200 mgonce daily , 400 mgonce daily , and 
200mgtwice daily  given as tablets) versus placebo in combination with metformin. Prespecified 
secondary  efficacy  endpoints were proportion of subjects achieving an HbA1c value of <7 .0% at 
Week 12, change from Baseline in FPG and 3 -hour oral glucose tolerance test, and changes from 
Baseline in bod y weight, BP , and trigly cerides. Sotagliflozin reduced mean HbA 1c from Baseline
to Week 12 to a statistically  and clinically  significant degree for all four dose regimens compared 
to placebo (p = 0.025, p = 0.018, p <0.001, and p <0.001), respectivel y. The arithmetic mean 
change from Baseline in HbA1c was greatest for the 400 mgonce daily group ( -0.92%), followed 
by the 200 mgtwice daily group ( -0.80%). The least squares ( LS)mean difference from placebo 
was also greatest for the 400 mgonce daily group ( -0.79%; p <0.001), followed b y the 200 mg
twice dail ygroup ( -0.61%; p <0.001). The LS mean differences from placebo were similar for the 
200mgonce daily group ( -0.34%) and the 75 mgonce dail ygroup ( -0.33%) .
More information on the safety of sotagliflozin and on the clinical program can be found in the 
IB.
4.3 RATIONA LE FOR SELECTION OF DOSE
The proposed 400 mgonce daily dosage is based on the results of the Phase 2b study  
LX4211.1 -202- DM(15). In this study ,dosages of 75 mgonce daily, 200 mgonce daily, 200 mg
twice da ily, and 400 mgonce dail ysotagliflozin were tested over a 12- week, double -blind period. 
The 400 mgonce daily dosage was chosen for further evaluation based on its HbA1c lowering 
effect and the overall safety  and tolerabilit y observed at this dose. At 12 weeks, the 400 mgonce 
daily dosage lowered HbA1c by  a mean of 0.92%, while placebo lowered HbA1c b y a mean of 
0.09%. L ower doses were less effective than the 400- mgdose and did not have an y advantages in 
safet y or tolerability. The overall incidence of AEs at the 400mgonce daily dosage was similar to 
placebo. In addition for this active controlled trial, it is appropriate to compare the projected 
maximum dose for sotagliflozin versus the approved maximum dose for the comparator
(empagliflozin) (12).
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 31 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 31In Stud y LX4211. 202, patients with SBP â‰¥130 mmHg at Baseline had a reduction in SBP after 
12weeks of treatment with sotagliflozin ( 15). The reduction noted in patientswith Baseline
SBP â‰¥130 mmHg was 1, 3, 10, 16 ,and 17 mmHg ,respectivel y,in placebo, sotagliflozin 75 mg
once dail y, sotagliflozin 200 mgonce daily, sotagliflozin 400mgonce daily , and sotagliflozin 
200mgtwice daily . Similar to other parameters, the sotagliflozin 400mgdaily  dose has optimal 
effect on the SBP reduction.
From a safet y perspective, sotagliflozin was well tolerated across studies. In healthy subjects,
sotagliflozin was well tolerated following single doses up to 2 000mg, and in mult iple doses up to 
800mgover 10 days. Furthermore, in a thorough QT study , single doses of sotagliflozin (800 mg
and 2000 mg) were well tolerated and did not prolong the QT interval. Additionally , evaluation of 
metabolites in urine and plasma of health y subjects resulted in no safet y concerns following single 
doses of 400 mgsotagliflozin. I npatients with T2D, single doses of 400 mgin combination with 
sitagliptin, and multiple doses up to 400 mgin combination with metformin over 12 weeks were 
also well t olerated. Additional details on these studies are available in the IB.
4.4 RATIONA LE FOR STUDY DESIGN A ND CONTROL GROUPS
This study  is designed to demonstrate the efficacy  in lowering HbA1c, lowering BP and safet y of 
sotagliflozin when used as add- on therapy  inpatients with T2D who have inadequate gl ycemic 
control . Based on the study  design, the protocol stipulates that patients be provided antidiabetic 
agent rescue therap y according to a predefined algorithm. Safet y, tolerability , pharmacokinetic 
(PK),and pharmacod ynamic effects of sotagliflozin are supported b y Phase 1 and Phase 2 studies 
and animal toxicology  data in rats up to 26 weeks and dogs up to 39 weeks as well as 2- year 
carcinogenicit y data in rats.
The study  will be a double -blind design. There will be 3 arms in this study : placebo, 
empagliflozin, and sotagliflozin. The control group will be treated with the maximum tolerated 
dose of empagliflozin (SGL T2 inhibitor) or placebo ,and the double -blind de sign willallow for an 
unbiased assessment of treatment effects and safety data. Bias will be minimized by  randomizing 
the patients to treatment groups; blinding the patients, the Investigators, the Sponsor, and the 
service provider to the treatment alloca tions; and by  adjudicating the endpoints in a blinded 
fashion. A placebo arm was included to support the primary  objective of demonstrating benefit of 
sotagliflozin as add -on therapy  to patients inadequately  controlled on a DPP4(i) with or without 
metformi n.
A parallel -group, randomized ,controlled design was selected because trial participants are 
exposed to a single treatment and assignment to that treatment is based solely  on chance . This 
design is free of the limitations of competing designs such as cro ssover in which there may  be a 
carryover of effect from one treatment to the second treatment . Although this carry over effect can 
be minimized with a washout period, it is possible that some longer -term effects may  persist . 
While the sample size of the par allel-group design is larger to account for more variabilit y when 
participants cannot serve as their own control, the above mentioned limitations of the crossover 
design have led the randomized controlled trial design to be the standard for therapeutic confirmatory  trials for regulatory approval such as this trial.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 32 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 324.5 BENEFIT/RISK OF SOTA GLIFLOZIN
Sotagliflozin is currently  being investigated as an adjunct to diet and exercise to improve 
glycemic control in adults with T2D. The program will also provide effica cy and safet y data for 
sotagliflozin in combination with other antidiabetic medications. The use of sotagliflozin in the 
treatment of T1D is also being studied in a separate development program.
Sotagliflozin may  benefit a wide variet y of diabetic patients based on multiple potential beneficial 
effects of dual SGLT2/SGL T1 inhibition, and its insulin- independent mechanism of action. 
Improvements in HbA1c, FPG, and postprandial glucose (PPG ) were observe d with sotagliflozin 
in multiple studies. As anticipated from the mechanism of action, treatment with sotagliflozin 
resulted in increased UGE (from inhibition of SGLT2) as well as increased incretin levels (from inhibition of SGLT1). In addition, the impro vements in body  weight, BP, and trigl ycerides
observed with sotagliflozin treatment have the potential to benefit patients with diabetes through 
their effects on common diabetic comorbidities.
Overall, sotagliflozin has been well tolerated in all studies t o date, with the majority of events 
assessed as mild to moderate; most of which resolved spontaneousl y. Serious AEs and 
discontinuations due to AEs have been limited and balanced between treatment and comparator 
groups. Based on an evaluation of the cumulative safet y data for the sotagliflozin clinical 
program, genital infections are monitored closely as an important identified risk. However, reports 
of these events have been infrequent and have responded to standard treatment.
The improvement in gly cemic c ontrol, the reductions in weight and BP, and the tolerability  and 
safet y profile of sotagliflozin to date, demonstrate a favorable benefit -risk assessment for 
sotagliflozin.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 33 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 335 STUDY OBJECTIVES
5.1 PRIMA RY
The primary  objective of this study  is to demonstrate the superiorit y of sotagliflozin 400 mg
versus placebo on hemoglobin A1c (HbA1c) reduction at Week 26 in patients with T2D who have 
inadequate gl ycemic control on a DPP4(i) with or without metformin.
5.2 SECONDA RY
The secondary  objectives of this study  areto dem onstrate :
ï‚·Noninferiorit y of sotagliflozin 400 mg versus empagliflozin on HbA1c reduction from 
Baseline at Week 26
ï‚·Superiority  of sotagliflozin 400 mg versus placebo with respect to:
- C hange from Baseline in 2- hour PPG reduction following a mixed meal tolera nce test 
(MMTT) at Week 26
- C hange from Baseline in FPG reduction at Week 26
- C hange from Baseline in Bod y weight reduction at Week 26
- P roportion of patients with HbA1c <6.5% and <7.0% at Week 26
-Change from baseline in sitting SBP reduction at Week 12 in P atients with SBP
â‰¥130 mmHg at Baseline
-Change from baseline in sitting SBP reduction at Week 12 in a llpatients
ï‚·Superiority  of sotagliflozin 400 mg versus empagliflozin with res pect to change from 
baseline in:
-HbA1c reduction at Week 26
- Sitting SBP reduction at Week 12 in patients with SBP â‰¥130 mmHg at Baseline
- S itting SBP reduction at Week 12 in all patients
ï‚·To evaluate the safety  of sotagliflozin 400 mgversus empagliflozin 25 mg, and placebo,
throughout the 26 -week trial .
5.3 OTHER
Other objectives of this study  are:
ï‚·Tocompare sotagliflozin versus empagliflozin and placebo with respect to change from 
Baseline in:
- Estimated glomerular filtration rate (eGFR)
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 34 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 34- Serum creatinine
-Urinary  glucose excretion andurine glucose to creatinine ratio ( UGCR )
-Urine albumin to creatinine (UACR) for all patients and patient swith UACR
>30mg/g at Baseline
- Sitting SBP for patients with Baseline SB P <130 mmHg at Weeks 12 and 26
- Sitting SBP for patients with Baseline SBP â‰¥130 mmHg at Week 26
-Sitting SBP for all patients at Week 26
-Sitting DBP for patients with Baseline SBPâ‰¥130 mmHg at Week s 12 and 26
-Reduction in body  weight by  â‰¥2%, â‰¥5%, and â‰¥10%
ï‚·To compare sotagliflozin versus empagliflozin with respect to change from B aseline in:
- 2- hour PPG reduction following a nMMTT at Week 26
-FPG reduction at Week 26
-Body weight reduction at Week 26
ï‚·Tocompare the use of rescue medications for h yperglycemia in the sotagliflozin and 
empagliflozin treatment groups
ï‚·To assess plasma levels of sotagliflozin and sotagliflozin-3-O- glucuronide in t he 
sotagliflozin treatment arm
ï‚·To compare hemod ynam ic markers ( including plasma renin activit y [PRA ], aldosterone, 
angiotensinogen 1, angiotensinogen 2 and glucagon) in the sotagliflozin and empagliflozin 
treatment groups.
5.4 AMBULATO RY BLOOD PRE SSURE MONITORING SUB STUDY
The objective of the ABPM substudy  is to compare the effect of sotagliflozin ,empagliflozin ,and
placebo in a subset of patients based on:
ï‚·24-hour average SBP and DBP
ï‚·Average adjusted awake time BP as measured b y SBP and DBP with adjustment based on 
actigraph y
ï‚·Average adjusted sleeping time BP as measured by  SBP and DBP with adjustment based 
on actigraph y.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 35 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 356 STUDY DESIGN
6.1 DESCRIPTION OF THE STUDY
This study  is a Phase 3, multicenter and multinational, 2:2:1 randomized, double -blind
(single -blind Run- in Phase ), placebo -and active -controlled, double -dummy, parallel -group study  
that is anticipated to enroll approximatel y 700patients.
The study  comprises a n up to 4-week Screening Period (consisting of a Screening Phase of up to 
2weeks and a 2- week single -blind placebo Run -in Phase ), a 26-week Double -blind Treatment 
Phase ,and a 4 -week post -treatment Follow -up visit. To qualify for randomization, patients must 
demonstrate compliance based upon tablet and capsule count (â‰¥80%) during the Run-in Phase .
The study  design is presented graphically in Section 1.1.
6.1.1 Screening Period
6.1.1.1 Screening Phase
The Screening Phase will last up to 2 weeks . It must be long enough to collect the data required to 
establish whether the patient satisfies the inclusion/exclusion criteria.
Patients with T2D who have inadequate gl ycemic control on DPP4(i) with or without metformin 
for at least 12 weeks prior to Screening are eligible for en rollment in this study .To ensure an 
approximately  equal number of patients have Screening SBP <130 mmHg or SBP â‰¥130 mmHg, 
the number of patients enrolled in each category  will be limited to 60% of all patients 
(â‰¤420 patients).
At the Screening Visit (Visit 1) after signing the informed consent form (ICF ), eligibility  criteria 
will be assessed and Screening assessments will be performed.The Interactive Response Technology  (IRT; either I nteractive Voice Response Sy stem or 
Interactive Web Respons e System) will be contacted at Visit 1 for notification of Screening and 
for patient number allocation.
6.1.1.2 Single -blind Placebo Run -in Phase
The Run-in Phase will last 2 weeks. Patients will be treated in a single- blind manner with placebo 
(identical to sotag liflozin 200 mg and empagliflozin 25 mg in appearance) administered once 
daily  during the Run- in Phase, starting from Visit 2, to assess patientsâ€™ compliance to the study  
medication.During the Run-inPhase , patients will receive a glucose meter and study  diary . Patients will be 
trained to perform blood glucose measurements and complete the stud y diary correctly .  
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 36 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 366.1.2 Double -blind Treatment Period
Eligible patients will be randomized on Day 1 (Visit 3). To qualify  for randomization, patients
must also demonstr ate compliance during the single- blind placebo Run -in Phase based upon tablet 
and capsule count (â‰¥80%) and, as assessed, at the Investigatorâ€™s discretion.
Randomization will be stratified b y:
ï‚·HbA 1c at Screening ( â‰¤8.5%, >8.5%)
ï‚·SBP at Screening (<130 mmHg , â‰¥130 mmHg )
ï‚·Metformin useat Screening (Yes, No).
Following randomization, patients will be treated in a double-blind manner for 26 weeks. 
Approximately  700 patients will be randomly  assigned 2:2:1 to the following 3 treatment groups 
on top of DPP4(i) with or without metformin:
ï‚·Sotagliflozin arm (estimated N = 280) : sotagliflozin 400 mg, given as two (2) 200 mg
tablets and one (1) placebo capsule (identical to empagliflozin capsule), once dail y before 
the first meal of the day
ï‚·Empagliflozin arm (estimated N = 280) : placebo, given as two (2) placebo tablets 
(identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once 
daily  before the first meal of the day
ï‚·Placebo arm(estimated N = 140) : placebo, given as two (2) placebo tablets (iden tical to 
sotagliflozin) and one placebo capsule (identical to empagliflozin) , once daily  before the 
first meal of the day .
The doses of the OADs (DPP4[i] ) and/or metformin should be held constant throughout the entire 
26-week double -blind Treatment Period (ie, not changed except for safet y reasons) , and the dose 
of all antihy pertensive medications should be held constant for t he first 12 weeks except for safety  
reasons.
6.1.3 Ambulatory  blood pressure monitoring substudy
In several preselected study  sites, approx imately  180 patients will participate in a substudy  of 
ABPM to further assess BP changes over time. In sites participating in the ABPM substudy , 
patients must consent to conducting ABPM to participate in this study  until the plan ned number of 
subset patien ts has been reached ( sites will be informed).
Baseline ABPM will be measured starting at an additional study  visit 1week before 
Randomization (Visit 3A). P ostrandomization ABPM will take place at 2 additional in -person 
study  visits 1 day prior to the Week 12 (Visit 6A ) and Week 26 (Visit 8A) visits. The details of 
the ABPM substudy  procedures are provided in Appendix B .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 37 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 376.1.4 Follo w-up period
Following the last dose of the investigational medicinal product ( IMP; either as scheduled or 
prematurel y), a post -treatment Follow -up Visit should be scheduled for all patients 28days
(4weeks ) Â±5days after permanent IMP discontinuation to collect safet y infor mation.
6.2 DURA TION OF STUDY PA RTICIPA TION
6.2.1 Duration of study  participation for each patient
The total duration of the study  for each patient will be up to 34 weeks and will include a 
Screening Phase of up to 2 weeks , a 2 week Run- in Phase, a 26-week double -blind Treatment 
Period, and a 4-week Follow -upPeriod after completion of study  treatment.
6.2.2 Determination of end of clinical trial (all patients)
The end of the stud y is defined as being the â€œlast patient last visitâ€ planned with the protocol, 
including the Follow -up Visit .
The Sponsor can terminate the trial prematurel y based on the advice of the i ndependent data 
monitoring committee (DMC ) (Section 6.4.2) or other unforeseen developments.
6.3 INTERIM A NALYSIS
No interim anal ysis is planned.
6.4 STUDY COMMITTEES
6.4.1 Steering Committee
The Steering Committee (SC ) will be composed of experts in diabe tes and scientists with clinical 
and methodological expertise.
This Committee, led by  a Chair, will be responsible for producing and conducting a scientificall y 
sound study  and for ensuring accurate reporting of the study. In that capacity , the SC will nee d to
address and resolve scientific issues encountered during the study . The members will remain 
blinded until completion of the study .
Among its responsibilities, the SC will receive blinded study  status reports from Sponsor, and will 
review the recommend ations from the DMC throughout the stud y. The SC members will 
participate in face -to-face meetings at regular intervals throughout the study  and in regularl y 
scheduled teleconferences.
Details of the activities and responsibilities of the SC are provided in a separate SC Charter.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 38 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 386.4.2 Data Monitoring Committee
A DMC with members who are independent from the Sponsor and the Investigators will meet on 
a regular basis and will be responsible for:
ï‚·Review of accumulating clinical study  safet y data by  treatment
ï‚·Make a recommendation to the Sponsor regarding the study  following each meeting.
Safet y data to be reviewed will be unblinded and include events and outcomes described in 
Section 6.4.3 for adjudicat ion, as well as an y additional safety data considered relevant. To 
maintain continuous blinding and stud y integrit y, the anal ysis will be conducted by  an 
independent statistician and measures will be taken to ensure the validit y of the data.
Details of theDMC processes and procedures are outlined in a separate DMC Charter.
6.4.3 Clinical Endpoint Committee
The Clinical Endpoint Committees ( CEC s) are comprised of experts in cardiology  and nephrology  
(and other appropriate medical specialties such as neurology  and endocrinology  as needed) who 
are independent of the Sponsor and the contract research organization (CRO ). The CECs will 
review a nd adjudicate all deaths, major adverse cardiovascular events (MACE )/selected CV 
events (MI, stroke, unstable angina leading to hospitalization, and heart failure leading to hospital ization), selected renal events, bone fracture ,and DKA.
The details regarding the CEC processes and procedures will be outlined in the CEC Charter(s).
6.4.4 Safety  adjudication of events requiring ongoing monitoring
Two independent committees will review safet yevents that require ongoing monitoring to ensure 
timing protocol amendments in case a safety signal is identified. These events are: 1) potential cases of drug-induced liver injury  (DILI ), and 2) cases of amputations.
The two committees will review the cases in a treatment- blinded manner and will present their 
assessment to the DMC.
The members, roles and responsibilities of the two committees will be described in separate 
Charters.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 39 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 397 SELECTION OF PATIENTS
Note: A patient must not be randomized more than once. In cases where original screen failure 
was due to reasons expected to change at rescreening and based upon the Investigatorâ€™s clinical 
judgment, the patient can be rescreened once prior to entering Run- in for this study .
For stud y sites participating in the ABPM substudy, patients must also consent tothe ABPM to 
participate in this study  until the planned the number of participants has been reached.
7.1 INCLUSION CRITERIA
I 01. Patients with Ty pe 2 Dia betes on DPP4(i) with or without metformin at a stable dose for at 
least 12 weeks prior to Screening Visit . Metformin dose will be â‰¥1500 mgper day  
(ormaximum tolerated dose [documented]). DPP4(i) dose must be the appr opriate dose per 
local label.
I 02. Signed written informed consent.
7.2 EXCLUSION CRITERIA
Patients who have met all the inclusion criteria listed in Section 7.1 will be screened for exclusion 
criteria .
7.2.1 Exclusion criteria related to study  methodology
E 01. At the time of Screening age <18 years or less than legal age of majority , whichever is 
great er
E 02. Body mass index (BMI ) â‰¤20kg/m2or >45 kg/m2at Screening
E 03. Use of s ystemic glucocorticoids (excluding topical ,ophthalmic, nasal spray  or inhaled 
applications) for more than 10 consecutive dayswithin 90 daysprior to the Screening Visit
E 04. Use of weight loss medications or weigh t change of 5 kgor more during the 12 weeks
before Screening
E 05. Likelihood of requiring treatment during the study  period with drugs not permitted by  the 
study  protocol (eg, long -term sy stemic glucocorticoids) and refusing to or unable to take 
alternative treatment
E 06. Patients who have previously  participated in an y clinica l trial of sotagliflozin/L X4211
E 07. Patients with severe anemia, severe CV (including congestive heart failure New York 
Heart Association IV), respiratory, hepatic, neurological, psy chiatric, or a ctive malignant 
tumor or other major s ystemic disease or patients with short life expectancy  that, according 
to the Investigator, will preclude their safe participation in this study , or will make 
implementation of the protocol or interpretation of th e study  results difficult
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 40 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 40E 08. Known presence of factors that interfere with the central laboratory HbA1c measurement 
(eg, genetic Hb variants), compromising the reliability  of HbA1c assessment ,or medical 
conditions that affect interpretation of HbA1c results (eg, blood transfusion or severe blood 
loss in the last 3 months prior to Randomization Visit , any  condition that shortens 
erythrocy te survival )
E 09. History  ofdrug or alcohol abuse within 6 months prior to Screening
E 10. Patient is an employ ee of the Sponsor, or is the Investigator or an y Sub -investigator, 
research assistant, pharmacist, study  coordinator, other staff or relative thereof directly  
involved in conducting the study
E 11. At the sites with participating ABPM patients, patients work night (third) shift (defined as
11:00 PM [23 :00] to 7 :00AM [07 :00])
E 12. Patient hasan upper arm circumference <24 cm or >42 cm
E 13. Patients unwilling or unable to perform self- monitoring of blood glucose (SMBG ),
complete the p atient diary , or comply  with study  visits and other study  procedures as 
required per protocol.
7.2.2 Exclusion criteria related to mandatory  background therapies
E 14. Type 1 diabetes mellitus
E 15. HbA1c <7 .0% or > 11.0% at Screening Visit (central laboratory )
E 16. FPG >270 mg/dL (>15 .0mmol/L) measured b y the central laboratory  at Screening 
(Visit 1), and confirmed by  a repeat test (>270 mg/dL  [>15.0mmol/L ]) before 
Randomization Visit
E 17. Use of an y antidiabetic drug other than DPP4(i) and metformin within 12 weeks preceding 
the Sc reening Visit
E 18. Previous use of an y types of insulin for >1 month (except for treatment of gestational 
diabetes)
E 19. History  of DKA or nonketotic hy perosmolar coma within 12 weeks prior to the Screening 
Visit
E 20. Use of a selective SGLT2 inhibitor (eg, canagliflozin, dapagliflozin, or empagliflozin) 
within 3months prior to Screening Visit
E 21. Patient who has taken other investigational drugs or prohibited therap y for this study  
within 12 weeks or 5 half -lives from prior to Screening, whichever is longer
E 22. Patients with contraindication to metformin as per local labeling.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 41 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 417.2.3 Exclusion criteria related to the current kno wledge of sotagliflozin and 
empagliflozin
E 23. Patients with contraindication to empagliflozin as per local labeling.
E 24. Pregnant (confirmed b y serum pregnancy  test at Screening) or breast -feeding women.
E 25. Women of childbearing potential (WOCBP )not willing to use highl y effect ive method(s) 
of birth control during the study  treatment period and follow -up period, or who are 
unwilling or unable to be tested for pregnancy  (see Appendix A ), during the study .
E 26. Mean of 3 separate BP measurements >180 mmHg (SBP) or >100 mmHg (DBP).
E 27. History  of hypertensive crisis resulting in emergency  medical care within 12 weeks prior to 
Screening Visit .
E 28. History  of gastric surgery  including history  of gastric banding or inflammatory  bowel 
disease within 3 years prior to the Screening Visit .
E 29. Known allergies, h ypersensitivity , or intolera nce to SGL T2 inhibitor or an y inactive 
component or placebo (ie, microcrystalline cellulose, croscarmellose sodium [disintegrant], 
talc, silicone dioxide, and magnesium stearate [nonbovine]), or intolerance of 
empagliflozin unless the reaction is deemed ir relevant to the study  by the Investigator.
E 30. Laboratory  findings with the central laboratory  tests at Visit 1
-Alanine aminotransferase (ALT ) or aspartate aminotransferase (AST) >3 times the 
upper limit of the normal laboratory  range ( x ULN )
- Total bilirubin >1.5 x ULN (except in case of Gilbertâ€™s s yndrome)
- Neutrophils <1500/mm3(or ac cording to ethnic group) and/or platelets <100 000/mm3
-Amy lase and/or lipase >3 x ULN
- P atients with renal impairment as defined by  the eGFR criterion that precludes
initiation of empagliflozin as per t he approved local label (eg, <45 mL/min/1.73 m2in 
US; <60mL/min/1.73 m2in EU) .
E 31. Secondary  hypertension of any  etiology  (eg, renovascular disease, pheoch romocy toma, 
Cushing's s yndrome)
E 32. Forpatients on hy pertensive medications, the antihy pertensive has changed in the 8 weeks
prior to Screening (new drug or new dose).
E 33. Current diagnosis of chronic hepatitis, and/or other clinically  active liver disease requiring 
treatment.
E 34. Any country -related specific regulation that would prevent the patient from entering the 
study (eg, individuals committed to an institution by virtue of an order issued either by  the 
judicial or the admini strative authorities) .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 42 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 427.2.4 Additional exclusion criteria during or at the end of screening before randomization
E 35. Patients insufficiently  compliant during Run-in Phase . Noncompliance will be based on
tablet and capsule count (<80%) or based on the opinion of the I nvestigato r
E 36. Patient withdraws i nformed consent before randomization (patient who is not willing to 
continue) or patient fails to return
E 37. Any clinically  significant abnormality identified on ph ysical examination, laboratory  tests, 
electrocardiogram ( ECG ) , or vital signs at the time of Screening Period or any  AE during 
Screening Period which, in the judgment of the investigator or an y Sub -investigator, would 
preclude safe completion of the study  or constrains efficacy  assessment
E 38. Lower extremity  complications (such as skin ulcers, infection, osteomy elitis and gangrene) 
identified during the Screening period, and still requiring treatment at Random ization.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 43 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 438 STUDY TREA TMENTS
8.1 INVESTIGA TIONA L MEDICINA L PRODUCT(S)
The IMPs are sotagliflozin 400 mg, empagliflozin 25 mg, and matching placebo. Patients will be 
provided with kits containing wallets of sotagliflozin or empagliflozin, or their 
sotagliflozin- matching placebo ( supplied as tablets identical to sotagliflozin 200 mg tablets in 
appearance) or empagliflozin -matched placebo ( supplied as capsules identical to empagliflozin 
25 mg capsules in appearance). Each patient will be supplied with the appropriate number o fkits, 
on a schedule according to the dispensing scheme indicated in the study  flow chart 
(See Section 1.2).
Table 1provides a summary  of the IMP (dose and timing).
Table 1 -Summary of investigational medicinal products during Treatment Period
Treatment group Sotagliflozin 400 mggroup Empagliflozin 25 mggroup Placebo group
Name of IMP Sotagliflozin (SAR439954) Empa gliflozin Placebo
Pharmaceutical form Sotagliflozin (SAR439954) 
will be supplied as 200 mg
tabletsEmpagliflozin will be supplied as 25 mgcapsulesPlacebo will be supplied as tablets (identical to 
sotagliflozin in appearance)
and capsules (identical to empagliflozin in 
appearance)
Dose, timing, and route of 
administrationTwo 200- mgtablets, taken 
orally once daily, before first 
meal of the day
One placebo capsuleOne 25 mgcapsule, taken 
orally once daily, before first 
meal of the day
Two placebo tablet sTwo placebo tablets and 
one placebo capsule , taken 
orally once daily, before 
first meal of the day 
Duration of treatment 26-week double -blind 
Treatment Period following randomization26-week double -blind 
Treatment Period following randomization2weeks Run-in and 
26weeks following 
randomization
Storage conditions Store between +15Â°C and +30Â°C (59Â°F and 86Â°F)
IMP = investigational medicinal product
No dose reductions a re planned.
8.2 NONINVESTIGA TIONAL MEDICINA L PRODUCT(S)
Noninvestigational medicinal pr oduct (NIMP ) treatment is defined as the rescue medication(s) 
that will be used to treat hy pergl ycemia when a patientâ€™s hypergl ycemia reaches the rescue 
threshold. I t also includes th e background medications DPP4(i) and metformin.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 44 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 448.2.1 Background medications
Patients will be enrolled with a background therapy consisting of their existing DPP4(i) treatment 
and metformin treatment (for patients on metformin at Screen ing). Background metformin and 
DPP4(i) are considered to be NIMPs.
Metformin (commercial formulation) will be administered orally according to the I nvestigatorâ€™s 
recommendation and the locally  approved label. The metformin dose must be â‰¥1500 mgper day  
(or maximum tolerated dose [documented]). The dose of metformin must be stable for at least 
12 weeks before Screening. The metformin dose should remain unchanged during the 26-week 
treatment period unless down-titration or discontinuat ion is required for safety  reasons , or the 
patient â€™srequirement for rescue medication .
TheDPP4(i) will be administered orall y at the appropriate dose per local label. The dose of 
DPP4(i) must be stable for at least 12 weeks before the Screening Visit and should r emain 
unchanged during the 26-week treatment period unless as needed for safet y reason s, or the 
patient â€™srequirement for rescue medication .
Metformin and DPP4(i) treatment will be reported in the electronic case report form ( eCRF ).This 
information should include specific drug name, dose, route of administration, and frequency .
The cost of the background treatment metformin and DPP4(i) not covered by health insurance will 
be reimburse d where permitted by  local regulations.
Rescue therapies (see Section 8.2.2) will also be considered as NIMPs.
8.2.2 Rescue therapy
The threshold values for rescue are defined as follows, depending on the study  period:
ï‚·From Baseline Visit (Visit 3, Day 1) to Visit 5 (Week 8) (including value at Visit 5): 
FPG >270 mg/dL (>15.0 mmol/L )
ï‚·From Visit 5 (Week 8) to Visit 6 (Week 12) (including value at Visit 6): FPG >240 mg/dL 
(>13.3 mmol/L )
ï‚·From Visit 6 (W eek12) up to the end of the treatment period Visit 8 (Week 26): FPG 
>200 mg/d L (>11.1 mmol/L ) or HbA1c â‰¥8.5%. 
Note: The 8.5% criteri ondoes not apply  if the HbA1c decrease from Baseline was 
â‰¥1.0%) .
Routine fasting SMBG and central laboratory alerts on FPG (and HbA1c after Week 12 and 
onwards) are set up to ensure that gly cemic parameter re sults remai n within predefined thresholds.
ï‚·If one fasting SMBG value exceeds the specific gly cemic limit on 1 day , the patient will 
check it again during the 2 following days. If all the values in 3 consecutive daysexceed 
the specific limit, the patient s hould contact the Investigator and a central laboratory  FPG 
measurement (and HbA1c after Week 12 and onwards) will be performed as soon as 
possible, preferabl y within 7 daysto confirm the hy pergly cemia.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 45 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 45ï‚·Upon receipt of a central laboratory  rescue alert a central laboratory  retestmust be 
completed and confirmed as exceeding the criterion for rescue before rescue therap y is 
initiated. The retest confirmation should be performed as soon as possible, but within 
7daysof receipt by  unscheduled visit.
In the e vent that a confirmatory  FPG and/or HbA1c exceed the threshold, the Investigator should 
ensure that no reasonable explanation exists for insufficient glucose control and in particular that:
ï‚·The increased FPG has been tested at a fasting status (ie, no food and drink [with the 
exception of water] intake for â‰¥8 hours )
ï‚·IMP is given at the planned dose
ï‚·There is no intercurrent disease, which may  jeopardize gly cemic control (eg, infectious 
disease)
ï‚·Compliance to treatment is appropriate
ï‚·Compliance to diet and li festy le is appropriate.
If any of the above can reasonabl y explain insufficient gl ycemic control, the I nvestigator should 
consider not initiating rescue medication and should undertake appropriate action, ie:
ï‚·Assess plasma glucose in fasting condition (ie, after at least 8- hours fast)
ï‚·Initiate an evaluation and treatment of intercurrent disease (to be reported in 
AE/concomitant medication parts of the eCRF and the medical record)
ï‚·Stress the absolute need to be compliant with treatment
ï‚·Organize a specific in terview with the patient and a Registered Dietician or other qualified 
nutrition professional and to reinforce on the absolute need to be compliant to diet and 
lifesty le recommendations, and schedule a FPG/HbA1c a ssessment at the next visit 
(incase the ne xt visit is a phone call, it should be replaced by  an on -site visit).
If none of the above mentioned reasons can be found, or if appropriate action fails to decrease 
FPG/HbA1c under the threshold values, rescue medication may  be introduced:
ï‚·Sulfony lurea ( eg, glimepiride) should be added first, unless there is a contraindication to 
sulfony lurea treatment per label. In case of contraindication to sulfony lurea, another 
rescue medication (oral or injectable) can be added at the Investigatorâ€™s decision except 
for SGLT2 inhibitors
ï‚·The patient continues the study  treatment (blinded) and stay s in the study  to collect 
efficacy  and safet y information. The planned visits and assessments should occur until the 
last scheduled visit
ï‚·Rescue therap y is considered a NIMP. Re scue the rapy is to be reported in the e CRF. This 
information should include specific drug name, dose, route of administration, and 
frequency .
If not covered by health insurance, the cost of rescue therap y will be reimbursed where permitted 
by local regulations.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 46 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 468.3 BLINDING PROCEDURES
8.3.1 Methods of blinding
To maintain blinding sotagliflozin, empagliflozin, and their matching placebo tablets (including 
packaging) will be blinded and indistinguishable.
During the double -blind treatment period, each treatment packag e will be labeled with a number, 
which is generated b y a computer program from Sanofi . Investigators will not have access to the 
randomization (treatment) code except under circumstances described in Section 8.3.2.
The randomization and the treatment allocation will be performed centrally by  an IRT. The stud y 
biostatistician provides the randomization scheme to the I RT. Then, the IRT generates the patient 
randomization list from which it alloca tes treatment arms to the patient s.
To prevent partial unblinding, results of laboratory assessments of HbA1c, FPG, PPG ,UGE , and 
UGCR will be masked to study  centers and patient safter randomization and until study  end. 
Additionally  urinal ysis by  dipstick will not include the measurement of urine glucose. Urine 
glucose, albumin, calcium, and creatinine will be measured separately at Visit 3, 6, and 8by the 
central laboratory .
The CEC members will perform adjudication in a blinded manner.
8.3.2 Randomization cod e breaking during the study
In case of an AE, the randomization code should only  be broken in circumstances when 
knowledge of the IMP is required for treating the patient.
Code breaking can be performed at an y time b y using the proper module of the I RT and /or b y 
calling an y other phone number provided b y the Sponsor for that purpose. Code breaking can be 
performed b y a local study Investigator, sponsor phy sician, or healthcare professional with direct 
responsibility  for patient care. If the blind is broken, the Investigator should document the date, 
time of day  and reason for code breaking. The identity  of the unblinded personnel, how the code 
was broken, and the treatment kit number should also be recorded. The Sponsor should also be 
informed. If the code i s broken by  the Investigator (or other medical doctor in emergency  
situation); the patient must be withdrawn from IMP administration.
Randomization code breaking will also be performed during the analy sis of the Pharmacokinetic
plasma concentration samples . Only  the Project manager and lead scientist at the Bioanal ytical 
laboratory  will have access to the randomization code to allow for the sorting of the sotagliflozin 
plasma samples. The Bioanal ytical lab oratory and responsible personnel will follow standa rd 
operating procedures to ensure the protection of the blind within the Sponsorâ€™s clinical team. The randomization code or the individual anal ytical results will not be disclosed to any  clinical team 
personnel prior to the database lock.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 47 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 488.6 STORA GECONDITIONS A ND SHELF LIFE
Investigators or other authorized persons (eg, pharmacists) are responsible for storing the IMP in a 
secure and safe place in accordance with local regulations, labeling specifications, policies, and 
procedures.
Control of I MP st orage conditions, especially  control of temperature and instructions for handling 
the compounds should be managed according to the rules provided b y the Sponsor.
The expiry  date and storage conditions are written on the I MP labels. The IMP s should be stored 
between +15ÂºC and +30ÂºC (59ÂºF and 86ÂºF).
8.7 RESPONSIBILITIES
The Investigator, the hospital pharmacist, or other personnel allowed to store and dispense the 
IMP will be responsible for ensuring that the IMP used in the clinical trial is securel y maintained 
as specified b y the Sponsor and in accordance with applicable regulatory  requirements.
All IMP will be dispensed in accordance with the Investigator's prescription and it is the 
Investigator's responsibility  to ensure that an accurate record of IMP issued and returned is 
maintained.
Any quality  issue noticed with the receipt or use of an IMP ( deficiency  in condition, appearance, 
pertaining documentation, labeling, expiration date, etc.) must be promptly  notified to the 
Sponsor. Some deficiencies may  be reco rded through a complaint procedure.
A potential defect in the quality  of IMP may be subject to initiation of a recall procedure by  the 
Sponsor. In this case, the I nvestigator will be responsible for promptly  addressing any  request 
made b y the Sponsor, to r ecall the IMP and eliminate potential hazards.
Under no circumstances will the I nvestigator supply  IMP to a third part y allow the IMP to be used 
other than as directed b y this clinical trial protocol, or dispose of IMP in any  other manner.
8.7.1 Treatment accoun tability  and compliance
Accounting and compliance for IMPs will be performed at Visit 3 (Treatment Day 1) and all 
subsequent on -treatment visits.
The Investigator will check the compliance to the study  treatments based on the patient diary  and 
will complete the appropriate site treatment and patient treatment log forms. Returned IMP should 
be counted b y site staff. In addition, the dosing information will be recorded on the appropriate 
pages of the eCRF.
Rescue therap y (Section8.2.2) is to be reported in the eCRF. This information should include 
specific drug name, dose, route of administration, and frequency .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 49 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 49If compliance is inadequate as determined b y the Investigator, patients will be trained again and 
mentored. If suboptimal compliance continues after training and mentoring, patients may be 
discontinued at the discretion of the I nvestigator after discussion with the Sponsorâ€™s/CROâ€™s 
medical monitor.
8.7.2 Return and/or destruction of treatments
Patients are to return all IMP (unused, in- use,or empty  wallet[s]) at each on- site visit, or at on- site 
visits after premature treatment discontinuation, as described in Section 1.2.
Patients a re to return all the used, in -use and unused IMP at Visit 8(or final assessment 
on-treatment visit in case of permanent premature discontinuation).
All used, partially  used or unused IMPs will be retrieved b y the Sponsor or delegate. A detailed 
sitelogand patient treatment log of the returned IMP will be established with the I nvestigator 
(orthe pharmacist) and countersigned by  the Investigator and the monitoring team.
For NIMP not provided by the Sponsor (ie, rescue therap y), tracking and reconciliation is to be 
undertaken b y the Investigator (or pharmacist if appropriate) according to the system proposed b y 
the CRO.
8.8 CONCOMITA NT MEDICATION
A concomitant medication is any  treatment received by  the patient concomitantly  to an y IMP. 
TheIMP includes sotagli flozin 400 mg, empagliflozin 25 mg, and placebo.
All concomitant medications should be documented on the Medications pages of the eCRF. This 
includes all NIMP treatments that are taken b y the patient sat an y time during the clinical study, 
beginning at Vis it1.
Additionally , all medications taken in the 3 months prior to Visit 1 and any  prior use of SGLT2
inhibitor should be reported.
8.8.1 Prohibited prior and concomitant medications
During the study  treatment period, the following medications are prohibited:
ï‚·Initiation of any  antidiabetic agents, including oral or injectable antihy pergly cemic agents 
other than the IMP is not allowed before the rescue therap y. The existing background 
medication (NIMP) should not be modified before the rescue
Note :Short term use (<10 consecutive days) of the prohibited medication, eg, short- acting insulin 
for treatment of acute illness or surgery ,is allowed
ï‚·Systemic use of glucocorticoids is not allowed for more than 10 consecutive dayswithin 
90daysprior to the Screening Visit .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 50 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 50Note : Topical, ophthalmic, nasal spray ,or inhaled applications are allowed.
ï‚·SGL T2 inhibitors (eg, canagliflozin, dapagliflozin) are not allowed for rescue or post -IMP 
treatment until the planned end of the stud y (Visit 9, Week 30)
ï‚·Modification of antih ypertensive medication before Week 12 is not al lowed unless for 
safety reasons
ï‚·Use of investigational medication in any  other clinical study
ï‚·Initiation of an y weight loss dr ugs (eg, phentermine, orlistat)
ï‚·Patients taking sotagliflozin with concomitant digo xin should have digoxin concentrations 
monitored and doses reduced as needed. In addition, other P -gp substrates may  be affected 
and the labels of P -gp substrate drugs should be consulted with regards to monitoring and 
dose adjustments.
Other medications w hich are unlikel y to interfere with the PKs or pharmacody namics of the IMP 
or confound interpretation of the study  endpoints are allowed as needed, following discussion 
between the Investigator and the Sponsor/CRO . However, doses of chronically  administere d 
medicines should be kept fixed during the trial if at all possible.
The dose of all antihy pertensive agents should be kept constant during the 12 weeks following 
randomization and no antihy pertensive agents should be added or withdrawn for the 12 weeks
following randomization unless it is considered necessary  for safet y reasons.
8.9 POSTSTUDY TREA TMENT
Because sotagliflozin may reduce BP, adjustment of antihy pertensive medication may  be needed 
during the stud y inpatients with hy pertension. Conversel y, monito ring for an increase in BP 
should be performed after withdrawal of study  medication. If the BP is elevated after withdrawal 
of study  treatment, the Investigator should consider adding or adjusting antihy pertensive 
medication.Sotagliflozin will not be prov ided after End of Treatment ( EOT) . Patientâ€™s further treatment, for 
diabetes and other pathologies , will be at the Investigatorâ€™s discretion based on his/her clinical 
judgment .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 51 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 519 ASSESSMENT OF INVESTIGA TION AL M EDICINA L PRODUCT
9.1 EFFICA CYENDPOINT
The methods of assessment of efficacy  endpoints are detailed in Section 9.1.4.
9.1.1 Primary  efficacy  endpoint
The primary  efficacy  endpoint is the change from Baseline to Week 26 in HbA1c .
9.1.2 Secondary  efficacy  endpoints
The secon dary efficacy  endpoints are:
ï‚·Change from Baseline to Week 26 in 2- hour PPG following a nMMTT
ï‚·Change from Baseline to Week 26 in FPG
ï‚·Change from Baseline to Week 26 in body  weight
ï‚·Proporti on of patients with HbA1c <6.5%, <7.0% at Week 26(HbA1c responders)
ï‚·Change from Baseline to Week 12 in sitting SBP in patients with SBP â‰¥130 mmHg at 
Baseline
ï‚·Change from Baseline to Week 12 in sitting SBP in all patients.
9.1.3 Other efficacy  endpoints
Other ef ficacy  endpoints include :
ï‚·Change from Baseline in:
-eGFR
- Serum creatinine
-UGE and UGCR
-UACR for all patients and patients with UACR >30mg/g
-Sitting SBP for patients with Baseline SB P <130 mmHg at Weeks 12 and 26
-Sitting SBP for patients with Baseline SBP â‰¥130 mmHg at Week 26
-Sitting SBP for all patients at Week 26
-Sitting DBP for patients with Baseline SBP â‰¥130 mmHg at Weeks 12 and 26
- R eduction in body  weight â‰¥2%, â‰¥5%, and â‰¥10% .
ï‚·Use of rescue medications for hy pergl ycemia in the sotagliflozin and empagliflo zin 
treatment groups
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 52 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 52ï‚·Plasma concentration of sotagliflozin and sotagliflozin-3-O- glucuronide for patients 
receiving sotagliflozin
ï‚·Hemody namic markers ( including plasma renin activity  [PRA ], aldosterone, 
angiotensinogen 1, angiotensinogen 2 and glucagon) .
9.1.4 Assessment methods of efficacy  endpoints
9.1.4.1 Hemoglobin A1c
Hemoglobin A1c will be assessed at Screening ( Visit 1), Baseline ( Visit 3), Week 8 (Visit 5), 
Week 12 (Visit 6), and Week 26 (Visit 8), measured b y a certified Level I â€œNational 
Glycohemoglobin Standar dization Programâ€ central laboratory .
9.1.4.2 Blood pressure
Blood pressure is measured as part of the vital signs assessment that is performed at allstudy  
visits, except for ABPM substudy  visits, for both safet y and efficacy endpoints. At Screen ing, BP
will be m easured on both arms to identify  and select the appropriate arm for future measurements. 
Full details and directions for the measurement of BP and heart rate (HR )arepresented in 
Appendix E . The investigator will assess for volume contraction and correct volume status if 
indicated before randomization.
9.1.4.3 Postprandial glucose via MMTT
Postprandial glucose will be assessed at Baseline ( Visit 3, Week 0) and at Visit 8 (Wee k26) via 
MMTT toallow estimation of change from Baseline to Week 26 in 2- hour PPG following a mixed 
meal. For the efficacy  assessments of the study , PPG will be measured at a central laboratory .Full 
details of the MMTT procedure at Baseline and Week 26 are presented in Appendix C . At 
Baseline (Visit 3) and Visit 8 (Week 26), PPG will be assessed b y MMTT at Baseline (fasting) 
and 2 hours after consuming a standard mixed liquid breakfast meal.
The first dose of double -blind I MP (and dosing with DPP4[i] and metformin, if applicable) on 
Day 1 (Visit 3) will be given after collection of the 2- hour PPG sample is completed.
For the Week 26 (Visit 8) standardized MMTT, the patient should take the dose of double -blind 
IMP immediatel y after the fasting blood samples are obtained, and approximately 30 minutes 
before ingestion of the standardized mixed meal begins. At Week 26, DPP4(i) and metformin (if 
applicable) dosing will occur after collection of the 2 -hour PPG sample and 3 -hour PK sample is 
completed .
Plasma concentration samples at Week 26 (Visit 8) should be taken at the same time as the fasting 
blood sample and 3 hours postdose (30minutes after the 2- hour PPG sample collection; 
seeSection 9.3.1.1).
The composition and the quantity  of the standard mixed liquid breakfast meal must be identical 
throughout the stud y; see Appendix C for further details. In some s tudy sites ,for which the 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 53 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 53standard meal supplies are not approved b y the local regulatory  agency , the patients will not 
participate in the MMTT. Any patient who requires the addition of rescue medication prior to 
Week 26 should still have the standardized MMTT performed as scheduled.
In case of permanent discontinuation of the treatment with I MP before Week 26, every  effort will 
be made to have the patient return to the site at the time of their Week 26 visit; however ,the 
MMTT should not be performed at these or an y other visit following a Premature EOT visit.
On the day s of the MMTT, patients will come to the investigational site in the morning, in fasted
conditions for at least 8 hours and must not eat any food or drink, except water, before the 
scheduled standardized meal test.
The exact times of the IMP administration, standard mixed liquid breakfast meal intake, and the 
blood draws are to be documented.
9.1.4.4 Fasting plasma glucose
Fasting plasma glucose will be assessed at all study  visits except at the Run-in Phase Visit 
(Week -2, Visit 2),the Follow -up Visit (Week 30, Visit 9), and ABPM substudy  visits. Fasting is 
defined as no food and drink (with the exception of water) intake for â‰¥8 hours. The FPG 
assessment is performed on the morning of the visit. For the efficacy assessments of the study , 
FPG is measured at a central laboratory .
9.1.4.5 Body weight
Body weight is measured at every stud y visit. Body  weight should be obtained w ith the patient 
wearing undergarments or very  light clothing and no shoes, and with an empty  bladder. The same 
scale should be used throughout the stud y, and calibrated on a regular basis as recommended b y 
the manufacturer. Calibration should be documented in source documents. The use of balance 
scales is recommended; if digital scales are used, testing with standard weights is of particular 
importance. The floor surface on which the scale rests must be hard and should not be carpeted or 
covered with other soft material. The scale should be balanced with both weights at zero and the 
balance bar aligned. The patient should stand in the center of the platform, as standing off -center 
may affect measurement. The weights are moved until the beam balances (the arr ows are aligned). 
The weight is read and recorded in the e CRF and source data. Self -reported weights are not 
acceptable; patients must not read the scales themselves.
9.1.4.6 Kidney function parameters
Serum creatinine will be assessed at Screening (Visit 1),Base line (Visit 3),Week 4 (Visit 4),
Week 12 (Visit 6), Week 26 (Visit 8), and the Follow -up Visit (Visit 9). H ome-collected urine 
albumin, total protein, creatinine, calcium, phosphorus, magnesium, and glucose will be assessed 
at Baseline ( Visit 3), Week 12 (Visit 6), Week 26 (Visit 8), and the Follow -up Visit (Visit 9)
(Section 1.2). Details of urine collection and analy sis are provided in Section 9.2.1.4.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 54 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 549.1.4.7 Use of rescue medications for hy perglycemia
The use of rescue medications for hy pergl ycemia will be assessed and reported throughout the 
double -blind Treatment Period. Routine alerts on FPG and/or HbA1c will be sent to the 
Investigator from the central laboratory  to ensure that gl ycemic parameter results remain within 
predefined thresholds. For details and further actions should FPG values fall above thresholds, 
refer to Section 8.2.2.
9.2 SAFETY ENDPOINTS
Assessments for safet y include AEs, SMBG, clinical laboratory assessments, physical 
examination, ECG, weight, and vital signs. An independent DMC will meet on a regular basis to review accumulating clinical trial safety  data by treatment.
Adjudication of all deaths, MACE ,and other selected CV events, selected renal events, bone 
fracture, and DKA will be performed in a blinded manner b y a CEC. Further details are available 
in Section 6.4.3 and in the CEC Charter.
Two expert committees will review all potentia l cases of DILIs and cases of amputation in a 
treatment -blinded manner.
The following safet y endpoints will be assessed throughout the 26- week double -blind Treatment 
Period :
ï‚·Adverse e vents, h ypogl ycemia ( all, severe, and /ordocumented s ymptomatic 
hypoglycemia ), events of special interest ( EOSI ), adverse events of special interest 
(AESI ), AEs leading to discontinuation from the IMP, SAEs, and deaths
ï‚·Acute renal failure (seeSection 9.1.4.6)
ï‚·Clinical laboratory  result s, (including fasting lipids; see Section 9.2.1.3), vital signs, and 
ECG results.
Observation period of safety endpoints
The observation period of safety data will be divided into 3 segments:
ï‚·The pretreatment period is defined as the time between the date of the informed consent 
and the first dose of double- blind I MP
ï‚·The on-treatment period (TEAE period) is defined as the time from the first dose of double -blind I MP up to 10 days(1 day  for hy pogly cemia) after the last dose of 
double -blind I MP, regardless of the introduction of rescue therapy . The 10- day interval is 
chosen based on the half -life of the IMP (approximately  5 times the half -life of 
sotagliflozin) in patients with moderate renal dy sfunction .
ï‚·The post -treatment period is defined as the time starting 11 daysafter the last dose of 
double -blind I MP (after the on- treatment period).
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 55 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 55The Baseline value for safet y endpoints in the safety population is the last available value (or the 
averag e of all values for creatinine or eGFR) prior to the first administration of the double -blind 
IMP.
9.2.1 Assessment methods of safety  endpoints
9.2.1.1 Adverse events
Adverse events including SAEs, AESI , and EOSI will be assessed. Refer to Section 10.4 to 
Section 10.7 for details.
9.2.1.1.1 Adverse events of special interest
Adverse events of special interest are listed in Section 10.4.1.3; reporting requirements for AESI 
are presented in Section 10.4.4.
9.2.1.1.2 Events of special interest
Events of special interest are a separate category from AESI . For a list of events defined as EOSI 
and their reporting requirements see Section 10.4.1.4 andSection 10.4.4, respectivel y.
9.2.1.2 Hypoglycemia
Hypoglycemia events ( all, severe, and /ordocumented sy mptomatic hy pogly cemia ) will be 
assessed starting with signing of the ICF until 4 weeks after the last dose of I MP ( Note:For 
patients who discontinue treatment bef ore Week 26, safet y data will be collected until scheduled 
study  end). Patients will also complete the patient diary , which will be regularly  reviewed by  
Investigators. See Section 10.6.1 for further details.
9.2.1.3 Laboratory safety variables
The clinical laboratory  data consist of blood anal ysis (including clinical chemistry , hematology  
amylase,lipase, fasting lipid profile , and additional evaluations ) and urinalysis, according to the 
schedule presented in Section 1.2. Clinical laboratory  values will be evaluated after conversion 
into standard international units. I nternational units will be used in all listings and tables. Table 2
lists the blood safety  parameters to be assessed by the central laboratory .Urinaly sis parameters 
are presented in Section 9.2.1.4.
In addition, for WOCBP ,a serum pregnancy  test is performed at Screening (Visit 1, Week -4) and 
urine pregnancy  tests are taken at all visits during the double -blind Treatment Period (there is no 
pregnancy  testing at the Run -in Phase Visit (Visit 2, Week -2). Any positive urine test result must 
be confirmed b y a serum pregnancy  test. The Investigator may  perform additional pregnancy tests 
at their discretion or as required b y local regulations.
For women of nonreproductive potential ( Appendix A ), follicle -stimulating hormone (FSH ) 
and/orestradiol levels should be tested if the definition of postmenopausal or premenopausal 
cannot be satisfied, eg, no medical document ation ofhysterectomy  or cessation of menses 
<12months without an alternative medical cause .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 56 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 56Table 2 -Blood safety parameters
Clinical chemistry Hematology Other parameters
Sodium Complete blood count (CBC) Fasting l ipid profile
Potassi um Differential WBC Total cholesterol (TC)
Chloride Platelet count High-density lipoprotein cholesterol (HDL -C)
Carbon dioxide (bicarbonate) Hemoglobin Low-density lipoprotein cholesterol (LDL -C)b
Blood urea nitrogen (BUN) Hematocrit Nonâ€“HDL-Cc
Creatinine ( for eGFR calculationa) Erythrocyte count Triglycerides (TG)
Glucose (serum)
Alanine aminotransferase (ALT) Other tests
Aspartate aminotransferase (AST) Amylase
Total bilirubin (TB) Lipase
Alkaline phosphatase (ALP)
Uric acid
Phosphorus
Total protein
Albumin
Magnesium
Creatine phosphokinase (CPK)
Lactic acid dehydrogenase (LDH)
All asses sments to be performed by central laboratory. All assessment measured in serum.
aThe eGFR will be calculated. The recommended equation for estimating eGFR from serum creatinine is the 4 -variable Modification of Diet in 
Renal Disease (MDRD) Study equation ( 18, 19). The IDMS -traceable version of the MDRD Study equation will be used. Either equation 
below may be used based on whether the laboratory reports conventional units or Standardized International (SI) units.
Conventional Units (for use predominantly in the US): http://nkdep.nih.gov/lab -evaluation/gfr -calculators/adults -conventional -unit.asp
SI Units (for use predomina ntly outside the US): http://nkdep.nih.gov/lab- evaluation/gfr -calculators/adults -SI-units.asp.
bLDL-C will be calculated by Friedwald equation.
cNonâ€“HDL-C will be calculated as the difference between TC and HDL-C.
9.2.1.4 Urinalysis
Urinal ysis (urine dipstick with microscopy ) will be performed at theScreenin gVisit (Visit 1), 
Baseline Visit (Visit 3), and at the end of the Double -Blind Treatment Period (Visit 8, Week 26). 
Central laboratory  urinaly sis includes:
ï‚·Urine dipstick will include : specific gravit y, pH, protein, blood, ketones, bilirubin, 
urobilinogen, Nitrite , and leukocy te esterase
ï‚·Urine microscop y will include, but will not be limited to: detection of formed cellular 
elements, casts, bacteria, yeast, parasites, and cry stals in centrifuged urine sediment.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 57 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 57To prevent partial unblinding, the central la boratory  urine dipstick will not include the 
measurement of urine glucose.
In the event of abnormal urinaly sis findings suspicious of urinary  tract infection ( UTI), urine 
culture should be performe d. Positive urine culture determination will be based upon the criteria 
of the reporting laboratory. Additionall y, urine culture should be performed if at an y point the 
Investigator suspects the presence of a UTI.
If the urine dipstick is positive for bloo d, the central laboratory  will perform reflexive testing to 
include microscop y. Additional testing will be performed according to the judgment of the 
Investigator. Referral to urology/urologic evaluation is recommended for new or unexplained 
cases of confi rmed hematuria (urology /urologic evaluation is not required where hematuria is 
considered to be related to diabetic nephropath y).
Serum creatinine will be assessed at Screening (Visit 1),Baseline (Visit 3),Week 4 (Visit 4),
Week 12 (Visit 6), Week 26 (Vi sit8),and the Follow -up Visit (Visit 9). H ome-collected urine 
albumin, total protein, creatinine, calcium (adjusted for creatinine) , phosphorus (adjusted for 
serum phosphorus and creatinine) , magnesium (adjusted for serum magnesium and urinary  
creatinine ), and glucose will be assessed at Baseline (Visit 3), Week 12 (Visit 6), and Week 26 
(Visit 8) (Section 1.2).
Patient s will collect home overnight urine samples during the night prior to Visits 3 (Week 0), 
6(Week 12) and 8 ( Week 26). The urine sample before the sleep will be discarded and all urine 
during sleep and the first urine after getting up the next morning will be collected. 
A central laboratory  will anal yze samples and estimate change from Baseline in UACR, UGE, 
UGCR, serum creatinine, and eGFR. To prevent partial unblinding, results of laboratory  
assessments of HbA1c, FPG, PPG, UGE, and UGCR will be masked to study  centers and patients 
after randomization and until study  end.
9.2.1.5 Vital signs and physical exam ination
Vital signs, including sitting BP and HR , will be assessed at all study  visits, except for ABPM 
substudy  visits, for safet y and efficacy endpoints . Full details and directions for the measurement 
of BP and HR are presented in Appendix E .
Physical examinations will be performed at every  study  visit.
A complete ph ysical examination will be performed at Visit 1 (Screening) and Visit 8 (Week 26). 
Body weight measurements are discussed in Section 9.1.4.5. The complete phy sical examination 
will include recording height, body  weight, and vital signs. Height will be measured onl y at 
Screening Visit, for BMI calculations .
An abbreviated phy sical exam ination will be performed at the Run- in Phase Visit (Visit 2, 
Week - 2), at every  visit during the Double- blind Treatment Period except for Visit 8, and at the 
Follow -up or Premature EOT Visit (within 4 weeks of the last dose of IMP or after patient 
withdraws earl y from treatment). The abbreviated phy sical exam ination should focus on cardiac 
and respiratory  systems, as well as any  areas important for assessment of AEs, if necessary .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 58 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 589.2.1.6 Electrocardiogram variables
Twelve -lead ECG record ingwill be performed locally  at the Run -in Visit (Visit 2), and at 
Week 26 (Visit 8).
The 12-lead ECG should be performed after the patient has spent at least 10 minutes in supine 
position and prior to I MP administration. The Investigator should review the E CG trace and 
document the interpretation, sign and date the ECG print out, and report the interpretation in the 
eCRF. Each subsequent ECG trace will be analyzed in comparison tothe Screening ECG trace. 
All original ECG traces are retained as source data.
The ECG results will be evaluated as â€œnormalâ€ or â€œabnormalâ€.
Note: Any new ECG abnormality  should be rereviewed for confirmation and reported as 
appropriate for that finding.
9.2.1.7 Self -monitor edblood glucose
A meter for the self -assessment of blood glucose wil l be dispensed at the start of Run- in (Visit 2). 
Patients will receive a patient diary  at each visit except for the Follow -up Visit (Week 30)and 
ABPM substudy  visits. The patient will enter SMBG levels into this diary .The diary  will be 
collected and reviewed by  investigators and study  staff at each visit (except ABPM substudy  
visits).
Patients will be asked to self- assess blood glucose levels 3 times a week (at least 3 times in the 
week prior to a study  visit) from the Run -in Visit (Visit 2) through the e nd of the study  (Visit 9).
Patients will be requested to self -assess blood glucose levels in the fasted state and whenever they  
experience an y illnesses (eg, cold, flu), or s ymptoms of hy pergl ycemia or hypogl ycemia. 
Symptoms of hy poglycemia may  include sha kiness, dizziness, sweating, hunger, headache, pale 
skin color, sudden moodiness or behavior changes (such as cry ing for no apparent reason), clumsy  
or jerk y movements, seizure, difficult y paying attention or confusion, or tingling sensations 
around the mouth. Patients will be instructed to record the presence or absence of hy poglycemic 
episodes or h ypogl ycemic symptoms in the patient diary provided. Patients will also be instructed 
to record SMBG values that are â‰¤70mg/dL ( â‰¤3.9 mmol/L) in the patient diary . 
SMBG for h ypergl ycemia: patients should be instructed to contact the site if fasting SMBG values 
over 3 consecutive day s are:
ï‚·>270 mg/dL (15.0 mmol/L) from Baseline Visit (Visit 3, Day 1) to Visit 5 (Week 8) 
(including value at Visit 5)
ï‚·>240 mg/dL (13.3 mmol/L) from Visit 5 (Week 8) to Visit 6 (Week 12) (including value 
at Visit 6)
ï‚·>200 mg/dL (11.1 mmol/L) from Visit 6 (Week 12) to Visit 8 (Week 26) (including value 
at Visit 8).
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 59 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 599.3 OTHER ENDPOINTS
9.3.1 Pharmacokinetics of sotagliflozin
The PK endpoint for sotagliflozin is the plasma levels of sotagliflozin and 
sotagliflozin-3-O- glucuronide in the sotagliflozin treatment arms .
Pharmacokinetic sotagliflozin d ata may  be subjected to a population PK analy sis, which will be 
reported separatel y from the clinical study  report (CSR ).
9.3.1.1 Sampling time
At Weeks 4, 18, and 26(Visits 4, 7, and 8, respectively ), blood samples for PK assessment are to 
be drawn with the other laboratory  assessments, prior to administration of IMP. An additional 
blood sample will be drawn at Week 26 (Visit 8), 3 hours after administering the dose of IMP
(30minutes after the 2 -hour PPG sample collection ). The time of the last intake of study  drug 
prior to visits PK samples were taken should be recorded by  the patient in the patient diary . 
Patients should be reminded of this at visits preceding PK time points to ensure these details are captured. In the case of premature IMP discontinuation, PK samples should not be drawn at the 
Premature EOT Visit, or at subsequent visits. See Table 3for identification of samples.
Table 3 - S otagliflozin samples identification
Visit Week Relative to dosing PK
Visit 4 Week 4 Predose P00
Visit 7 Week 18 Predose P01
Visit 8 Week 26 Predose P02
Visit 8 Week 26 3 hours postdose P03
PK: pharmacokinetic
9.3.1.2 Pharmacokinetics handling procedure
Detai led procedures for sample preparation, storage ,and shipment are described in the laboratory  
manual developed b y the central laboratory .
9.3.1.3 Bioanalytical method
Concentration of sotagliflozin and its 3 -O-glucuronide metabolite
Plasma samples will be analy zed at Covance US using validated high performance liquid 
chromatograph y-tandem mass spectrometry , with a lower limit of quantification of 2 ng/mL for 
sotagliflozin and a lower limit of quantification of 10 ng/mL for sotagliflozin-3-O- glucuronide.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 60 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 62The concentration of HbA1c reflects the gl ycemic history  of the previous 120 daysand is thus an 
index of mean gl ycemia, documenting gl ycemic control over the past 2 to 3 months. 
Hemoglobin A1c has also been shown to correlate with the development of long -term 
complications of diabetes, and reduction of HbA1c is known to reduce the risk of long -term 
microvascular complications. Therefore, HbA1c is considered an appropriate primary  endpoint for 
assessing the effect of a treatment on glycemic control. The duration of study  treatment (26 weeks
for the primary  HbA1c endpoint) is considered to be sufficient for achieving stable conditions 
with I MP and for enabling an adequate assessment of time -dependent changes in HbA1c.
The problem of w eight gain in T2D is widely  recognized. More than 80% of individuals with T2D 
are overweight, man y at the time of diagnosis. Consequently , iatrogenic weight gain is not onl y 
unwelcome, but represents an important clinical issue that can become a barrier to the successful 
management of gl ycemic control. Therefore, in this study , assessing change in body  weight from 
Baseline to Week 26 is a secondary  endpoint.
Improvements in FPG have been observed with sotagliflozin in multiple studies. Therefore ,
assessment of FPG is relevant in this study . This parameter is also considered b y regulatory 
agencies to be supportive of efficacy  of an antidiabetic agent.
Phase 2 data indicated that sotagliflozin may  reduce SBP by  10 to 15 mmHg inpatients with SBP 
â‰¥130 mmHg at Baseline, while having no significant effect in patients with SB P <130 mmHg , and 
did not induce hypotension in normotensive patients. Since this could be of benefit to patients
with T2D, this finding is being followed up as a secondary  objective in this tri al, as well as the 
potential in patients with DBP >80 mmHg . Although effects on BP in Phase 2 data were observed 
with the 400- mgdose at 12 weeks , the effects will be examined at Weeks 12 and26.
To further evaluate the diurnal effect of sotagliflozin on SBP compared with the comparator arms 
(placebo and empagliflozin) and to avoid the white- coat effect, a subset of patients (180 patients) 
similar to the full study  population in BP levels (ie, equal distribution in SBP <130 mmHg or 
â‰¥130 mmHg) will be evalua ted by  ABPM.
Safet y anal yses focus on the TEAE sinclude occurrences with SAE, AESI , EOSI , AE leading to 
IMP discontinuation, and hy poglycemic events. Other standard safety  parameters such as vital 
signs, ECG and laboratory measurements will also be evaluat ed.The other efficacy  and safet y 
assessments in this study  are standard, well -established measurements for a Phase 3 study  
evaluating the treatment of T2D in adult participants.
The length of the stud y is considered appropriate for detection of the primar y endpoint given the 
power estimates (see Section 11).
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 63 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 6310 STUDY PROCEDURES
10.1 VISIT SCHEDULE
The visit schedule and procedures and assessments are listed in the Study  Flow Chart 
(Section 1.2). The aim of this section is to provide details on how some of the procedures and 
assessments should be performed.
This is an out -patient study  and consists of 9 on- site visits (a total of 12 on -site visits for patients 
participating in the ABPM substudy ).
The patient sneed to arrive at the stud y site in a fasting state for Visit 1 through Visit 8
(Week -4/Screening through Week 26/end of double -blind Treatment Period ), unless instructed 
otherwise b y the Investigator. Throughout the study , â€œfastingâ€ is defined as â‰¥8 hours without 
food. Note: If the patient is not fasting at the visits specified above, the blood sample will not be 
collected and a new appointment should be given to the patient for the following day  if possible, 
with instruction to be fasted. O ther pr ocedures can be performed as sched uled. With the exception 
of PPG, a ll laboratory  assessments will occur prior to I MP administration on the day  of the visit.
The Run- in Visit (Visit 2) can be performed up to 2weeks after the Screening Visit and once the 
results of all Screening tests are available and the patient is confirmed to be eligible for 
participation in the study . The visit window sforthe Double -blind Treatment Period visits will be 
as follows: Visit 4through Visit 6should occur at the schedule Â±3days; Visit 7 through Visit 8
should occur at the schedule Â±5 days. For the Follow -up Visit (Visit 9), the visit window should 
occur within Â±5 days, 4weeks after last dose of IMP.
If one visit date is changed, the next visit should occur according to t he original schedule, ie, 
calculated from the date of Baseline V isit (Visit 3, Week 0).
For a complete list of procedures scheduled for each study  visit please refer to the Study  Flow 
Chart ( Section 1.2), which details the procedures to be performed.
All data obtained during the study  visits are reviewed by  the Investigator and Sub -Investigators 
who are qualified in treatment of T2D and are trained on the study .
10.1.1 Screening Period
The Screening P eriod is up to 4 weeks and includes a Screening Phase and aRun-in Phase .
10.1.1.1 Screening phase
The Screening Phase will be up to 2 weeks in duration and includes Visit 1 (Week -4) onl y. The 
Screening Phase must be long enough to collect the data to establish wh ether the patient satisfies 
the inclusion/exclusion criteria.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 64 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 65ï‚·The following laboratory testing (b y the central laboratory ):
-FPG
-HbA1c
-Serum pregnancy  testing for WOCBP or s erum FSH and/or estradiol (for wom enof 
nonreproductive potential if definition of postmenopausal or premenopausal cannot be 
satisfied; see Appendix A )
-Clinical chemistry  (including am ylase, lipase, and uric acid) and hematology .
ï‚·AEs/SAEs/AESI /EOSI and hy poglycemia (if an y) are reported.
ï‚·Urinal ysis (dipstick and microscopy ).
ï‚·Patients will be instructed to return to the site in the fasting state for Visit 2 (Week -2).
10.1.1.2 Run-in Phase
The Run- in Phase is 2 weeks and includes Visit 2 (Week -2).
10.1.1.2.1 Run-in Visit, Visit 2 (Week -2)
The following procedures and assessments will be performed at Visit 2 (Week -2):
ï‚·Measurement of bod y weight
ï‚·Abbreviated ph ysical examination :
-The abbreviated ph ysical examination should focus on cardiac and respiratory  systems, 
as well as an y areas important for assessment of AEs, if necessary ) and vital signs 
(SBP and DBP, and HR). After 5 minutes of rest, seated SBP, DBP, and HR will be assessed 3 times with at least 1 minute between each measurement (see Appendix E for 
details on BP and HR measurement).
ï‚·Diet and exercise instruction will be provided
ï‚·Instructions on basic GU hy giene and h ydration is provided
ï‚·Patient diary  is dispensed and ins tructions/training are provided
ï‚·Blood glucose meter is dispensed and instructions/traini ng are provided
ï‚·Fasting SMBG is assessed.
ï‚·Instructions on DKA s ymptoms, glucose testing, basic genitourinary  (GU) hygiene ,and 
hydration (see Appendix D )
ï‚·The IRT is notified for registration of Run- inVisit and allocat ion of single -blind Run- in 
kit
ï‚·The AEs/SAEs/AESI /EOSI  and h ypogl ycemia occurring since Visit 1 (if any ) are reported
ï‚·Run-in kit/placebo is dispensed
ï‚·Changes i n conc omitant medication are reported
ï‚·12-lead ECG is conducted
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 66 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 66ï‚·Patients are instructed to return to the site in the fasting state with used/not- used 
single -blind Run- in kit for Visit 3 (Randomization).
10.1.1.2.2 Ambulatory Blood Pressure Monitoring visit (Week -1)
Asubset of patients (180 patients) will complete ABPM. The first ABPM visit will occur 1 week 
before Randomization ( Visit 3A, Week -1). Patients will return the ABPM device b y mail after 
24-hour monitoring is complete. At least 70% recording of the expecte d BP recording is needed in 
each 24 -hour period. The measurement will be done on the nondominant arm. Additional details 
on ABPM procedures are provided in Appendix B .
10.1.2 Double -blind Randomized Treatment Period ( Day1 to Week 26)
Upon successful completion of the Run- in phase, patients will be randomly allocated to either 
sotagliflozin 400 mg, empagliflozin 25 mg,or ma tching placebo for the 26 -week Double -Blind 
Treatment Period. All randomized patients will be fol lowed at regular on -site visits for the 
duration of the Treatment Period.
In addition to routine laboratory testing, the following will be performed at specified time points: 
PK samples for sotagliflozin and sotagliflozin metabolite plasma concentration; c ollection of 
home overnight urine for assessment of albumin, total protein, creatinine, calcium (adjusted for 
creatinine), phosphorus (adjusted for serum phosphorus and creatinine) , magnesium (adjusted for 
serum magnesium and urinary  creatinine) , and gluco se.
The date and time of the last intake of IMP prior to visits where PK samples are taken should be recorded b y the patient in the patient diary. Patients should be reminded of this at visits preceding 
PK time points to ensure these details are captured.
In the event of abnormal urinaly sis findings suspicious for UTI, urine culture should be 
performed. Positive urine culture determination will be based upon the criteria of the reporting 
laboratory . Additionall y, urine culture should be performed if at an y point the Investigator 
suspects the presence of a UTI.
10.1.2.1 Visit 3, Randomization ,Day 1 (Baseline; Week 0)
The following procedures will be performed at this visit:
ï‚·Exclusion criteria are to be reviewed, including asse ssment of compliance during Run -in 
Phase
ï‚·Concomitant medications are assessed
ï‚·Measurement of bod y weight
ï‚·Abbreviated ph ysical examination and vital signs
ï‚·IMP accountability  and compliance with single -blind placebo Run -in treatment
ï‚·IRT to be notified and randomization to occur
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 67 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 67ï‚·AEs/SAEs/AESI /EOSI a nd hy poglycemia (if an y) are reported
ï‚·Diet and exercise instruction
ï‚·Patient diary  collected and reviewed and a new one is dispensed. Instructions/training are 
provided as needed
ï‚·Instructions on DKA s ymptoms, glucose testing, basic GU h ygiene , and hy dration is 
provided
ï‚·Fasting SMBG is assessed
ï‚·Patients are evaluated for gl ycemic rescue (see Section 9.1.4.7)
ï‚·The following laboratory testing (b y the central laboratory ):
-FPG
-HbA1c
-Urine pregnancy  testing for WOCBP
-Clinical chemistry  (including am ylase, lipase, and fasting lipids)
- H ematology
-Hemody namic markers
-Urinal ysis (dipstick and microscopy )
-Collection of home overnight urine for albumin, total protein, creatinine, calcium 
(adjusted for creatin ine), phosphorus (adjusted for serum phosphorus and creatinine), 
magnesium (adjusted for serum magnesium and urinary  creatinine) , and glucose .
ï‚·Collection of samples for a dditional laboratory  testing:
-
-
ï‚·PPG assessment via M MTT 2 hours after consuming a standard mixed liquid breakfast 
meal
ï‚·IMP is dispensed
ï‚·Patients are instructed to return to the site in the fasting state for their next visit ( Visit 4; 
Week 4)
ï‚·Patients should be reminded to record the time of study  drug intake on the day  before their 
next visit
ï‚·For accountabilit y and compliance purposes, patients are instructed to return to the site 
with their used, in- use and not -used wallet(s) dispensed during Visit 3.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 68 of 298

Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 6810.1.2.2 Week 4 to Week 18 (Visit 4to Visit 7)
The following pro cedures will be performed at Visit 4 (Week 4), Visit 5 (Week 8), Visit 6
(Week 12), and Visit 7 (Week 18), except as specified:
ï‚·Concomitant medications will be assessed
ï‚·Measurement of bod y weight
ï‚·Abbreviated ph ysical examination and v ital signs
ï‚·IMP account ability  and compliance for double -blind I MP
ï‚·IRT willbe notified IMP for resuppl y
ï‚·AEs/SAEs/AESI /EOSI and hy poglycemia (if an y)occurring since the previous visit will 
bereported
ï‚·Patients will be evaluated for gly cemic rescue
ï‚·Patient diary  will be collecte d and reviewed and a new one will be dispensed. 
Instructions/training will be provided as needed
ï‚·Instructions on DKA s ymptoms , glucose testing, basic GU h ygiene ,and hy dration will be 
provided
ï‚·Fasting SMBG will be assessed
ï‚·Central laboratory  testing:
-FPG: all visits
- HbA1c: Visit 5 (Week 8) and Visit 6 (Week 12)
- C linical c hemistry , including am ylase and lipase : Vis it4 (Week 4) and Visit 6 
(Week 12)
-Hematology : Visit 4 (Week 4) and Visit 6 (Week 12)
-Pregnancy  test (WOCBP): all visits
-FSH and/or estradiol: as needed
-Predose PK (plasma concentration samples for sotagliflozin and 
sotagliflozin-3-O- glucuronide): Visit 4 (Week 4) , Visit 7 (Week 18)
-Hemody namic markers : Visit 6 (Week 12)
-Collection of home overnight urine for albumin, total protein, creatinine, calcium 
(adjusted for creatinine) , phosphorus (adjusted for serum phosphorus and creatinine), 
magnesium (adjusted for serum magnesium and urinary  creatinine) , and glucose will 
be done prior to Visit 6 (Week 12)
-
-
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 69 of 298

Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 69ï‚·Patients participating in the ABPM assessments will have an additional visit 1 day before 
the Week 12 visit (Visit 6A ) for placement of the ABPM device. The ABPM device will 
be returned at the Week 12visit (Visit 6) the following day
ï‚·IMP is dispensed
ï‚·Patients are instructed to return to the site in the fasting state for each subsequent visit
ï‚·Patients should be reminded to record the time of study  drug intake on the day  before their 
next visit
ï‚·For accountabi lity and compliance purposes, patients are instructed to return to the site 
with their kit(s) dispensed during the previous visit.
10.1.2.3 Week 26 (Visit 8) -End of Treatment
The following procedures will be performed at this visit:
ï‚·Concomitant medi cations are assessed
ï‚·Measurement of bod y weight
ï‚·Complete phy sical examination including vital signs
ï‚·IMP accountability  and compliance
ï‚·Diet and exercise instruction
ï‚·Instructions on DKA s ymptoms ,glucose testing, basic GU h ygiene ,and hy dration
ï‚·IRT will be notified
ï‚·AEs/SA Es/AESI /EOSI and hy poglycemia (if an y)occurring since the previous visit will 
be reported
ï‚·Patients evaluated for glycemic rescue
ï‚·Patient diary  will be collected and reviewed and a new one will be dispensed. 
Instructions/training will be provided as needed
ï‚·12-lead ECG
ï‚·Fasting SMBG will be assessed.
ï‚·The following laboratory testing (b y the central laboratory ):
-FPG
-HbA1c
-Clinical chemistry  (including am ylase, lipase, and fasting lipids)
- H ematology
-Hemody namic markers
-Urine pregnancy  testing for WOCBP
-Urinal ysis sample collection (dipstick and microscopy )
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 70 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 70-Collection of home overnight urine for albumin, total protein, creatinine, calcium 
(adjusted for creatinine) , phosphorus (adjusted for serum phosphorus and creatinine), 
magnesium (adjusted for serum magnesium and urinary  creatinine) , and glucose .
-
- Predose PK (plasma concentration sample for sotagliflozin and 
sotagliflozin-3-O- glucuronide) and postdose PK (collected 3 hours after IMP 
administration.
ï‚·PPG assessment via MMTT 2 hours after consuming a standard mixed liquid breakfast 
meal
ï‚·Patients participating in the ABPM assessments will have an additional visit 1 day before 
the Week 26 visit (Visit 8A ) for placement of the ABPM device. The ABPM device wi ll 
be returned at the Week 26 visit (Visit 8) the following day
ï‚·Patients are to return all the used, in -use,and unused IMP at Visit 8 (or final assessment 
on-treatment visit in case of permanent premature discontinuation).
10.1.3 Post -treatment Follow -up Period
The post -treatment Follow -up Period will include an on- site visit, 4 weeks Â± 5daysafter the last 
dose of IMP.
The following procedures will be performed at this visit:
ï‚·Concomitant medications will be assessed.
ï‚·Measurement of bod y weight.
ï‚·Abbreviated ph ysical examination including vital signs.
ï‚·IRT to be notified.
ï‚·AEs/SAEs/AESI /EOSI and hy poglycemia (if an y) since the previous visit will be reported.
ï‚·Collect glucose meter.
ï‚·Patient diary  is collected and reviewed.
ï‚·Central laboratory  testing :
-Clinic al chemist ry (including am ylase and lipase) .
10.2 DEFINITION OF SOURCE DA TA
10.2.1 Source data to be found in patientâ€™s file
Evaluations recorded in the eCRF must be supported by  appropriatel y signed source 
documentation related but not limited to the following:
ï‚·Agreement and signature of I CF with the study ID
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 71 of 298

Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 71ï‚·Study  ID (name)
ï‚·Patient number, confirmation of randomization, treatment batch number, dates and doses 
of study  medication administration.
ï‚·Medical, surgical, diabetes history , including information on:
-Demograph y, inclusion, and exclusion criteria
- Last participation in a clinical trial
- Contraception method for WOCBP- Previous and concomitant medication.
ï‚·Dates and times of visits and assessment s including examination results
ï‚·Vital signs, height, bo dy weight, laboratory  report s, investigation results (e g, ECG traces, 
imaging reports)
ï‚·AEs and follow -up:
- In case of SAE, the site should file in the source documents at least copies of the 
hospitalization reports and any  relevant examination reports documenting the follow -
up of the SAE.
ï‚·Date of premature treatment disc ontinuation (if any ) and reason
ï‚·Date of premature study  discontinuation (if an y) and reason
ï‚·Nursing notes
ï‚·Dieticianâ€™s notes
ï‚·Physicianâ€™s notes.
10.2.2 Source data verification requirements for screen failures
For screen failure patients , the following source data must be verified: patientâ€™ s ID details, the 
informed consent signed by  the patient, the study  ID (name), dates of stud y visits, and the main 
reasons for screen failure.
10.3 HANDLING OF PA TIENT TEMPORA RY OR PERMA NENT TREA TME NT 
DISCONTINUA TION A ND OF PA TIENT STUDY DISCONTINUA TION
The IMP should be continued whenever possible. In case the IMP is stopped, it should be 
determined whether the stop can be made temporarily ; permanent IMP discontinuation should be 
a last resort. An y IMP discontinuation must be fully  documented in the eCRF . In an y case, the 
patient should remain in the study  and followed for the remainder of the study  to collect vital 
safet y status and endpoint data.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 72 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 7210.3.1 Temporary  treatment discontinuation with investigati onal medicinal product(s)
Temporary  treatment discontinuation may  be considered by  the Investigator because of suspected 
AEs. Lowerextremity  complications (such as skin ulcers, infection, osteomy elitis and gangrene) 
requiring treatment should lead to temp orary  discontinuation of I MP.Reinitiating treatment with 
the IMP will be done under close and appropriate clinical and/or laboratory monitoring once the 
Investigator has considered, according to his/her best medical judgment, thatthe occurrence of the 
concerned event was unlikely to be related to the IMP.
Since the IMP received is blinded, patients must return to the site and IRT will be contacted for 
IMP reinitiation.
It is in the interest of the patient to monitor their blood glucose during the temporar y 
discontinuation period, therefore regular determination of SMBG is to be performed and 
documented (see Section 9.2.1.7).
For all temporary  treatment discontinuations, duration should be reco rded by  the Investigator in 
the appropriate pages of the eCRF when considered as confirmed.
Temporary  treatment discontinuation decided by  the Investig ator corresponds to more than 1 dose 
not administered to the patient.Use of an y other anti hypergl ycemic medication during the time of temporary  treatment 
discontinuation (ie, insulin during a hospitalization) will be recorded as concomitant medication 
with the name and dose recorded in the eCRF.
10.3.2 Permanent treatment discontinuation with investigational medici nal product(s)
Permanent treatment discontinuation isdefined as any  treatment discontinuation associated with 
the definitive decision from the I nvestigator or the patient not to re -expose the patient to the IMP 
at an y time.
10.3.3 List of criteria for permanent treatment discontinuation
Patients may  withdraw from treatment with the IMP if they  decide to do so, at any  time ,and 
irrespective of the reason, or this may be the Investigatorâ€™s decision. Patients should discuss 
stopping study  medication with the site be fore doing so , to allow for questions to be addressed, 
glycemic therap y to be adjusted, and a follow- up assessment to be arranged. All efforts should be 
made to document the reasons for treatment discontinuation; this reason should be documented in the eCR F.
The following reasons can lead to permanent discontinuation:
ï‚·At the patientâ€™s own request (ie, withdrawal of consent for treatment)
ï‚·If, in the Investigator's opinion, continuation with the administration of the study  treatment 
would be detrimental to th e patient's well -being
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 73 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 7410.3.5 Procedure and consequence for patient withdrawal from study
Patients ma y withdraw from the study before study completion if they decide to do so, at an y time 
and irrespective of the reason. Withdrawal of consent for treatment should be distinguished from 
withdrawal of consent for follow- up visits. Patients will be told that t hey are free to withdraw 
from the study  at any  time without any  adverse effect on their care. However, if they no longer 
wish to take the IMP, they  will be encouraged to remain in the study  and attend the remaining 
study  visits. The value of all their stud y data collected during their continued involvement will be 
emphasized as important to the public health value of the study .
If possible, the patient s are assessed using the procedure normall y planned for the Week 26 (EOT)
visit.
Patients who withdraw should be explicitly  asked about the contribution of possible AEs to their 
decision to withdraw consent, and any AE information elicited should be documented. All confirmed study withdrawals should be recorded by the Investigator in the appropriate screens 
ofthe e CRF and in the patientâ€™s medical records. In the medical record, at least the date of the 
withdrawal and the reason should be documented.
Forpatients who fail to return to the site, unless the patient withdraws consent for follow -up,the 
Investigator should make the best effort to recontact the patient (eg, contact patientâ€™s famil y or 
private ph ysician, review available registries or health care databases), and to determine his/her 
health status, including at least his/her vital status. Attempts (3 p hone call attempts followed by  a 
certified letter) to contact such patients must be documented in the patientâ€™s records (eg, times and 
dates of attempted telephone contact, receipt for sending a registered letter).Patients who have withdrawn from the stud y cannot be rerandomized (treated) in the study. Their 
inclusion and treatment numbers must not be reused.
10.4 OBLIGA TION OF THE INVESTIGA TOR REGA RDING SA FETY REPORTING
10.4.1 Definitions of adverse events
10.4.1.1 Adverse event
An AE is an y untoward medical occurrence in a p atient or clinical investigation patient 
administered a pharmaceutical product and which does not necessarily  have to have a causal 
relationship with the I MP.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 75 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 7510.4.1.2 Serious adverse event
An SAE is any  untoward medical occurrence that at any  dose:
ï‚·Results in death, or
ï‚·Is life -threatening, or
Note: The term â€œlife -threateningâ€ in the definition of â€œseriousâ€ refers to an event in which 
the patient was at risk of death at the time of the event; it does not refer to an event which 
hypothetically  might have caused death if it were more severe.
ï‚·Requires inpatient hospitalization or prolongation of existing hospitalization, or
ï‚·Results in persistent or significant disability /incapacity , or
ï‚·Is a congenital anomal y/birth defect ; or
ï‚·Is a medicall y important event .
Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events t hat may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the p atient or may  require 
medical or surgical intervention (ie, specific measures or corrective treatment) to prevent one of the other outcomes listed in the definition above.
Note: The following list of medicall y important events is intended to serve as a gui deline for 
determining which condition has to be considered a medicall y important event. The list is not 
intended to be exhaustive:
ï‚·Intensive treatment in an emergency  room or at home for:
-Allergic bronchospasm
-Blood d yscrasias (ie, agranulocytosis, aplast ic anemia, bone marrow aplasia, 
myelodysplasia, pancy topenia, etc.)
-Convulsions (seizures, epilepsy , epileptic fit, absence, etc).
ï‚·Development of drug dependence or drug abuse
ï‚·ALT >3 xULN + total bilirubin >2 xULN or as ymptomatic AL T increase >10 xULN
- S uicide attempt or an y event suggestive of suicidality
-Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling)
-Bullous cutaneous eruptions
-Cancers diagnosed during the stud y or aggravated during the stud y
-Chronic neurodegene rative diseases (newl y diagnosed) .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 76 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 7610.4.1.3 Adverse event of special interest
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
Sponsorâ€™s product or program, for which ongoing monitoring and immediate notification b y the 
Investigator to the Sponsor is required. Such events may  require further investigation to 
characterize and understand them. Adverse events of special interest may  be added, modified or 
removed during a stud y by protocol amendment.
The AESI for this stud y are:
ï‚·Pregnancy  of a female patient entered in a study as well as pregnancy occurring in a 
female partner of a male patient entered in a study with I MP/NIMP :
-Pregnancy  occurring in a female patient entered in the clinical trial or in a female 
partner of a male patient entered in the clinical trial. I t will be qualified as an SAE only  
if it fulfills one of the seriousness criteria (see Section 10.4.1.2)
-In the event of pregnancy in a female particip ant, IMP should be discontinued
-Follow -up of the pregnancy  in a female participant or in a female partner of a male 
participant is mandatory  until the outcome has been determined (see Appendix A ).
ï‚·Symptomatic ove rdose with I MP/NIMP :
-A symptomatic overdose (accidental or intentional) with the I MP/NIMP is an event 
suspected by the Investigator or spontaneousl y notified by the patient and resulting in 
clinical sy mptoms and/or signs accompanied by  administration of mo re than twice the 
intended daily  dose within a 24- hour period. It will be recorded in the eCRF as an 
AESI  with immediate notification â€œSy mptomatic OVERDOSE (accidental or 
intentional)â€ in all cases and will be qualified as an SAE only  if it fulfills the SA E 
criteria.
Note: An asy mptomatic overdose with the IMP/NIMP, accidental or intentional, is defined as 
administration of more than twice the intended daily  dose within a 24 -hour period, without 
clinical sy mptoms and/or signs, either suspected by  the Invest igator or spontaneously  notified b y 
the patient, not based on accountabilit y assessment. I t will be recorded as an AE â€œAs ymptomatic 
OVERDOSE, accidental or intentionalâ€.
ï‚·ALT increase >3 x ULN (refer to related flowchart, Appendix F ).
10.4.1.4 Events of special Interest
An EOSI  is a serious or nonserious AE of scientific and medical concern specific to the Sponsorâ€™s 
product or program, for which ongoing monitoring may  be appropriate. Such events may  require 
further investi gation to characterize and understand them. These events should be reported on the 
specific eCRF page (where applicable) and will only  qualify  for expedited reporting when serious 
(fulfilling SAE criteria).
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 77 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 77The EOSI for this stud y are:
ï‚·MACE (CV death, MI, or stroke) and other specific CV events (eg, heart failure leading to 
hospitalization)
ï‚·Severe h ypogl ycemia (see Section 10.6.1)
ï‚·Genital my cotic infections (to include vulvovaginal candidiasis in females and candidal 
balanitis in males)
ï‚·UTIs
ï‚·Clinically  relevant volume depletion and events related/possibly  related to volume 
depletion
ï‚·Diarrhea
ï‚·Pancreatitis
ï‚·Bone fractures
ï‚·Venous thrombotic events, to include deep venous thr ombosis and thromboemboli sm 
(toinclude pulmonary  embolism)
ï‚·DKA
ï‚·Renal events, to include 50% decline in eGFR, end- stage kidney  disease, renal death
ï‚·Malignancies of special interest (breast, bladder, renal cell, Ley dig cell, pancreatic, 
prostate, and th yroid cancer)
ï‚·AEsleading to an amputation.
10.4.2 General guidelines for reporting adverse events
ï‚·All AEs, regardless of seriousness or relationship to I MP/NIMP, spanning from the 
signature of the ICF until the end of the study  as defined b y the protocol for that patient, 
are to be rec orded on the corresponding pages of the eCRF
ï‚·Whenever possible, diagnosis or single s yndrome should be reported instead of symptoms. 
The Investigator should specify  the date of onset, intensity , action taken with respect to 
IMP, corrective treatment/therapy giv en, additional investigations performed, outcome, 
and his/her opinion as to whether there is a reasonable possibility  that the AE was caused 
by the IMP or by  the study  procedure(s)
ï‚·In this stud y, the use of concomitant medications including antidiabetic medications, as 
well as metformin and DPP4(i), may make it difficult to assess the causal relationship, 
particularl y for h ypoglyc emia. The Global Safet y Officer with input from other 
appropriate stud y team members will determine the causal relationship when it is not 
clear ly provided by  the Investigator
ï‚·The Investigator should take appropriate measures to follow all AEs until clinical recovery  
is complete and laboratory results have returned to normal, or until progression has been stabilized, or until death, to ensure the safet y of the patient s. This may  imply  that 
observations will continue bey ond the last planned visit per protocol, and that additional 
investigations may  be requested by  the monitoring team up to as noticed by  the Sponsor.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 78 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 78ï‚·When treatment is prematurely  discontinued, the patientâ€™s observations will continue until 
the end of the stud y as defined b y the protocol for that patient
ï‚·Laboratory , vital sign ,or ECG abnormalitie s are to be recorded as AEs ifthey are 
medically  relevant based on the inv estigatorâ€™s medical judgment , eg,:
-Symptomatic ,and/or
- Requiring either corrective treatment or consultation, and/or
- Leading to IMP discontinuation or modification of dosing, and/or-Fulfilling a seriousness criterion, and/or
-Defined as an AESI or EOSI .
10.4.3 Instructions for reporting serious adverse events
In the case of occurrence of an SAE, the Investigator or an y designees must immediately:
ï‚·ENTER (within 24 hours) the information related to the SAE in the appropriate screens of 
the e CRF ; the s ystem will automatically  send a notification to the monitoring team and 
pharmacovigilance after approval of the Investigator within the e CRF
ï‚·SEND (preferably  by fax or e -mail) a photocopy  of all examinations carried out and the 
dates on which these examinations were perfo rmed, to the representative of the monitoring 
team whose name, fax number, and e -mail address appear on the clinical trial protocol. 
Care should be taken to ensure that the patient's identity  is protected and the patient's 
identifiers in the clinical trial are properl y mentioned on an y cop y of a source document 
provided to the Sponsor. For laboratory  results, include the labora tory normal ranges
ï‚·All further data updates should be recorded in the e CRF as appropriate, and further 
documentation as well as addi tional information (for laboratory  data, concomitant 
medications, patient status, etc.) should be sent (b y fax or e -mail) to the monitoring team 
within 24 hours of knowledge of the SAE. In addition, every  effort should be made to 
further document an y SAE t hat is fatal or life -threatening within a week (7 days) of the 
initial notification
ï‚·A back -up plan (using a paper CRF process) must be available and should be used when 
the e CRF system does not work.
Any SAE brought to the attention of the Investigator at an y time after the end of the study for the 
patient and considered by  him/her to be caused by  the I MP with a reasonable possibility , should 
be reported to the monitoring team.
10.4.4 Guidelines for reporting adverse events of special interest
For AESI, the Sponsor must be informed immediately  (ie, within 24 hours), as per SAE 
notification guidelines described in Section 10.4.3, even if not fulfilling a seriousness criterion, 
using the corresponding pages of the CRF (to be sent) or screens in the eCRF.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 79 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 7910.4.5 Guidelines for reporting events of special interest
If an EOSI fulfills the criteria of an SAE, reporting should be performed according to the 
instructions for reporting of SAEs (see Section 10.4.3). Otherwise, reporting should follow the 
instructions for an AE (see Section 10.4.2).
10.4.6 Guidelines for management of specific laboratory abnormalities
Decision trees for the management of certain laboratory  abnormalities by  Sanofi are provided in 
Appendix F .
The following laboratory abnormalities should be monitored, documented, and managed 
according to the related flow chart in Appendix F .
ï‚·Neutropenia
ï‚·Thrombocy topenia
ï‚·ALT increase
ï‚·Acute renal insufficiency
ï‚·Suspicion of rhabdomy olysis.
10.4.7 Guidelines for reporting product complaints (IMP/NIMP)
Any defect i n the IMP/NIMP must be reported as soon as possible by  the Investigator to the 
monitoring team that will complete a product complaint form within required timelines.
Appropriate information (eg, samples, labels or documents like pictures or photocopies) re lated to 
product identification and to the potential deficiencies may  need to be gathered. The Investigator 
will assess whether or not the quality  issue has to be reported together with an AE or SAE.
10.5 OBLIGA TIONS OF THE SPONSOR
During the course of the stud y, the Sponsor will report in an expedited manner:
ï‚·All SAEs that are both unexpected and at least reasonabl y related to the IMP (SUSAR), to 
the regulatory authorities, I ndependent Ethics Committee (IEC s)/Institutional Review 
Board (IRB s) as appropriate and to the Investigators
ï‚·All SAEs that are expected and at least reasonably  related to the IMPs to the regulatory  
authorities, according to local regulations
ï‚·The following AESI to those regulatory authorities who require such reporting:
-Pregnancy
-Symptomatic overdose
-ALT increase >3 times ULN.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 80 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 80Adverse events that are considered expected will be specified b y the reference safet y information 
provided in the current IB.
If required, unblinding of SUSARs will be the responsibility of the Sponsor.The Sponsor will report all safety observations made during the conduct of the trial in the CSR.
10.6 SAFETY INSTRUCTIONS
10.6.1 Hypoglycemia
During the study ,patients are instructed to document an y hypoglycemic episodes in their study  
diary . Hypogl ycemia will be reported in the specific eCRF page with onset date and time, 
symptoms and/or signs, the SMBG value if availa ble, and the treatment. If t heevent fulfills SAE 
criteria, h ypogl ycemia will alsobe reported as an SAE.
Hypoglycemia is categorized according to the American Diabetes Association workgroup on 
hypoglycemia classification ( 20, 21) and summarized in Figure 1.
In addition to the threshold of â‰¤70mg/dL ( â‰¤3.9 mmol/L ), hypogl ycemia episodes with a plasma 
glucose of <54 mg/dL ( <3.0 mmol/L) will be analyzed separatel y.
Figure 1 -Hypoglycemia classification in Study EFC14867
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 81 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 81PG = plasma glucose; SAE = serious adverse event .
Severe hypoglycemia
Severe h ypogl ycemia is an event requiring assistance of another person to activel y administer 
carboh ydrate, glucagon, intravenous glucose ,or other resuscitative actions. These episodes may  
be associated with sufficient neurogl ycopenia to induce seizure, unconsciousness or coma. 
Self-monitored blood glucose values may  not be available, but neurological recovery  attributable 
to the restoration of plasma glucose to normal is considered sufficient evidence that the event was 
induced b y a low plasma glucose concentration.
Note :â€œRequiring assistance of another personâ€ means that the patient could not help himself or 
herself to treat the h ypogly cemia. Assisting a patient out of kindness, when assistance is not 
required, should not be considered a â€œrequires assistanceâ€ incident.
Any hypoglycemic event which leads to unconsciousness, coma, or seizure should also be 
repor ted as an SAE .
Documented symptomatic hypoglycemia
Documented s ymptomatic hy poglycemia is an event during which t ypical symptoms of 
hypoglycemia accompanied by  a measured plasm a glucose concentration of â‰¤70mg/dL
(â‰¤3.9 mmol/L ).
Clinical sy mptoms that are c onsidered to result from a hy poglycemic episode include increased 
sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, 
headache, sleep disorder, confusion, seizures, unconsciousness, or coma.
Asymptomatic hypoglyce mia
Asymptomatic hy poglycemia is an event not accompanied by  typical s ymptoms of hy poglycemia 
but with a measured pl asma glucose concentration â‰¤70 mg/dL (â‰¤3.9 mmol/L ).
Note : Low plasma glucose values without sy mptoms or signs should not be reported more than 
once within 30 minutes. Repeated low glucose values within a short period could be due to 
malfunction of the device, error testing ,or follo wing up a low glucose reading. The Investigator 
should try  not to document false low SMBG values or redundant low glucose values as 
asymptomatic hy poglycemic events. Further clarification with the patient sis needed.
Probable symptomatic hypoglycemia
Proba ble sy mptomatic hypogl ycemia is an event during which sy mptoms of hy poglycemia are not 
accompanied b y a plasma glucose determination, (but that was presumabl y caused b y a plasma 
glucose concentration â‰¤70mg/dL [ â‰¤3.9 mmol/L ]), ie, sy mptoms treated with oral carbohy drate 
without a test of plasma glucose.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 82 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 82Relative hypoglycemia
Relative hy poglycemia, recentl y termed â€œpseudo -hypoglycemiaâ€ ( 22), is an event duri ng which 
the patient reports t ypical symptoms of h ypoglycemia, and interprets the s ymptoms as indicative 
of hy poglycemia, but with a measured plasma glucose concentration >70mg/dL ( >3.9 mmol/L ).
10.7 ADVERSE EVENTS MONITORING
All events will be managed and reported in compliance with all applicable regulations, and 
included in the final CSR.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 83 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 8311 STATISTICA L CONSIDERA TIONS
11.1 DETERMINA TION OF SA MPLE SIZE
The sample size/power calculations were performed based on the primary  endpoint.
A sample size of 280 patients in the sotagliflozin group and 140 patients in the placebo group will 
provide more than 90% power to detect a difference of 0.6% for change from Baseline to 
Week 26 in HbA1c between sotagliflozin and placebo ( standard deviation [ SD]=1.1%; 5% 
significance level 2-sided).
A sample size of 280 patients in the sotagliflozin group and 280 patients in the empagliflozin 
group will ensure that the upper bound of the 2 -sided 95% CI of the adjusted mean difference 
would not exceed 0.3% with more than 80% power to show non inferiority for intent -to-treat (ITT ) 
analysis and for completer analy sis considering 15% dropout . This calculation assumes a common 
SD of 1.1%, and the true difference between sotagliflozin and empagliflo zin is zero for change 
from Baseline to Week 26in HbA1c .
The total sample size will be approximately  700 patients to be randomized (sotagliflozin group: 
280; empagliflozin group: 280; placebo group: 140).
11.2 DISPOSITION OF PA TIENTS
The total number of patien tsfor each of the following categories will be presented in the CSR:
ï‚·Screened patients: patients who have signed the ICF
ï‚·Run-inpatients
ï‚·Randomized patients: patients with a treatment kit number allocated and recorded in IRT 
database, regardless of whethe r the treatment kit was used or not
ï‚·The safety  population (ie, randomized and treated patients)
ï‚·The ITT population
ï‚·The randomization strata (HbA1c at Screening [ â‰¤8.5%, >8.5%] ,SBP at Screening 
[<130 mmHg , â‰¥130 mmHg ], and metformin use at Screening [Yes, No] ). Any discrepancy  
between the strata assigned by  IRT and the information reported on eCRF will be listed for 
all randomized patients.
ï‚·Patients who have completed the 26 -week Double -Blind Treatment Period
ï‚·Patients who discontinued the I MP during the 26 -week Double- Blind Treatment Period , 
and the reasons for treatment discontinuation
ï‚·Patients who have completed the study
ï‚·Patients who discontinued the study , and the reasons for study  discontinuation .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 84 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 84For all categories of patients except screened, percentages will be calculated using the number of 
randomized patients as denominator for each treatment group.
A list ingof patients prematurel y discontinued from the treatment, along with reasons for 
discontinuation, will be provided. Similarly , a list ingofpatients prematurely discontinued from 
the study , along with reasons for discontinuation, will be provided.
Patients trea ted but not randomized, patients randomized but not treated ,and patient s randomized 
but not treated as randomized, will be identified and described in separate listings. The safet y 
experience of patients treated and not randomized will be reported separat ely, and these patients
will not be included in the safety population.
For an y patient randomized more than once, onl y the data associated with the first randomization 
will be used in an y anal ysis population. The safety experience associated with any  later
randomization will be assessed separatel y.
11.3 ANAL YSIS POPULA TIONS
11.3.1 Efficacy  populations
Efficacy  analy ses will be based on the treatment group allocated by  the IRT according to the 
randomization schedule at randomization visit (as randomized), irrespective o f the treatment 
actuall y received.
11.3.2 Intent â€“to-treat population
Efficacy  analy ses (with the exception of MMTT analy ses) will be based on the ITT population, 
defined as all randomized patients, irrespective of compliance with the study  protocol and 
procedures . Patients will be anal yzed for efficacy  anal yses according to the treatment group to 
which they  are randomized.
For some sites for which the standard meal supplies are not approved b y the local regulatory 
agency , the patients will not participate in the M MTT. Those patients in the specific region will 
not be included in the efficacy  population for MMTT anal yses (change from Baseline to Week 26 
in 2-hour PPG following an MMTT).
11.3.3 Safety  population
Safet y anal yses will be based on the safet y population, define d as all randomized patients who 
receive at least 1 dose of double -blind I MP (regardless of the amount of treatment administered).
Patients will be analy zed for safety  anal yses according to the treatment actually  received.
In addition:
ï‚·Nonrandomized, but t reated, patients will not be part of the safet y population, but their 
safet y data will be presented separatel y
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 85 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 85ï‚·Randomized patients for whom it is unclear whether they  took the study  medication will 
be included in the safet y population as randomized
ï‚·When a patient is exposed to both active treatment group and placebo, the patient will be 
analyzed in the corresponding active treatment group
ï‚·When a patient is exposed to both sotagliflozin and empagliflozin, the patient will be 
analyzed in the sotagliflozin gro up
ï‚·Randomized patients will be excluded from the safety population onl y if there is 
documented evidence (ie, all study  dates recorded as no medication taken) that patients 
have not taken at least 1 dose of double -blind IMP.
11.4 STATISTICA L METHODS
Continuous data will be summarized by treatment group using the number of observations 
available (N), mean, SD , minimum, median, and maximum.
Categorical data will be summarized by  treatment group using count and perc entage.
In general, descriptive statistics of quantitative efficacy  and safet y parameters (result and change 
from Baseline) b y scheduled visits will be provided on observed cases (OCs ), ie, inclusion of only
patients having nonmissing assessments at a specific visit.
The Baseline value is defined generally  as the last available value before the first dose of 
double -blind I MP or the last available value prior to randomization for patients who were 
randomized but never exposed to I MP.
For serum creatinine andeGFR, the Baseline value is defined a s the average of all values before
the first dose of double -blind I MP for those randomized and exposed or before randomization for 
those who were randomized but never expo sed to IMP.
Analy sis of demographics and Baseline characteristics, prior and concomitant medications will be 
provided in detail in the SAP .
11.4.1 Extent of study treatment exposure and compliance
The extent of study  treatment exposure and compliance will be asse ssed and summarized by  
actual treatment received within the safet y population.
11.4.1.1 Extent of investigational medicinal product exposure
The extent of study  treatment exposure will be assessed by  the duration of treatment exposure 
during the stud y.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 86 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 86The duration of treatment exposure will be the total number of daysof administration of the 
double -blind I MP, regardless of unplanned intermittent discontinuations. The duration of IMP 
exposure will be calculated as:
(Date of the last double -blind I MP taken â€“ Date of the first double -blind IMP taken) + 1
The number (%) of patients randomized and exposed to double -blind I MP will be presented by  
specific time periods for each treatment group. The time periods of interest will be defined in the 
SAP.
Descriptive statistics of duration of treatment exposure (number, mean, SD, minimum, median, 
and maximum) and cumulative exposure in patient y ear will also be presented by  treatment group 
in the safet y population.
11.4.1.2 Compliance
A given administration will be considered noncompli ant if the patient did not take the planned 
dose of treatment as required b y the protocol. No imputation will be made for patients with 
missing or incomplete data.
Treatment compliance, above- planned, and under -planned dosing percentages will be summarized
descriptivel y (N, mean, SD, median, min, and max). The percentage of patients with compliance
<80% will be summarized. I n addition, the number and percentage of patients with at least 1 day 
above -planned dose, as well as numbers and percentages of patient swith 0 to 20% and >20% of 
days under -planned dose.
11.4.2 Analyses of efficacy  endpoints
Efficacy  analy ses will be performed on the ITT population. Statistical testing will be performed 
for primary  endpoint and secondary  endpoints at Week 26 (or Week 12 for SBP ).
11.4.2.1 Analysis of primary efficacy endpoint
The statistical test will be two- sided tests at a nominal 5% significance level (Î± level) .
Analy sis of the primary  efficacy  endpoint (change from Baseline to Week 26 in HbA1c 
comparing sotagliflozin 400 mgversus placebo) will be performed on the ITT population, using 
HbA1c measurements obtained from visits during the study, includin g those obtained after IMP 
discontinuation or introduction of rescue therap y.
The primary  efficacy  endpoint of change from Baseline to Week 26 in HbA1c will be anal yzed 
with missing post -baseline values imputed b y placebo control -based copy reference multiple 
imputation method under the missing not at random framework:
ï‚·For placebo patients , missing data will be imputed based on the placebo group data
ï‚·For patients in the active arms (sotagliflozin and empagliflozin), missing data will be 
imputed as if the pa tientswere on placebo throughout the study , where all patients' 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 87 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 87measurements including the on-treatment measurements will be considered as if the 
measurements were from the placebo group in the imputation model.
Each of the complete datasets will be anal yzed by the analysis of covariance ( ANCOVA )model 
with treatment groups (sotagliflozin, empagliflozin, placebo), randomization strata of Screening 
HbA1c ( â‰¤8.5%, >8.5%), randomization strata of Screening SBP (<130 mmHg , â‰¥130 mmHg ) and 
metformin useat Screening (Yes, No) and country as fixed effects, and Baseline HbA1c value as 
a covariate. Results from each complete dataset will be combined to provide the adjusted mean 
change in HbA1c from Baseline to Week 26 for each treatment group, as well as the 
between -group difference (comparing sotagliflozin 400 mgvs placebo) and the 95% CI for the 
between -group difference .
Summary  statistics (for Screening value, Baseline value, observed values, and observed changes 
from Baseline ) at scheduled visits will be provided for each treatment group. The summary  will 
include the number of observations, mean, SD, standard error (SE ), minimum, median, and 
maximum. Graphical presentations will also be used to examine trends over time using mean values (Â±SE) and mean changes from Baseline (Â±SE) at each of the scheduled visits (using OC s).
Assessment of treatment eff ect by subgroup
Descriptive anal yses will be performed on the primary  endpoint to summarize the treatment 
effects across subgroups defined b y the following Baseline or Screening factors:
ï‚·Race
ï‚·Ethnicity  (Hispanic, Not Hispanic)
ï‚·Age group (<50 years, â‰¥50 to <65 y ears, â‰¥65 y ears)
ï‚·Gender
ï‚·Baseline BMI level (<30 kg/m
2, â‰¥30 kg/m2)
ï‚·Baseline HbA1c ( â‰¤8.5%, >8.5%)
ï‚·Baseline SBP (<130 mmHg, â‰¥130 mmHg)
ï‚·Country
ï‚·Metformin use at Screening (Yes, No)
ï‚·Baseline eGFR ( â‰¥30 to <60 mL /min/1.73m2[Mode rate decrease in GFR], â‰¥60 to 
<90mL/min/1.73m2[Mild decrease in GFR], and â‰¥ 90 mL /min/1.73m2[Normal])
ï‚·Duration of diabetes (<10, â‰¥ 10 years).
The treatment effects across the subgroups defined for each of these factors will be estimated for 
the change from Baseline to Week 26 in HbA1c in the ITT population, and using a similar 
approach to the anal ysis for the primary  efficacy  endpoint. The adjusted estimates of treatment 
mean differences (comparing sotagliflozin 400 mg versus empagliflozin and placebo) wit h SE and 
95% CI s will be provided as appropriate across the subgroups using contrast statements.
In the event that the subgroup factor is identical or similar to a r andomization strata factor 
(eg,Baseline HbA1c category ); onl y the subgroup factor (as a si ngle factor and/or an interaction 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 88 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 88term) will be included in the model to avoid the issue of co -linearit y in the anal ysis. The 
corresponding strata factor will not be included in the model.
11.4.2.2 Analyses of secondary efficacy endpoints
For each of the continuous secondary  endpoint s, a similar approach to the primary  efficacy  
endpoints will be used, with missing values imputed by placebo control -based copy reference 
multiple imputation method under the missing not at random framework:
ï‚·For patients receiving placebo, missing data will be imputed based on the placebo group 
data
ï‚·For patients in the active arms (sotagliflozin and empagliflozin) missing data will be 
imputed as if the patient swere on placebo group throughout the stud y, where all patientsâ€™ 
measurements i ncluding the on -treatment measurements will be considered as if the 
measurements were from the placebo group in the imputation model.
Each of the complete datasets will be anal yzed by the ANCOVA model with treatment groups 
(sotagliflozin, empagliflozin, placebo), randomization strata of Screening HbA1c ( â‰¤8.5%, >8.5%), 
randomization strata of Screening SBP (<130 mmHg , â‰¥130 mmHg ) and metformin useat 
Screening (Yes, No) and country  as fixed effects, and Baseline value as a covariate. For anal ysis 
in patient s with Baseline SBP â‰¥130 mmHg, the randomization stratum of SBP will not be 
included in the ANCOVA model. Results from each complete dataset will be combined to provide 
the adjusted mean change from Baseline to Week 12/Week 26 for each treatment group, as we ll as 
the between -group difference s and the 95% CIs for the differences.
Categorical secondary  endpoints such as HbA1c responders (<6.5 %, <7.0 %) at Week 26 will be 
analyzed using a Cochran- Mantel -Haenszel method stratified by  randomization strata of 
Screen ing HbA1c ( â‰¤8.5%, >8.5%), Screening SBP (<130 mmHg , â‰¥130 mmHg ) and metformin 
useat Screening (Yes, No). The proportion in each treatment group will be provided, as well as 
the difference of proportions between sotagliflozin and placebo with associated 2 -sided 95% CI. 
For HbA1c responders at Week 26, all values at Week 26 will be used to determine whether a 
patient is a responder or not, even if they  are measured after IMP discontinuation or rescue 
medication use. Patients who have no HbA1c measurement at Week26 will be treated as 
nonresponders .
A sensitivity  anal ysis to noninferiorit y test will be conducted with the 26 -week treatment 
completers using the Week 26 values and the same ANCOVA model described above.
11.4.2.3 Analysis of other efficacy endpoints
The anal ysis of other endpoints will be descriptive with no formal testing. Summary  statistics at 
scheduled visits using OCs will be provided by  each treatment group. Graphical presentations will 
also be used to illustrate trends over time.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 89 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 8911.4.2.4 Multiplicity considerat ions
To cont rol for the family -wise T ype I error, a fixed -sequence testing procedure will be applied.
Once the primary  hypothesis (superiorit y of the change from Baseline to Week 26 in HbA1c 
comparing sotagliflozin 400 mg versus placebo) is established sta tistically  significant for the 
primary  efficacy  endpoint, the following secondary  hypotheses will be tested in the following 
prioritized order:
1.The noninferiorit y of sotagliflozin versus empagliflozin on HbA1c reduction at Week 26
2.The superiorit y of sotagl iflozin versus placebo on 2- hour PPG reduction at Week 26
3.The superiorit y of sotagliflozin versus placebo on FPG reduction at Week 26
4.The superiorit y of sotagliflozin versus placebo on body  weight reduction at Week 26
5.The superiorit y of sotagliflozin versu s placebo on HbA1c responder anal ysis 
(HbA1c<7.0% at Week 26)
6.The superiorit y of sotagliflozin versus placebo on sitting SBP reduction at Week 12 in
patients with Baseline SBP â‰¥130 mmHg
7.The superiorit y of sotagliflozin versus placebo on sitting SBP reducti on at Week 12
8.The superiorit y of sotagliflozin versus empagliflozin on HbA1c reduction at Week 26
9.The superiorit y of sotagliflozin versus empagliflozin on sitting SBP reduction at Week 12 
inpatients with Baseline SBP â‰¥130 mmHg
10.The superiorit y of sotaglifl ozin versus empagliflozin on sitting SBP reduction at Week 12.
If any hypothesis is found to be not statistically  significant, the testing procedure will be stopped 
and the following h ypotheses will not be tested. The noninferiorit y hypothesis will be decl ared 
statistically  significant if the upper bound of the 2 -sided 95% CI  for the adjusted mean difference 
is <0.3. The superiorit y hypothesis will be declared statistically  significant at Î± = 0.05 (2 -sided).
No multiplicity  adjustment will be made on efficacy  variables other than those mentioned above .
11.4.3 Analyses of safety  data
The summary  of safet y results will be presented by treatment group .All safet y summaries will be 
descriptive; no statistical significance tests will be performed on safety  data.
Safet y endpoints are presented in Section 9.1.2. These analy ses will be based on the Safet y 
Population as defined in Section 11.3.3. Patients will be anal yzed for safety  analy ses according to 
the treatment actuall y received. All safet y analyses will be performed on the safet y population as 
defined in Section 11.3.3 using the following common rules:
The following definitions will be applied to laboratory  parameters and vital signs:
ï‚·Potentiall y clinicall y significant abnormalit y (PCSA) values for clinical laboratory  tests 
and vital signs will be defined as abnormal values considered medicall y important by the 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 90 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 90Sponsorâ€™s Global Pharmacovigilance and Epidemiology  department and in effect at the 
time of the final SAP approval. The PCSA criteria for parameters not cited in the protocol 
as safet y parameters will not be anal yzed
ï‚·The PCSA criteria will determine which patients had at least 1 PCSA during the 
Double- blind Treatment Period, taking into account all evaluations performed during the 
Double- blind Treatment Period, including unscheduled or repeated evaluations. The 
number of all such patients will be the numerator for the on- treatment PCSA percentage.
The â€œobservation periodsâ€ defined in Section 9.2are applicable for classification of AEs, 
determination of on -treatment PCSA values and the last on- treatment value for the laboratory , 
vital sign and ECG parameters.
11.4.3.1 Analysis of adverse events
Pretreatment AEs are AEs that developed or worsened or became serious during the 
pretreatment period.
Treatment -emergent AEs are AEs that developed or worsened (accor ding to the I nvestigatorâ€™s 
opinion) or became serious during the on -treatment period.
Post-treatment AEs are AEs that developed or worsened or became serious during the 
post-treatment period.
The primary  focus of AE reporting in the CSR will be on TEAEs. P re-and post -treatment AEs 
will be described separately .
All adverse events
Adverse event incidence tables will present b y system organ class (SOC ) (sorted by  
internationally  agreed order), high level g roup term (HLGT ), high level term (HLT) and preferred 
term (PT ) sorted in alphabetical order for e ach treatment group, the number (N) and percentage 
(%) of patients experiencing an AE. Multiple occurrences of the same event in the same patient 
will be counted only  once in the tables within a treatment phase. The denominator for 
computation of percentages is the safet y population within each treatment group.
Summaries of all TEAEs in each treatment group will include:
ï‚·The overview of AEs, summarizing number (%) of patients with an y:
-TEAE
-Serious TEAE
-TEAE leading to death
- TEAE leading to permanent treatm ent discontinuation.
ï‚·The number ( n) and percentage (%) of patients with at least one TEAE b y primary  SOC, 
HLGT, HLT, and PT
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 91 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 91ï‚·Summary  of TEAEs by  maximal severity  (severe, moderate, mild), presented by  primary  
SOC and PT
ï‚·Summary  of TEAEs possibly  related to IMP, presented by primary SOC, HLGT, HLT, 
and PT.
A detailed listing of TEAE summaries will be provided in the SAP.
Death and serious adverse events
Death and treatment -emergent SAEs will be summarized and presented as number and percent of 
patients in eac h treatment group.
The following deaths summaries will be generated:
ï‚·Number (n) and percentage (%) of patients who die d by study  period (on- study , 
on-treatment, post study ) summarized on the safety  population by  treatment received
ï‚·Death in nonrandomized patients or randomized and not treated patients
ï‚·TEAE leading to death (death as an outcome on the AE eCRF page as reported by  the 
Investigator) b y primary  SOC, HL GT, HLT, and PT showing number (n) and percentage 
(%) of patients sorted b y internationally  agree d order of SOC and alphabetic order of 
HLGT, HLT, and PT .
Adverse events leading to permanent treatment discontinuationTreatment -emergent AEs leading to permanent treatment discontinuation will be summarized and 
presented as number (n) and percent age (%) of patients in each treatment group.
11.4.3.2 Analyses of hypoglycemia
The number (n) and percent age (%) of patients and rate in patient- years (2 ty pes: the number of 
patients with events or the total number of events per 100 patient- years) of all hy poglycemia, 
severe h ypogl ycemia, and documented s ymptomatic hy poglycemia will be summarized by  
treatment group ,respectively . In addition, documented h ypoglycemia will also be anal yzed by 
using a threshold of plasma glucose of <54 mg/dL (<3.0 mmol/L )if applicable . Their pattern of 
occurrence over time will also be assessed, as appropriate.
11.4.3.3 Analyses of adverse events of special interest
Pregnancy  and overdose will be included in overall AE summaries if any  are re ported. Any  ALT 
increase of >3 xULN will be included in laboratory  PCSA summary .
11.4.3.4 Analyses of events of special interest
The number (n) and percent age (%) of patients with each EOSI event will be summarized by  
treatment group. All events reported by the Investigators on the AE forms for special interests will 
be listed along with the adjudication outcome (if applicable).
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 92 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 9211.4.3.5 Analyses of laboratory variables
The number (n) and percent age (%) of patients with PCSA or by  the predefined categories (if no 
PCSA criterion is defined) at an y evaluation during the on -treatment p eriod will be summarized 
for each clinical laboratory test within each treatment group. The summaries will include patients
in the safet y population who have at least one laboratory  test performed during the on -treatment 
period and, when required by  the de finition of the abnormality , with an available Baseline value 
and available laboratory  normal ranges.
Descriptive statistics will be used to summarize the laboratory  results and the changes from 
Baseline by visit and for the last on -treatment value within each treatment group. Shift tables and 
other tabular and graphical methods may  be used to present the results for laboratory  tests of 
interest. L istings will be provided with flags indicating out of laboratory  range values and PCSA 
values.
The liver function tests, namely  ALT, AST, ALP, and total bilirubin, are used to assess possible 
drug-induced liver toxicity (DILI) . The proportion of patients with PCSA values at any  
post-Baseline visit by  Baseline status will be display ed by  treatment group for each par ameter.
11.4.3.6 Analyses of vital sign variables
The number (n) and percent age (%) of patients with PCSA at any  evaluation during the 
on-treatment period will be summarized for each vital sign parameter within each treatment 
group. The summaries will include patie ntsin the safet y population who have at least one 
parameter to be anal yzed during the on -treatment period. Descriptive statistics will be used to 
summarize the results and the changes from Baseline by visit and for the last on -treatment value 
within each treatment group. Tabular and graphical methods may  be used to present the results for 
parameters of interest. Listings will be provided with flags indicating the PCSA values.
11.4.3.7 Analysis of 12- lead electrocardiogram status
A shift table will be provided to pr esent the ECG on- treatment status according to the Baseline 
status, by  treatment group.
11.4.4 Analyses of other endpoints
11.4.4.1 Pharmacokinetic
The PK endpoints are presented in Section 9.3.1. Pharmacokin etic sotagliflozin data may  be 
subjected to a population PK analy sis, which will be reported separatel y.
Individual plasma concentrations of sotagliflozin and of sotagliflozin -3-O- glucuronide at nominal 
sampling times will be listed.
Concentration data wil l be summarized by  visit and, if appropriate, within visit by  nominal 
sampling times (predose, 3 hours postdose), using descriptive statistics by  N, geometric mean, 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 93 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 93coefficient of variation, median, minimum and maximum at each visit/nominal sampling time 
point for sotagliflozin-treated patients.
11.4.4.2 Hemodynamic markers
The hemod ynamic marker endpoints are presented in Section 9.3.3.
Hemody namic markers including PRA, aldosterone, angiotensinogen 1, angiotensinogen 2 ,and 
glucagon will be checked to provide better characterization of hemody namic markers in relation 
to sotagliflozin treatment.
11.4.4.3 Ambulatory blood pressure monitoring substudy
The anal ysis of ABPM endpoints will be descriptive with no form al testing. Summary  statistics at 
scheduled visits using OC of sufficient qualit y will be provided b y each treatment group.
11.5 INTERIM A NALYSIS
No formal interim analy sis for efficacy  is planned for this study .The stud y will not be terminated 
early for excel lent efficacy .
An independent DMC will monitor and assess the safet y of patients from this trial through 
periodic review of the accumulated safety  data provided by  an independent statistical group.
Related details are provi ded in separate documents (DMC Charter and DMC SAP).
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 94 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 9412 ETHICA L AND REGULA TORY CONSIDERA TIONS
12.1 ETHICA L AND REGULATORY STA NDA RDS
This clinical trial will be conducted b y the Sponsor, the Investigator, and delegated Investigator 
staff and Sub-investigator , in accordance with consensus ethics pr inciples derived from 
international ethics guidelines, including the Declaration of Helsinki, and the International 
Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH ) 
guidelines for good clinical practice (GCP), all applicable laws, rules and regulations.
This clinical trial wi ll be recorded in a free, publicly  accessible, internet- based registry , no later 
than 21 daysafter the first patient enrollment, in compliance with applicable regulatory  
requirements and with Sanofi public disclosure commitments.
12.2 INFORMED CONSENT
The Inve stigator (according to applicable regulatory  requirements), or a person designated by  the 
Investigator, and under the Investigator's responsibility , should full y inform the patient of all 
pertinent aspects of the clinical trial including the written inform ation giving approval/favorable 
opinion by  the ethics committee (I RB/IEC). All participants should be informed to the fullest 
extent possible about the study , in language and terms they  are able to understand.
Prior to a patientâ€™s participation in the clinical trial, the written ICFshould be signed, name filled 
in and personall y dated by the patient or b y the patientâ€™s legally acceptable representative, and b y 
the person who conducted the informed consent discussion. A cop y of the signed and dated 
written ICF will be provided to the patient.
Separate informed consent will be sought for participation in the ABPM substudy .
The ICF used b y the Investigator for obtaining the patientâ€™s informed consent must be reviewed 
and approved b y the Sponsor prior to submis sion to the appropriate ethics committee (I RB/IEC) 
for approval/favorable opinion
12.3 HEALTH AUTHORITIES A ND INSTITUTIONA L REVIEW BOA RD/INDEPENDENT 
ETHICS COMMITTEE (IRB/IEC)
As required b y local regulation, the I nvestigator or the Sponsor must submit this cli nical trial 
protocol to the health authorities (competent regulatory  authorit y) and the appropriate IRB/IEC, 
and is required to forward to the respective other part y a cop y of the written and dated 
approval/favorable opinion signed b y the chairman with I RB/IEC composition.
The clinical trial (stud y number, clinical trial protocol title and version number), the documents 
reviewed (clinical trial protocol, ICF, IBwith an y addenda or labeling documents, summary  of 
product characteristics, package insert, Investigatorâ€™s curriculum vitae, etc.) and the date of the 
review should be clearly  stated on the written (IRB/IEC) approval/favorable opinion.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 95 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 95The IMP will not be released at the stud y site and the Investigator will not start the study before 
the written and dated approval/favorable opinion is received by  the Investigator and the Sponsor.
During the clinical trial, any amendment or modification to the clinical trial protocol should be 
submitted to the health authorities (competent regulatory  authority ), as req uired b y local 
regulation, in addition to the I RB/IEC before implementation, unless the change is necessary  to 
eliminate an immediate hazard to the patient s, in which case the health authorities (competent 
regulatory  authority ) and the I RB/IEC should be in formed as soon as possible. They  should also 
be informed of an y event likely to affect the safet y of patients or the continued conduct of the 
clinical trial, in particular any  change in safet y. All updates to the IB or labeling information will 
be sent to the IRB/IEC and to health authorities (competent regulatory  authority ), as required by  
local regulation.
A progress report is sent to the I RB/IEC at least annually  and a summary  of the clinical trialâ€™s 
outcome at the end of the clinical trial.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 96 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 9613 STUDY MONITORING
13.1 RESPONSIBILITIES OF THE INVESTIGA TOR
The Investigator is required to ensure compliance with all procedures required by  the clinical trial 
protocol and with all study procedures provided b y the Sponsor (including securit y rules). The 
Investigator agree s to provide reliable data and all information requested by the clinical trial 
protocol (with the help of the eCRF , Discrepancy  Resolution Form , or other appropriate 
instrument) in an accurate and legible manner according to the instructions provided and t o ensure 
direct access to source documents by Sponsor representatives.
If any circuit includes transfer of data , particular attention should be paid to the confidentialit y of 
the patient's data to be transferred.The Investigator may  appoint such other ind ividuals as he/she may  deem appropriate as 
Sub-investigators to assist in the conduct of the clinical trial in accordance with the clinical trial 
protocol. All Sub- investigators shall be appointed and listed in a timely  manner. The 
Sub-investigators will b e supervised b y and work under the responsibility  of the Investigator. The 
Investigator will provide them with a cop y of the clinical trial protocol and all necessary  
information.
13.2 RESPONSIBILITIES OF THE SPONSOR OR SERVICE PROVIDER
The Sponsor and/or servi ce provider of this clinical trial is responsible to regulatory  authorities for 
taking all reasonable steps to ensure the proper conduct of the clinical trial regarding ethics, 
clinical trial protocol compliance, and integrit y and validity of the data reco rded on the eCRFs . 
Thus, the main duty  of the monitoring team is to help the Investigator and the Sponsor maintain a 
high level of ethical, scientific, technical and regulatory  quality  in all aspects of the clinical trial.
At regular intervals during the c linical trial, the site will be contacted, through monitoring visits, 
letters or telephone calls, by  a representative of the monitoring team to review study  progress, 
Investigator and patient compliance with clinical trial protocol requirements and any  eme rgent 
problems. These monitoring visits will include but not be limited to review of the following 
aspects: patient informed consent, patient recruitment and follow -up, SAE documentation and 
reporting, AESI documentation and reporting, AE and EOSI document ation, I MP allocation, 
patient compliance with the IMP regimen, IMP accountability , concomitant therap y use
(including rescue therap y),and qualit y of data.
13.3 SOURCE DOCUMENT REQUIREMENTS
According to the ICH GCP, the monitoring team must check the eCRF entries against the source 
documents, except for the preidentified source data directl y recorded in the eCRF . The ICFwill 
include a statement b y which the patient allows the Sponsorâ€™s duly  authorized personnel, the 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 97 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 97ethics committee (IRB/IEC), and the regulatory  authorities to have direct access to original 
medical records which support the data on the eCRF s(eg, patient's medical file, appointment 
books, original laboratory records, etc.). These personnel, bound by  professional secrecy , must 
maintain the confidentiality  of all personal identity  or personal medical information (according to 
confidentiality  and personal data protection rules).
13.4 USE A ND COMPLETION OF CA SE REPORT FORMS (CRFS) A ND ADDITIONA L 
REQUEST
It is the responsibility  of the Investigator to maintain adequate and accurate e CRF s(according to 
the technology  used) designed b y the Sponsor to record (according to Sponsor instructions) all 
observations and other data pertinent to the clinical investigation in a timely manner. All eCRFs
should be compl eted in their entiret y in a neat, legible manner to ensure accurate interpretation of 
data.
Should a correction be made, the corrected information will be entered in the eCRF overwriting 
the initial information. An audit trail allows identify ing the modifi cation.
Data are available within the sy stem to the Sponsor as soon as they  are entered in the eCRF.
The computerized handling of the data b y the Sponsor or service provider may generate additional 
requests (DRF) to which the Investigator is obliged to respond by  confirming or modify ing the 
data questioned. The requests with their responses will be managed through the eCRF.
13.5 USE OF COMPUTERIZED SYSTEMS
The complete list of computerized sy stems used for the study  is provided in a separate document 
which is ma intained in the Sponsor trial master file .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 98 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 9814 ADDITIONA L REQUIREMENTS
14.1 CURRICULUM VITA E
A current cop y of the CVdescribing the experience, qualification, and training of each 
Investigator and Sub-investigator will be signed, dated ,and provided to the Sponsor or service 
provider prior to the beginning of the clinical trial.
14.2 RECORD RETENTION IN STUDY SITES
The Investigator must maintain confidential ity forall study  documentation, and take measures to 
prevent accidental or premature destruction of these documen ts.
The Investigator should retain the study  documents at least 15 y ears after the completion or 
discontinuation of the clinical trial.
However, applicable regulatory  requirements should be taken into account in the event that a 
longer period is required.The Investigator must notify the Sponsor prior to destroy ing any  study  essential documents 
following the clinical trial completion or discontinuation.If the Investigator's personal situation is such that archiving can no longer be ensured b y him/her, 
the Investigator shall inform the Sponsor and the relevant records shall be transferred to a 
mutually  agreed upon designee.
14.3 CONFIDENTIA LITY
All information disclosed or provided b y the Sponsor (or an y compan y/institution acting on their 
behalf), or produced du ring the clinical trial, including, but not limited to, the clinical trial 
protocol, personal data in relation to the patient s, the e CRF , the IB, a nd the results obtained during 
the course of the clinical trial, is confidential, prior to the publication of results. The I nvestigator 
and an y person under his/her authorit y agree to undertake to keep confidential and not to disclose 
the information to an y third part y without the prior written approval of the Sponsor.
However, the submission of this clinical tri al protocol and other necessary documentation to the 
ethics committee (IRB/IEC) is expressly  permitted, the I RB/IEC members having the same 
obligation of confidentiality .
The Sub-investigator s shall be bound by  the same obligation as the Investigator. The Investigator 
shall inform the Sub-investigator s of the confidential nature of the clinical trial.
The Investigator and the Sub-investigator s shall use the information solel y for the purposes of the 
clinical trial, to the exclusion of any  use for their own or for a third part yâ€™s account.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 99 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 10014.6 INSURA NCE COMPENSA TION
The Sponsor certifies that it has taken out a liability  insurance policy  covering all clini cal trials 
under its sponsorship. This insurance policy is in accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve the Investigator and the collaborators from any  
obligation to maintain their own liability  insurance po licy. An insurance certificate will be 
provided to the IECs/I RBs or regulatory  authorities in countries requiring this document.
14.7 SPONSOR A UDITS AND INSPECTIONS BY REGULA TORY AGENCIES
For the purpose of ensuring compliance with the clinical trial protocol, GCP , and applicable 
regulatory  requirements, the Investigator should permit auditing by  or on the behalf of the 
Sponsor and inspection by regulatory  authorities.
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her stud y 
records for review, being understood that these personnel arebound by  professional secrecy , and 
as such will not disclose any  personal identit y or personal medical information.
The Investigator will make every  effort to help with the performance of the audits and inspections, 
giving access to all necessary  facilities, data, and documents.
As soon as the Investigator is notified of a planned inspection by  the authorities, he will inform 
the Sponsor and authorize the Sponsor to participate in this inspecti on.
The confidentialit y of the data verified and the protection of the patient sshould be respected 
during these inspections.
Any result and information arising from the inspections by  the regulatory  authorities will be 
immediately  communicated by  the Inve stigator to the Sponsor.
The Investigator shall take appropriate measures required b y the Sponsor to take corrective 
actions for all problems found during the audit or inspections.
14.8 PREMA TURE DISCONTINUA TION OF THE STUDY OR PREMA TURE CLOSE -OUT OF 
A SITE
14.8.1 By the Sponsor
The Sponsor has the right to terminate the participation of either an individual site or the study  at 
any time, for any  reason, including ,but not limited to ,the following:
ï‚·The information on the product leads to doubt as to the benefit/risk r atio
ï‚·Patient enrollment is unsatisfactory
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 101 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 101ï‚·The Investigator has received from the Sponsor all I MP, means, and information necessary  
to perform the clinical trial and has not included any  patient after a reasonable period of 
time mutually  agreed upon
ï‚·Noncompliance of the Investigator or Sub-investigator , delegated staff with any  provision 
of the clinical trial protocol, and breach of the applicable laws and regulations or breach of 
the ICH GCP
ï‚·The total number of patients is included earlier than expected .
Inany case the Sponsor will notify  the Investigator of its decision by written notice.
14.8.2 By the Investigator
The Investigator may  terminate his/her participation upon thirty  (30) days' prior written notice if 
the study  site or the Investigator for an y reason becomes unable to perform or complete the 
clinical trial.
In the event of premature discontinuation of the study  or premature close -out of a site, for an y 
reason whatsoever, the appropriate IRB/IEC and regulatory  authorities should be informed 
according to applicable regulatory  requirements.
14.9 CLINICA L TRI AL RESULTS
The Sponsor will be responsible for preparing a CSR and providing a summary  of study  results to 
the Investigator.
14.10 PUBLICA TIONS A ND COMMUNICA TIONS
The Investigator undertakes not to make an y public ation or release pertaining to the study  and/or 
results of the study  prior to the Sponsorâ€™s written consent, being understood that the Sponsor will 
not unreasonabl y withhold its approval .
As the study  is being conducted at multiple sites, the Sponsor agree s that, consistent with 
scientific standards, a primary  presentation or publication of the study  results based on global 
study  outcomes shall be sought. However, if no multicenter publication is submitted, underway , 
or planned within 12 months of the completion of this study  at all sites, the I nvestigator shall have 
the right to publish or present independentl y the results of this study  in agreement with other 
Investigators and stakeholders. The Investigator shall provide the Sponsor with a copy  of an y such
presentation or publication for review and comment at least 30 daysin advance of any  
presentation or submission for publication. In addition, if requested b y the Sponsor, any 
presentation or submission for publication shall be delayed for a limited time, not to exceed 
90days, to allow for filing of a patent application or such other justified measures as the Sponsor 
deems appropriate to establish and preserve its proprietary  rights.
The Investigator shall not use the name(s) of the Sponsor and/or its employees in advertising or 
promotional material or publication without the prior written consent of the Sponsor. The Sponsor 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 102 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 102shall not use the name(s) of the Investigator and/or the collaborators in advertising or promotional 
material or publication without having received his/her and/or their prior written consent(s).
The Sponsor has the right at any  time to publish the results of the study .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 103 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 10315 CLINICA L TRI AL PROTOCOL A MENDMENTS
All appendices attached hereto and referred to herein are made part of this clinica l trial protocol.
The Investigator should not implement any  deviation from, or changes to the clinical trial protocol 
without agreement b y the Sponsor and prior review and documented approval/favorable opinion 
from the IRB/IEC and/or notification/approval of health authorities (competent regulatory  
authority ) of an amendment, as required by  local regulation, except where necessary  to eliminate 
an immediate hazard(s) to clinical trial patients, or when the change(s) involves only  logistical or 
administrative aspects of the trial. Any change agreed upon will be recorded in writing ;the 
written amendment will be signed by  the Investigator and b y the Sponsor and the signed 
amendment will be filed with this clinical trial protocol.
Any amendment to the clinical trial protocol requires written approval/favorable opinion b y the 
IRB/IEC prior to its implementation, unless there are overriding safet y reasons.
In case of substantial amendment to the clinical trial protocol, approval from the health authorities 
(compete nt regulatory  authority ) will be sought before implementation.
In some instances, an amendment may  require a change to the ICF. The Investigator must receive 
an IRB/IEC approval/favorable opinion concerning the revised ICFprior to implementation of the 
change and patient signature should be re -collected if necessary .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 104 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 10416 BIBLIOGRA PHIC REFERENCES
1.Kahn SE, Cooper ME, Del Prato S. Pathophy siology  and treatment of t ype 2 diabetes: 
perspectives on the past, present, and future Lancet. 2014;383:1068-83.
2.Fowler MJ. Microvascular and Macrovasc ular Complications of Diabetes. Clinical Diabetes. 
2008;26(2):77 -82.
3.Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the y ear 2050 
burden of diabetes in the US adult population: dy namic modeling of incidence, mortalit y, and 
prediabe tes prevalence. Popul Health Metr. 2010;8:29.
4. International Diabetes Federation. IDF Diabetes Atlas, 7th ed. Brussels, Belgium: 
International Diabetes Federation, 2015. Available from URL : http://www.diabetesatlas.org. 
[Accessed November 2016].
5. World Health Organization, Regional Office for Europe, Data and Statistics. Available from 
URL : http://www.euro.who.int/en/health-topics/noncommunicable- diseases/diabetes/data -
andstatistics. [Accessed November 2016].
6.Hediger HA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of 
the Na+/glucose co -transporter. Nature. 1987;330(6146):379 -81.
7.Wright EM. I. Glucose galactose malabsorption. Am J Phy siol. 1998;275(5 Pt 1):G879-82.
8.Mudalier S, Polidori D, Zambrowicz B, Henry  RR.  Sodium â€“glucose cotransporte r inhibitors: 
Effects on renal and intestinal glucose transport:  from bench to bedside. Diabetes Care. 
2015;38:2344â€“53.
9.Raskin P. Sodium â€“glucose cotransporter inhibition:  therapeutic potential for the treatment of 
type 2 diabetes mellitus.  Diabetes Metab Res Rev. 2013;29(5):347â€“56.
10.Canagliflozin [package insert]. Titusville, NJ, Janssen Pharmaceuticals, Inc.;July  2016. p 1-15.
11.Dapagliflozin [package insert]. Wilmington, DE, AstraZeneca Pharmaceuticals L P;June 2016. 
p 1-10.
12.Empagliflozin [package insert]. Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals, Inc., 
and Indianapolis, IN, Eli Lill y and Compan y;July 2016. p 1 -25.
13. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl U, Woerle H. Empagliflozin 
reduces blood pressure in patients With ty pe 2 diabe tes and h ypertension. Diabetes Care. 2015 
Mar;38(3):420-8.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 105 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 10514.Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, et al. L X4211, a 
dual SGL T1/SGLT2 inhibitor, improved gl ycemic control in patients with ty pe 2 diabetes in a 
randomized, placebo -controlled trial. Clin Pharmacol Ther. 2012;92(2):158-169.
15.Rosenstock J, Cefalu WT, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P, Sands A. Greater 
dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of 
SGL T1 and SGLT2, in patie nts with ty pe 2 diabetes on metformin monotherapy . Diabetes 
Care. 2015 Mar;38(3):431-8.
16. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, 
Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2
Inhibitor, as Adjunct Therap y to Insulin in Type 1 Diabetes. Diabetes Care. 2015 
Jul;38(7):1181-8.
17.Lexicon Pharmaceuticals, I nc., Clinical Study  Report for: A Phase 1, Randomized, Double 
blind, Placebo controlled, Ascending Single and Multiple Dose Study  to Determine the Safet y 
and Tolerabilit y of Orally Administered LX4211 in Healthy  Human Subjects (LX4211.1 -114-
NRM).
18.Levey  AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to 
estimate glomerular filtration rate from serum creatinine : a new prediction equation. 
Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70.
19.Florkowski CM, Chew -Harris JS. Methods of Estimating GFR - Different Equations I ncluding 
CKD -EPI. Clin Biochem Rev. 2011;32(2):75-9.
20.Workgroup on Hy poglycemia, American Diabetes Association. Defining and reporting 
hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on 
Hypoglycemia. Diabetes Care. 2005;28(5):1245-9.
21.FDA Guidance for Industry :  Diabetes Mellitus - Developing Drugs and Therapeutic Biologics 
for Treatment and Prevention. L ines 1144 â€“ 1215. Available from: 
http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf. Accessed July 12, 2016.
22.Seaquist ER, Anderson J, C hilds B, Cry er P, Dagogo- Jack S, Fish L, et al. Hy poglycemia and 
Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society . Diabetes Care. 2013;36(5):1384-95.
23. Mancia G, Fagard R, Narkiewicz K,  Redon J, Zanchetti A, BÃ¶hm M, et al. 2013 ESH/ESC 
guidelines for the management of arterial hy pertension: the Task Force for the Management of 
Arterial Hy pertension of the European Society  of Hy pertension (ESH) and of the European 
Society  of Cardiology  (ESC). Eur Heart J. 2013; 34(28):2159â€“219.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 106 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 10617 APPENDICES
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 107 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 107Appendix A Contraceptive guidance and collection of pregnancy information
DEFINITIONS
Woman of childbearing potential (WOCBP)
A woman is considered fertile following menarch e and until becoming post menopausal unless 
permanentl y sterile (see below).
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
-Documented h ysterectomy
-Documented bilateral salpingectomy
-Documented bilateral oophorectom y.
3.Postmenopausal female
- A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high FSH level in the postmenopausal range may  be used to confirm 
a postmenopausal state in women not using hormonal contraception or hormon e
replacement therap y (HRT ). However, in the absence of 12 months of amenorrhea, a 
single FSH measurement is insufficient
-Females on HRT and whose menopau sal status is in doubt will be required to use one 
of the nonhormonal highly effective contraception methods if they  wish to continue 
their HRT during the study . Otherwise, they  must discontinue HRT to allow 
confirmation of postmenopausal status before stu dy enrollment.
CONTRACEPTION GUIDANCE
Female participants
Women of reproductive potential (WOCBP) must use a highly  effective method of contraception 
during the treatment period and the post- treatment follow up period (28 Â±5 day s). If another 
contraceptive method is used (such as a barrier method), it should be used in combination with 
one of the highly effective methods (such as an oral contraceptive).
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 108 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 108Table 4 -Highly Effective Contraceptive Methods
Highly Effective Contraceptive Methods that are User Dependenta
Failure rate of <1%  per year when used consistently and correctly
ï‚· Combined (estrogen -and progestogen -containing ) hormonal contraception associated with inhibition of ovulation :
- Oral
- Intravagi nal
- Transdermal .
ï‚· Progestogen -only hormone contraception associated with inhibition of ovulation :
- oral
- injectable .
Highly Effective Methods that a re User Independenta
ï‚· Implantable progestogen -only hormonal contraception associ ated with inhibition of ovulation :
- Intrauterine device 
- Intrauterine hormone- releasing system.
ï‚· Bilateral tubal occlusion .
Vasectomized partner
A vasectomized partner is a highly effective contraceptive method provided that the partner is the sole 
sexual p artner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.
Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
NOTES:
aTypical use failure rates may differ from those when used consistently and correctly. Use should be consistent with local reg ulations 
regarding the use of contraceptive methods for participants participating in clinical studies.
COLLECTION OF PREGNAN CY INFORMATION
Male participants with partners who become pregnant
ï‚·The Investigator will attempt to collect pregnancy  information on any  male participantâ€™s 
female partner who becomes pregnant while the male participant is in this study . This 
applies only  to male participants who receive study  treatment
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 109 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 109ï‚·After obtaining the necessary  signed informed consent from the pregnant female partner 
directl y, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 24 hours of learning of the partnerâ€™s pregnancy .The 
female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the Sponsor. 
Generally , the follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date. Any  termination of the pregnancy  will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for procedure.
Female participants who become pregnant 
ï‚·The Investiga tor will collect pregnancy  information on any  female participant who 
becomes pregnant while participating in this study. I nformation will be recorded on the 
appropriate form and submitted to the Sponsor within 24 hours of learning of a participant's pregna ncy. The participant will be followed to determine the outcome of the 
pregnancy . The Investigator will collect follow -up information on the participant and the 
neonate, and the information will be forwarded to the Sponsor. Generall y, follow -up will 
not be required for longer than 6 to 8 weeks bey ond the estimated delivery date. Any  
termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for procedure
Any pregnancy  complication or elective termin ation of a pregnancy  will be reported as an 
adverse event ( AE)or serious adverse event ( SAE ).A spontaneous abortion is alway s 
considered to be an SAE and will be reported as such. Any  poststudy  pregnancy -related 
SAE considered reasonably  related to the study  treatment by  the Investigator will be 
reported to the Sponsor as described in Section 10.4.3 . While the I nvestigator is not 
obligated to activel y seek this information in former study par ticipants, he or she may  
learn of an SA E through spontaneous reporting
ï‚·Any female participant who becomes pregnant while participating in the study  will 
discontinue study  treatment or be withdrawn from the study .
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 110 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 110Appendix B Ambulator y blood pressure monitoring substudy
Background
A Phase 2 trial of sotagliflozin (L X4211.1- 202) provided evidence that sotagliflozin reduced both 
systolic blood pressure ( SBP)and diastolic blood pressure ( DBP )in patients with elevated SBP 
and DBP at Baseline, but not in normotensive patients. I n this substudy  of approximately  
180patients, patients with similar Baseline BP distribution as the full study population (ie, equal 
numbers of patients with SBP <130 mmHg or â‰¥130 mmHg) will have ambulatory  blood pressure 
monitoring ( ABPM) assessed for 24 hours via ambulatory  blood pressure ( BP)monitoring 
technology . The ABPM substudy  includes 3 sets of assessments, at 1 week before the 
Randomization Visit , and the days before the Week 12 and 26 visits, respectively , to provide a 
more sy stematic assessment of the SBP and DBP lowering efficacy  of sotagliflozin.
Ambulatory  blood pre ssure monitoring will be performed with a validated device provided by  the 
Sponsor or Sponsor representative .The AB PMdata process will be facilitated by  a vendor,  
( , USA).
Substudy procedures
At the preselected stud y sites participating i n the ABPM substudy , patients must consent to be a 
part of the substudy  to participate in the main study  until the planned number of patients for 
substudy  has been achieved.
At Visit 1, patients will be provided with information on the ABPM substudy  and se parate written 
consent will be taken before ABPM substudy -specific procedures are performed. Patients who 
work a night (third) shift (defined as 11:00 PM [23 :00] to 7:00 AM [07 :00]) will be excluded 
from the ABPM substudy .
Patients in the ABPM substudy  will have 3 additional visits to the site for placement of the ABPM 
device. These will be Visits 3A, 6A, and 8A. Visit 3A will occur at Week -1, 1 week before the 
Randomization Visit . Visit 6A,and Visit 8Awill occur the day  before Visit 6 (Week 12) and Visi t 
8 (Week 26).Patients do not need to be fasting at these 3 visits.
Patients who discontinued the Investigational Medicinal Product ( IMP)during the study  before 
the visit for ABPM will not continue in t he ABPM substudy  post -IMP discontinuation. Patients 
who receive rescue therapy  but remain on IMP will continue on the ABP Msubstudy  as planned.
On the 3 visit day s (Visits 3A, 6A ,and 8A ) each recording will start in the morning, preferabl y 
between 08:00 and 10:00 immediately  after the administra tion of study  medication, and will end 
after at least 24 hours of recording on the following day.
ï‚·Investigator and/or designee will help patients wear the ambulant BP monitor and the 
appropriate BP cuff (depending on the patientâ€™s arm size) on the nondomin ant upper arm
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 111 of 298

Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 111ï‚·Patients should be aware that the device will automatically inflate the cuff and measure the 
BP every  20 minutes during the day -time (08:00 and 21:59) and every  30 minutes during 
the sleeping time (22:00 and 07:59) over a 24- hour period
ï‚·During the ABPM period, patients should continue their daily  activities and concomitant 
medications, but avoid activities that may  interfere with functioning of the device such as 
vigorous exercis e, bathing, or taking a shower
ï‚·When the cuff starts to inflate, t he patient should remain still and avoid arm movement.
ï‚·Patients will record the time of sleep and any  unusual events or poor sleep quality  during 
the ABPM recording period in their study  diary
ï‚·Patients will be instructed to remove the BP device after 24-hour wearing the ABPM device:
-Once the ABPM de vice has been placed at Visit 3A , patients will be instructed to 
remove it 24 hours later and return it to the site by mail in appropriate packaging 
provided b y the site
- T went y-four hours after Visits 6A and 8A, patients will return to the site in a fasting 
state at Visits 6 and 8, respectively, and the device will be removed at the site.
All ABPM data will be reviewed following return of the device to ensure quality  of the recording. 
The quality  of a visit recording will be considered insufficient if the visit recording does not meet 
the criteria below:
1. Visit recording does not contain â‰¥17 nonconsecutive hours of data where each hour has at
least one valid BP measurement
2.Visit recording has <44 total measurements.
Patients with ABPM data not of sufficient qualit y will be asked to repeat the process as soon as 
possible. Patients with ABPM data not of sufficient quality  at Visit 3A should not be randomized 
until the Baseline ABPM recording has been repeated, and the Randomization Visit (Visit 3) will 
be postponed correspondingl y.
Patients must be well trained to understand the importance of the ABPM performance and 
compliance of the instruction. Technique support via a 24/7 help- line service for troubleshooting 
will be provided b y . The patients should immediately contact the sites if they encounter an y 
device -related events (malfunction) or any  questions about the ABPM. The investigator or site 
staff will help patients contact the  service line for problem solving.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 112 of 298

Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 112Appendix C Two-hour standardized mixed meal
A 2-hour postprandial glucose ( PPG)will be obtained after a standardized mixed meal in all 
patients at Baseline (Day 1, Visit 3) and at Week 26 (Visit 8). P atientsrequiring rescue therap y
prior to Week 26 (see Section 9.1.4.3) should still have the standa rdized mixed meal tolerance test 
(MMTT )performed at Week 26 .Patients who permanentl y discontinued the Investigational 
Medicinal Product (IMP) before Week 26 will not perform the MMTT at the planned Visit 8
(Week 26) .
The standardized MMTT must not be performed while patien ts are temporarily  off IMP; the 
Medical Monitor will address an y episodes on a case -by-case basis and the standardized MMTT 
will be rescheduled when the patient can resume IMP, if applicable.
The first dose of double -blind investigational medicinal product (IMP; and dosing with dipeptidy l 
peptidase 4 inhibitor [ DPP4 (i)] and metformin , if applicable) on Day  1 (Visit 3) will be given 
after completion of the 2 -hour PPG collection. For the Week 26 standardized MMTT , the patient 
should take the dose of double-bl ind IMP immediately  after the fasting blood samples are 
obtained, and approximately 30 minutes before ingestion of the standardized mixed meal begins. 
At Week 26, DPP4(i) and metformin (if applicable) dosing will occur after collection of the 
2-hour PPG sa mple and 3 hour PK sample are completed .
Standard Meal for the Standardized Mixed Meal:
The standard (breakfast) meal will be provided by the Sponsor as a liquid nutrition drink (BoostÂ®, 
EnsureÂ®, or similar), with approximately  40 g carbohy drate and approx imately  240 calories per 
bottle ( approximately  8 ounces). The cal oric composition of the meal is approximately  65% 
carboh ydrate, approximately  15% protein, and approximately  20% fat. The amount given is 
6mL/kg body  weight up to a maximum of 360 mL. Theref ore,for patients â‰¥60 kg, the standard 
meal consists of approximately  60 g carboh ydrate and 360 calories.
Patients are instructed to completely  consume the meal within 15 minutes, and every  effort should 
be made to complete the meal within 20 minutes after it is started. Water or noncaffeinated, zero 
calorie beverages may  be consumed ad libitum. No other food may  be consumed until the 2 -hour 
PPG plasma sample has been collected. If the patient is unable to consume at least 50% of the 
standard mixed meal, the MMTT should not be completed and the subsequent standardized 
MMTT should not be performed. If the patient is able to consume >50% of the standardized 
mixed meal, the approximate amount should be recorded, and an equivalent amount should be consumed at the subsequent standardized mixed meal.
Baseline Visit (Day 1, Visit 3) Standardized MMTT :
1.Record in the source documents the amount and brand name of the standard meal liquid 
nutrition drink the patient is instructed to consume
2.Fasting blood samples are obt ained, including Time 0 fasting FPG
3. Record the time of blood sample collection in the source documents
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 113 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 1134.Immediatel y after the fasting blood samples are collected, the patient starts consuming the 
standard meal
5.Record the time the meal ingestion starts in th e source documents
6.The 2 -hour countdown for the 2- hour plasma PPG starts immediately  after the patient 
begins ingestion of the standard meal
7.The patient is instructed to ingest the prescribed amount within 15 to 20 minutes.
8.Record the time ingestion is completed, measure the portion of the meal not ingested (if 
any), and record the assessed percent of prescribed amount ingested in the source 
documents
9.No blood samples for PK are collected at this visit
10.Two hours after the meal ingestion starts, the 2 -hour p lasma PPG is collected
11.Record the time the 2 -hour plasma PPG is collected in source documents
12. Double- blind IMP (and DPP4[i] and metformin, if applicable) are administered after the 
blood sample is drawn at 120 minutes
13.Record the time the double -blind I MP i s administered in the source documents.
Week 26 Visit (Visit 8) Standardized MMTT :
1.Record in the source documents the amount and brand name of the standard meal liquid 
nutrition drink the patient is instructed to consume
2.Fasting blood samples are obtained, including Time 0 FPG and predose PK samples
3. Record the time of blood sample collection in the source documents
4. Double-blind IMP is administered after the fasting blood samples are obtained5.Record the time the double -blind I MP is administered in the source documents
6.Thirty  minutes after the double -blind I MP is administered, the patient starts consuming the 
standard meal
7. Record the time the meal ingestion starts in the source documents8.The 2 -hour countdown for the 2- hour PPG starts immediately  after the pati ent begins 
ingestion of the standard meal
9.The patient is instructed to ingest the prescribed amount within 15 to 20 minutes
10. Record the time ingestion is completed, measure the porti on of the meal not ingested 
(ifany), and record the assessed percent of prescribed amount ingested in the source 
documents
11.Two hours after the meal ingestion starts, the 2 -hour PPG sample is collected
12.Two hours and 30 minute s after the meal ingestion starts, the 3 -hour PK sample is 
collected
13.DPP4(i) and m etformin (if applicable) are administered after the PK blood sample is 
drawn
14.Record in the source documents the time the 2- hour postprandial blood samples are 
collected.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 114 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 114Appendix D Recommendations on basic genito urinary hygiene, maintaining 
hydration and recognizing diabetic ketoacidosis
Basic genitourinary hygiene
Patients with Type 2 diabetes are at risk for developing genito urinary (GU) infections. The 
following guidelines should be communicated to females and uncircumcised males regarding GU
infections. Patient communication cards will b e printed with the following:
For females:
â€œThe following advice may  be useful in helping you to keep y our bladder and urethra free from 
infection:
ï‚·Go to the toilet as soon as y ou feel the need to uri nate, rather than holding it in
ï‚·Wipe from front to back after going to the toilet
ï‚·Practice good h ygiene b y washing your genitals e very day, and before having sex
ï‚·Empty  your bladder after having sex.â€
For uncircumcised males:
â€œThe following advice may  be useful in helping you to keep the foreskin free from infec tion:
ï‚·Wash the end of your penis and foreskin with soap and water (do n ot let soap get in the 
opening)
ï‚·After your shower or bath, dry  the end of y our penis and foreskin pr operl y and replace the 
foreskin
ï‚·Also, when you urinate, slide the foreskin back enoug h so that urine does not get on the 
foreskin- this helps to keep it clean.â€
Maintaining hydration:
Sodium -glucose cotransporter T ype 2 inhibitors are associated with osmotic diuresis and volume 
depletion, which may lead to dizziness or hy potension, especially  in the elderl y. Before initiating 
study  drug (at Screening, Run- in and Randomization) and during all on -site study  visits thereafter, 
assess volume status in patients with renal impairment, the elderl y, in patients with low systolic 
blood pressure , or if receiving diuretics, angiotensin- converting -enzy me inhibitors, or angiotensin 
receptor blockers. All patients will be advised to maintain proper fluid intake and to consider 
increasing it if they  sense greater thirst, more urine production, or if they  feel dizzy  or faint.
Patient communication cards will be printed with the following for patients with Type 2 diabetes :
â€œThe following advice may  be useful in helping you to maintain proper hydration and prevent 
dehy dration:
ï‚·Dehydration is when your body lose s too much fluid, frequentl y due to diarrhea or 
increased urination
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 115 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 115ï‚·Consider increasing the amount of fluids y ou drink if:
-You sense greater thirst than usual
-You have a dry  mouth or cracked lips
-You have a fever
-You have diarrhea or vomiting
-You urinate m ore frequently  or in larger amounts than usual
-You get up in the middle of the night to urinate (more than usual)
-You feel dizzy  or light -headed
-You exercise, or when it is hot outsideâ€ .
Recognizing d iabetic k etoacidosis
Potential gastrointestinal (GI) adverse events occurring with sotagliflozin may  mask presenting 
symptoms of diabetic ketoacidosis (D KA). Patient communication cards will be printed with the 
following:
â€œIf you have an y of these sy mptoms on the list, then contact y our study  site immediately  for 
assistance with managing y our diabetes:
ï‚·Inability  to maintain oral intake
ï‚·Generalized weakness
ï‚·Abdominal (belly ) pain
ï‚·Increased weight loss
ï‚·Fever
ï‚·Frequent urination, including at night
ï‚·Fruit y-scented breath
ï‚·Confusion
ï‚·Acute illness
ï‚·Consistently  elevated blood glucose
ï‚·Feeling very  thirsty  or drinking a lot
ï‚·Nausea or vomiting
ï‚·Having trouble thinking clearl y or feeling tired.
It is possible to have DKA even if your blood glucose is not elevated. Regardless of your blood 
glucose level, if you have an y of thes e symptoms on the list, then contact your study  site 
regarding the need to be evaluated for possible DKA, which will include specific blood testing. 
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 116 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 116Ifyour stud y site is closed and your study doctor is not available, go to the nearest emergency  
room for e valuation.
If you are scheduled for a procedure or surgery that requires you to not take an y food or liquids, 
please contact your stud y doctor for instructions on continuing stud y drug. In such cases your 
study  doctor may  advise y ou NOT to take y our study  drug from the day  prior to the procedure or 
surgery  until after the procedure or surgery  is complete, and y ou are taking food and liquids as 
you normally  do.â€
Whenever adverse event d ata are collected or the patient reports DKA or intercurrent illness 
(including infections), generalized weakness, increased weight loss, GIsymptoms including 
nausea, vomiting, or abdominal pain or other s ymptoms or signs that the Investigator believes 
may be consistent with DKA, then the site will determine if an assessment f or DKA is 
appropriate. If laboratory testing confirms presence of metabolic acidosis, then the â€œPossible 
DKAâ€ electronic case report form will be completed.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 117 of 298
Amended Clinical Trial Protocol No. 02 11-Apr -2018
EFC14867 -sotagliflozin Version number: 1
Property of the Sanofi Group -strictly con fidential Page 117Appendix E Measurement of blood pressure and heart rate
Equipment
1. Blood pressure measurements will be taken by an automated blood pressure ( BP)monitor 
or a manual sph ygmomanometer
2.Bladder length â€“ Should nearl y or completel y encircle the patientâ€™s arm. For man y adults, 
the standard â€œadultâ€ size bladder is not long enough and the â€œlargeâ€ size bladder is 
recommended
3.Bladder width â€“ Should be at least 40% of the bladder length.
Patient f actors
Extraneous variables associated with the measurement of BP should be minimized. These include:
1.Food intake, caffeine -containing beverages, cigarette smoking, or strenuous exerc ise 
within 2 hours prior to measurement
2.Full urinary  bladder
3. The patient should not be allowed to talk while BP is being measured
4. The patient should be placed in the examination room and the cuff should be placed on the 
patientâ€™s arm. The proper sized cuff should fit snugl y with the lower edge 2 to 3cm above 
the antecubital fossa
5.The patient should be allowed to sit quietly  in a comfortably  warm place (temperature 
around 25Â°C or 77Â°F) for 5 minutes with the arm supported at heart level, preferabl y with 
thecuff in place and with no restrictive clothing on the arm. The patient should be 
encouraged not to tense his or her muscles.
Determination of the arm with the highest blood pressure
At the Screening Visit (Visit 1, Week -4),BP will be measured on both ar ms to identify  and select 
the appropriate arm for future measurements. S eated BP should be measured in both arms after 
5-minute rest period, and then again after 1 minute in both arms in seated position. The arm with 
thehighest SBPwill be determined at t his visit, and BP should be measured in this arm 
throughout the stud y.
Measurement Technique (23)
At the Screening Visit (Visit 1, Week -4),immediately  following arm selection, with the patient in 
the same po sition, an additional seated BP should be measured in the selected arm (at least 
1minute after last measurement).
At all other visits, following the 5 -minute rest period, 3 separate seated BPs should be measured 
in the arm selected at Visit 1, with at lea st 1minute between BP measurements and with the cuff 
fully  deflated between measurements.
All 3 BPs will be recorded in the patientâ€™s eCRF. The mean of the 3 seated BPs will constitute the 
BP value for that visit.
Three seated HR measurements will also be obtained. The mean of the 3 seated HRmeasurements 
will constitute the HR value for that visit.
(electronic  
  
2.0)
(electronic  
  
1.0)
Page 118 of 298